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 PART-I: p-Methoxybenzyl (PMB) ethers are useful hydroxyl protecting groups 
in the synthesis of complex organic molecules, especially in oligosaccharide synthesis, 
peptide coupling and nucleoside chemistry. Our main aim was to develop a highly 
chemoselective reagent system for the p-methoxybenzylation of alcohols. Towards this 
end, 5-(p-methoxybenzylthio)-1-phenyl-1H-tetrazole (PMB-ST) was developed, which 
was prepared quantitatively in one-pot by using 1-phenyl-1H-tetrazole-5-thiol, 
diphosgene and p-methoxybenzyl alcohol. For high chemoselectivity, a complementary 
reagent system to activate both the electrophile and the nucleophile was proposed. This 
was achieved by combining compatible Lewis acids (AgOTf) with non-nucleophilic 
Brønsted bases (DTBMP). This allowed the PMB protection of alcohols under mild 
conditions. Optimization studies were performed using cyclohexanol. When optimized 
protection protocol was applied to substrates bearing acid and base sensitive 
functionalities, PMB ethers were obtained in moderate to good yields without undesired 
side reactions. The ease of preparation of PMB-ST and the mild conditions employed 
make the reported protocol promising for the PMB protection of multifunctional 
substrates. Expansion into other protecting group modalities is also conceivable. 
 PART-II: Malaria, caused by the infection of the blood-borne apicomplexan 
parasite Plasmodium, continues to be a threat to human populations by killing 1 to 3 
million people and infecting 300-500 million people annually. One of the major 
problems in treating malaria is the emergence of resistance to available antimalarial 
drugs. The search for new drugs active against new targets of the parasite is still highly 
desirable. As a new lead, the antimalarial peptide N1266 was isolated at MerLion 
 vii
Pharma from a Myxobacterium species during a screening campaign for inhibitors 
against the Plasmodium falciparum (Pf) cysteine proteases. It was found to show an 
IC50 of 6 µM against falcipain-2. The antimalarial peptide is composed of amino acids 
proline, valine, isoleucine, histidine and an isovaleric acid unit. As the stereochemistry 
was unknown, we first synthesized the peptide using all L-amino acids. After 
developing a poor yielding coupling sequence, a convergent synthesis starting from 
Boc-proline was achieved in an efficient manner. The absolute stereochemistry of 0.2 
mg of remaining natural material was best determined by microwave (MW) hydrolysis 
followed by Marfey’s derivatization. Marfey’s analysis led to the identification of D-
histidine in the natural peptide N1266. This determination led to the total synthesis of 
N1266, and subsequently a number of analogues of N1266 were synthesized and 
screened for antimalarial activity. While most analogues involved structural 
modification of the isovaleric unit of N1266, we also synthesized histidine surrogates 
via click chemistry and tagged a more potent lead compound with coumarin for future 
target validation studies. A CF3-analogue displayed an IC50 (Pf) value of 136 nM.  
 Lastly, in collaboration with the group of Dr. Kevin Tan at the NUS Department 
of Microbiology, we designed and synthesized fluorescent-tagged probes of 
chloroquine. One probe clearly showed concentration-dependent differences in drug 
localization and hallmark features of programmed cell death (PCD) in Plasmodium 
falciparum. We further showed the use of fluorescent-tagged chloroquine in 
distinguishing chloroquine sensitive versus resistant strains of Plasmodium falciparum. 
We envisage such probes to find a wide utility in malaria research. 
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Chapter-1: Mild Protection of Alcohols using Thiotetrazole Reagents 
 
1.1 Introduction-protecting groups 
Protecting groups play an important role in the synthesis of organic molecules. 
Although one can appreciate making multifunctional molecules without the need for 
any protecting group,1 and reduce the number of steps involved in the multistep 
synthesis, organic synthesis has not yet matured to a point where protecting groups are 
unnecessary. Most complex molecules being made today are only accessible in a 
practical fashion with the assistance of protecting groups. Typically, a protection–
deprotection strategy will influence the length, efficiency2 and even the success3 of a 
synthesis. As a consequence, a plethora of protecting group reagents and deprotection 
methods has been deployed for a wide range of functionalities.4  
For a protecting group to be widely employed in organic synthesis, it should 
meet the following minimum criteria.2 First, it must be introduced into the molecule 
under mild conditions in a selective manner without disturbing the other functionalities 
present in the molecule. Second, it should be stable to the reaction conditions being 
employed during the synthesis. Third, the protecting group should be removed under 
mild conditions in a highly chemoselective manner in high yields. Orthogonal stability 
and modulated lability are two fundamental concepts that should be kept in mind while 
designing a protecting group strategy for a synthesis. Orthogonal stability refers to the 
removal of different protecting groups under different reaction conditions without 
affecting other groups present in the molecule and modulated lability refers to the 
 2
cleavage of protecting groups differentially sensitive to one set of conditions. Thus, 
protecting group chemistry is continually being expanded to meet the challenges that 
are presented by modern-day synthesis programmes. Although the vast majority of 
orthogonal methods for the deprotection of protecting groups are well established and 
understood, the ready attachment of a simple protecting group often presents a problem 
in a multifunctionalised, hindered substrate. In a chemoselective context, new methods 
to introduce protecting groups are just as important as methods to remove protecting 
groups. This is particularly true when modulating the reactivity and stability of 
advanced intermediates during the developmental stages of a synthesis. Indeed, subtle 
changes in the chosen protecting group, stemming from steric, electronic and 
anchimeric effects, can often control the efficiency or even the success of a key step. 
New methods should therefore be compatible with a multitude of sensitive 
functionality. Ideally, these methods should also meet the challenging demands (steric 
or electronic) presented by advanced intermediates, particularly in complex total 
syntheses.1–3, 5 
The masking of hydroxyl functionalities early in a synthetic strategy is often 
necessary to successfully perform subsequent multistep synthetic manipulations. 
Hydroxyl functionalities are usually protected as ethers or esters.4 p-Methoxybenzyl 
(PMB) ethers are useful hydroxyl protecting groups in the synthesis of complex organic 
molecules, especially in oligosaccharide synthesis, peptide coupling and nucleoside 
chemistry. Like benzyl (Bn) ethers, PMB ethers withstand a wide range of reaction 
conditions and are not subjected to unwanted migration between neighbouring 
functional groups that is observed with ester, acetal and silyl ether protecting groups. 
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PMB ethers offer modulated lability3,6 over benzyl (Bn) and 2-naphthyl (NAP) ethers, 
for example, by using DDQ, CAN or TFA.7 The introduction of PMB ethers can, 
however, be problematic. Two common methods of introducing the PMB group 
involves the Williamson ether synthesis using NaH, DMF, PMB-halide8 (Scheme 1-1)  
or the coupling of an alcohol with PMB-trichloroacetimidate9 1-2 (Scheme 1-2).  
 
Scheme 1-1: Williamson’s ether synthesis 
 
Scheme 1-2: PMB formation using PMB-trichloroacetimidate 
The synthesis of PMB ethers via Williamson ether conditions requires the use of 
a strong base such as NaH to generate the alkoxide, which is then allowed to react with 
PMB chloride (a lachrymator). The coupling of the alcohol with PMB 
trichloroacetimidate (unstable to storage) requires acidic media to protonate and thereby 
activates the trichloroacetimidate for subsequent attack by the alcohol. These methods 
are thus limited to substrates that can tolerate strongly acidic or basic conditions and 
may not be compatible with complex systems.10 β-Hydroxy esters, for example, are 
susceptible to several acid and base-catalyzed reactions, including retro-aldol, 
elimination and epimerization of stereogenic centers α - to the carbonyl group.11 β-
 4
hydroxy silanes are known to undergo Peterson elimination giving rise to alkenes under 
acid or basic conditions.12 Such substrates are good tests for new reagent systems. 
1.2 Mild reagents related to alcohol protection 
In order to accommodate such sensitive functionalities on molecules, several 
reagent systems allowing mild PMB protection have been developed. Selected and 
related systems will be covered in the following sections. 
1.2.1 Dudley’s 2-(4-methoxybenzyloxy)-4-methylquinoline reagent 
In 2007, Dudley et al. developed the 2-(4-methoxybenzyloxy)-4-
methylquinoline reagent system.13  The protection protocol is carried out by in situ 
generation of an lepidine salt which transfers the PMB group onto alcohols with 
magnesium oxide as the acid scavenger (Scheme 1-3).  
 
Scheme 1-3: PMB protection using the 2-(4-methoxybenzyloxy)-4-methylquinoline 
reagent 
 
The reagent system was shown to tolerate molecules with sensitive 
functionalities through the protection of a β -hydroxysilane, which undergoes Peterson 
olefination under strongly acidic or basic conditions to form alkenes (Scheme 1-4). No 
elimination product was isolated after p-methoxybenzylation. 
 5
 
Scheme 1-4: Peterson elimination of β-hydroxysilanes 
One limitation of this reagent system is that hydroxyl groups on aromatic 
systems are not easily protected. The reason for this is that the reaction is postulated to 
proceed via a SN1 mechanism in which the p-methoxybenzyl cation is generated in the 
reaction mixture. The highly electrophilic carbocation easily undergoes aromatic ring 
substitution with aromatic groups. The ring substitution was predominant when toluene 
was used as the solvent instead of CF3C6H5. 
1.2.2 Hanessian’s PMB-TOPCAT reagent 
In 1999, Hanessian and Huynh reported p-methoxybenzyl-2-
pyridylthiocarbonate 1-7 (PMB-TOPCAT),14  a reagent that provides PMB ethers upon 
reacting alcohols in the presence of silver triflate (AgOTf) as shown in Scheme 1-5. 
 
Scheme 1-5: PMB protection using PMB-TOPCAT 
This reagent system depends on the affinity of thiophilic Ag+ towards the 2-pyridylthio 
group to affect a decarboxylation of PMB-TOPCAT, producing a highly electrophilic 
PMB species that is readily attacked by the alcohol. The conditions applied in this 
 6
protocol allow the PMB protection of alcohols to be carried out under near neutral 
conditions giving yields of between 70 to 92%. In addition, no N-alkylation was 
observed with amides, carbamates and pyrimidine-type nitrogens and no ester 
migration, β-elimination nor epimerization were observed.  
1.2.3 Marcune’s MOM-thiopyridyl reagent  
In 1999, Marcune et al.15 published the development of a new reagent system 
for the protection of alcohols with the methoxymethyl (MOM) moiety (Scheme 1-6). 
 
Scheme 1-6: MOM protection using 2-pyridyl thioether 1-8 
This system, similar to the PMB-TOPCAT reagent, is reported to execute protection of 
alcohols and phenols under very mild and neutral conditions. They reported a 
methoxymethyl (MOM) 2-pyridyl thioether 1-8 for the MOM protection of alcohols in 
conjunction with AgOTf and NaOAc. 
 
Scheme 1-7: Mechanism of Marcune protocol 
The protocol developed by Marcune et al. (Scheme 1-7) requires the presence of 
a suitable Lewis acid (LA) to activate the MOM-2-pyridylsulfide reagent. The 
underlying principle, similar to that of the PMB-TOPCAT reagent, relies on the affinity 
of Ag+ towards the 2-pyridylthio group to produce a stabilized, highly electrophilic 
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methoxymethyl carbon-centre that can react with alcohols to form MOM ethers with 
good efficiencies. 
1.2.4 Proposed modification of PMB-TOPCAT reagent 
In 2001, Lear et al. published studies on various thiophilic activators with 
application to a straightforward, direct and stereoselective glycosylation of the 
kedarcidin chromophore using 2-deoxythioglycosides.16 Numerous thiophilic activators, 
such as PhSOTf and PhSeOTf, used in glycosylation studies gave encouraging yields 
and α-selectivity in the presence of 2,6-di-tert-butyl-4-methylpyridine (DTBMP). In 
particular, silver hexafluorophosphate (AgPF6) gave a rapid reaction, even at -80 oC, 
and a high α/β ratio in favour of the α anomer. The efficiency and potency of AgPF6 as 
a thiophilic activator when used in conjunction with DTBMP was thus demonstrated in 
the construction of the kedarcidin chromophoric subunit (Scheme 1-8). 
 
Scheme 1-8: Selective glycosylation 
Inspired by these reports and the success of Ag (I)-activation of 2-deoxy 
thioglycosides in a complex total synthesis setting,17-18 we proposed to develop a new 
thiotetrazole-based system to transfer PMB groups onto alcohols in a mild fashion. We 
 8
replaced the pyridyl group of Hanessian PMB-TOPCAT with 1-phenyl-1H-tetrazole 
group, since 5-(p-methoxybenzylthio)-1-phenyl-1H-tetrazole would be a better suited 
leaving group compared to PMB-TOPCAT (Figure 1-1).  
 
Figure 1-1: Modification to PMB-TOPCAT 
Notably, we planned to employ the virtues of the complementary activation of 
both the electrophile and the nucleophile by combining compatible Lewis acids 
(AgOTf, AgPF6) with non-nucleophilic Brønsted bases (DTBMP and 
Pentamethylpiperidine (PMP). We envisaged the concerted action of a compatible 
Lewis acid/Brønsted base pairing; the concept being to activate both the thiocarbonate 
(in 1-12) and facilitate deprotonation of the alcohol. We further selected 1-phenyl-1H-











1.3 Results & discussion 
First, we reproduced the literature using the PMB-TOPCAT reagent developed 
by Hanessian.14 PMB-TOPCAT was synthesized in a one-pot procedure from readily 
available starting materials 2-mercaptopyridine, triphosgene and p-methoxybenzyl 
alcohol (PMB-OH) (Scheme 1-9). To develop the two-step reaction into a one-pot 
procedure, modifications were made to the reported procedures.14, 20  
    
 
Scheme 1-9: Synthesis of PMB-TOPCAT 
In an attempt to reproduce the literature results, the p-methoxybenzylation of 
alcohols was first carried out on phenol and other alcohol substrates, using PMB-
TOPCAT according to the reported procedure. Although, the literature procedure was 
followed, we could not observe any trace of the protected alcohols. Instead 1-7 
decomposed in the reaction mixture to give a significant amount of side-product, which 
was identified as the 2-pyridyl-p-methoxybenzylthioether 1-17 according to 1H NMR. 




Table 1-1: PMB-protection using PMB-TOPCAT 
1.3.1 Synthesis of PMB-ST reagent system 
We next targeted the PMB-thiocarbonyl tetrazole 1-12 akin to Hanessian’s 
PMB-TOPCAT reagent (Scheme 1-10). Although, the thiocarbonate 1-12 was too 
unstable to be investigated systematically, it conveniently underwent decarboxylation to 
a new PMB-transfer reagent, 5-(p-methoxybenzylthio)-1-phenyl-1H-tetrazole (PMB-










































Scheme 1-10: Synthesis of PMB-ST 1-23 
We presume that the PMB-thiocarbonate formed was very unstable and entropy 
would favour formation of the PMB thioether (1-23) with spontaneous evolution of CO2 
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similar to the mechanism proposed by Ogura et al.19 for the synthesis of allylic sulfides 
from S,S’-bis (1-phenyl-1-H-tetrazol-5yl) dithiocarbonate (1-22). By modification of 
reported procedures,20 the PMB-ST reagent 1-23 could be prepared quantitatively in 
one-pot. Diphosgene was first reacted with 1-phenyl-1H-tetrazole-5-thiol 1-21 to give 
the S,S’-bis(1-phenyl-1H-tetrazol-5-yl)dithiocarbonate 1-22. Upon addition of p-
methoxybenzyl alcohol 1-16, the mono-thiocarbonate 1-12 that formed decarboxylated 
spontaneously to give PMB-ST 1-23..  
 
Scheme 1-11: In situ formation PMB-ST with elimination of CO2 
To reduce the reaction time, we have also developed alternative methods for the 
synthesis of PMB-ST. A Mitsunobu synthesis21 of PMB-tetrazole involved the one pot 
reaction of 1-phenyl-1H-tetrazole-5-thiol, p-methoxybenzylalcohol, triphenylphosphine 
with diethyl azodicarboxylate (DEAD). This gave the desired product in 95% yield in 1 
hour.  (Scheme 1-12) 
 
Scheme 1-12: Mitsunobu method for PMB-ST 1-23 synthesis 
An alternative method of synthesizing PMB-tetrazole was to synthesis the thioether via 
Williamson ether synthesis (Scheme 1-13). The overnight reaction gave a yield of 92%.  
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Scheme 1-13: Williamson ether synthesis of PMB-ST 1-23 
Importantly, the PMB transfer reagent (PMB-ST, 1-23) was stable for use in air, 
at room temperature, and can be stored in a refrigerator for several months without 
decomposition. In order to design functional group tolerance into our reagent system, 
we envisaged the concerted action of a compatible Lewis acid/Brønsted base pairing; 
the concept being to activate both the thioether (in 1-23) and facilitate deprotonation of 
the alcohol.22 We further selected 1-phenyl-1H-tetrazole thiol 1-21 for two reasons: its 
leaving group potential and lack of odour.19,23 The mechanism of PMB protection using 
PMB-ST (Scheme 1-14) depends on the affinity of thiophilic Ag(I) cations towards the 
thiogroup of the reagent to produce an electrophilic p-methoxy benzyl carbocation that 
is reactive towards the nucleophilic hydroxyl group of alcohols. 
 





1.3.2 PMB protection protocol of alcohols using PMB-ST 
The first issue to address was the choice of thiophilic activator and solvent. For 
this, various thiophilic activators were tested. We found silver triflate gave good yields 
compared to other silver salts. Screening with different solvents led to the selection of 
dichloromethane as the most suitable solvent for the desired transformation. The use of 
more polar solvents such as acetonitrile (Table 1-2, entry 9) and dimethylformamide 
(Table 1-2, entry 10) gave negligible yields, possibly due to the strong coordination of 
the solvent molecules to the Ag(I) cation, reducing its thiophilic ability. 
α,α,α-Trifluorotoluene, frequently used as an industrial substitute for dichloromethane, 
did not give yields comparable to that of dichloromethane (Table 1-2, entry 11). 
 
 
Entry Activator Solvent Time (h) Yield (%) 
1 AgPF6 CH2Cl2 4 68 
2 AgOTf CH2Cl2 4 89 
3 AgBF4 CH2Cl2 12 43 
4 AgSbF6 CH2Cl2 12 41 
5 CuOTf CH2Cl2 12 65 
6 ZnCl2 CH2Cl2 12 No reaction 
7 AgOTf THF 12 35 
8 AgOTf ClCH2CH2Cl 12 30 
9 AgOTf CH3CN 12 No reaction 
10 AgOTf DMF 12 Trace 
11 AgOTf CF3Ph 12 38 
 
Table 1-2: Screening of thiophilic activators and solvents 
We next optimized the PMB protection of cyclohexanol using AgOTf/DTBMP. 
Equimolar amounts of PMB-ST 1-23 and AgOTf were found best (Table 1-3, entry 3).  
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(eq) Yield (%) 
1 1.2 1.5 - No reaction. 
2 1.4 1.6 1.25 75 
3 1.6 1.6 1.25 89 
4 2.0 2.0 1.25 79 
5 1.6 1.6 2.0 72 
6 1.6 1.6 1.5 74 
7 1.6 1.6 1.0 77 
8 1.6 1.6 0.5 43 
 
Table 1-3: Optimization of reaction conditions 
 
The presence of at least one equivalent of DTBMP was found to be essential in 
achieving a good yield (entries 2-8). Trace amounts of water were removed with 
activated molecular sieves (4 Å MS), which improved the yields and minimized the 
generation of the bis- PMB ether side product 1-27.  
 
Under the established protocol, primary, secondary, tertiary, phenolic and propargylic 
alcohols were found to give the corresponding PMB ethers in moderate to good yields 
















5  65 
 
Table 1-4: PMB protection of primary, secondary and tertiary alcohols. 
 
The test for compatibility of the reagent system with alcohols bearing sensitive 
functionalities has to address the possibility of undesired reactions occurring in the 
reaction flask. The use of DTBMP as a non-nucleophilic base could cause side reactions 
in base sensitive groups and the use of silver triflate as thiophilic activator could lead to 
Lewis acid catalyzed undesired reactions. Although it is postulated that the silver (I) 
cation associates with the 1-phenyl-1H-tetrazole-5-thionate anion to form a salt, the 
presence of the nucleophilic thionate anion could cause undesired reactions involving 
the attack of the thionate anion on good leaving groups or initiate elimination reactions. 
Several substrates bearing labile or sensitive functionalities were synthesized in order to 
investigate the mildness of the reagent (Scheme 1-15). The substrates were 
subsequently subjected to the protection protocol (Table 1-5) 
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Scheme 1-15: Synthesis of acid and base sensitive substrates for PMB protection. 
 
Both acid and base labile functionalities were tolerated (Table 1-5, entries 1, 2, 4, 5); 
for example, the successful PMB protection of the acid/base-sensitive β-hydroxy silane 









Table 1-5: PMB protection of acid and base sensitive substrates. 
Entry ROPMB Yield (%) 
1 OPMB
TESO












p-Methoxybenzylation of substrates bearing the realtively labile trimethylsilyl 
(TMS) or triethylsilyl (TES) group was executed with no cleavage of the silyl group 
(Table 1-5, entries 1, 5). Protection of 2-(trimethylsilyl)-1-phenylethanol 1-35 gave no 
elimination product of styrene (Table 1-5, entry 2). In comparison to 1-(trimethylsilyl)-
4-phenylbutan-2-ol tested by Dudley, the hydroxyl group in 2-(trimethylsilyl)-1-
phenylethanol is positioned at a more electrophilic carbon making it more susceptible to 
Peterson elimination. The absence of the elimination product illustrates the mildness of 
the reagent system. Deprotection of the Fmoc group occurs via a β-elimination 
mechanism, as initiated by the action of a base. p-Methoxybenzylation of (9H-fluoren-
9-yl)methyl-1-hydroxy-2-methylpropan-2-ylcarbamate 1-38 did not undergo Fmoc 
deprotection (Table 1-5, entry 2). In practice, however, separation of the protected 
alcohol was difficult due to the product eluting with the PMB-tetrazole and side product 
1-27 during silica-gel chromatography. 2-Hydroxyethyl 3-(2-methyl-1,3-dithiolan-2-yl) 
propanoate 1-39 was also tested in response to the observation that deprotection of the 
1,2-dithiane group can be executed using silver (I) salts4. Interestingly, p-
methoxybenzylation of 1-39 caused deprotection of the 1,2-dithiane group with 
simultaneous protection of the primary hydroxyl to give 2-(4-methoxybenzyloxy)ethyl 
4-oxopentanoate 1-46 in 72% yield. 
 
Dichloroacetate groups are known to be hydrolyzed 16000 times faster than 
their corresponding acetates and can be removed simply by stirring the protected 
alcohol in methanol at room temperature for 24 hours4. During substrate preparation, 
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attempts to monoprotect allyl-4,6-O-benzylidene-α-D-mannopyranoside 1-48 with a 
dichloroacetate group was not successful and the diprotected allyl-2,3-O-
bis(dichloroacetyl)-4,6-O-benzylidene-α-D-mannopyranoside 1-49 was obtained 
instead.  
 
Scheme 1-16: Synthesis of carbohydrate substrates 
 
The protection protocol was still carried out on the diprotected substrate in an attempt to 
observe possible deprotection of the dichloroacetate group through the action of silver 
triflate via a similar mechanism to the trityl protection of alcohols with trityl chloride 
and silver triflate. However, no cleavage of the dichloroacetate groups was observed 
and the substrate was recovered. The lack of reaction of 1-48 under the reaction 
conditions encouraged us to attempt to protect a substrate bearing the dichloroacetyl 
group on a more labile primary hydroxyl position. Allyl-2,3-di-O-carbonyl-6-O-
dichloroacetyl-α-D-mannopyranoside 1-51 was subsequently PMB protected using the 
reagent system with no deprotection of the dichloroacetyl group. Attempts to attach a 
good-leaving tosyl group to the primary hydroxyl group of allyl-2,3-di-O-carbonyl-α-D-
 19
mannopyranoside 1-50 was not successful; instead, the ditosylated allyl-2,3-di-O-
carbonyl-4,6-O-di-O-tosyl-α-D-mannopyranoside 1-52 was formed. 1-52 was subjected 
to the protection protocol and was recovered quantitatively after workup. No side 
reactions involving the deprotection or elimination of both the tosyl groups occurred.  











Table 1-6: PMB protection of carbohydrate substrates 
Next, the (regio)selectivity of the reagent system was investigated using diols. 
Application of the protection protocol to allyl-4,6-O-benzylidene-α-D-mannopyranoside 
(1-48) gave the 3-O-p-methoxybenzylated product 1-53 exclusively in 57% yield. This 
selectivity is similar to that of the dibutyltin oxide reagent system.24 Despite the yield 
being lower than that with dibutyltin oxide, the PMB-tetrazole system does not involve 
the use of tin compounds, which is known to be harmful. Our protocol was also applied 
to allyl-2,3-di-O-carbonyl-α-D-mannopyranoside 1-50 and the reaction was allowed to 
stir for 48h due to the low solubility of 1-50 in dichloromethane (starting material 
remained undissolved after 24 hours). The protocol yielded 80% of the 6-O-p-
methoxybenzylated alcohol 1-54 and 16% of the 4,6-O-di-p-methoxybenzylate product. 
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Thus, a regioselective protection of carbohydrate diol functionality could be achieved 
with this protocol.   
1.3.3 Epimerization study 
An important test for the efficiency of PMB-ST 1-23 was to generate PMB 
ethers from chiral β-hydroxy esters such as 1-57. PMB ethers derived from such 
substrates are difficult to obtain under Williamson ether conditions due to potential 
formation of β-eliminated products and epimerization of the stereogenic center α to the 
ester.  
 
Scheme 1-17: Synthesis of racemic Roche ester 1-58. 
 As HPLC reference material, the racemic β-hydroxy ester 1-57 was first 
synthesized from 1-56 via the Baylis-Hillman reaction of formaldehyde with methyl 
acrylate according to the procedure of Yu et al.25 (Scheme 1-17). Next, the enantiopure 
β-hydroxy ester 1-59 was efficiently protected as its PMB ether 1-60 using our PMB-ST 
system. Chiral HPLC analysis clearly provided evidence that no racemization took 
place (Scheme 1-18). 
 








                                          Racemic                                  Enantiopure  
Figure 1-2: Chiral HPLC analysis of racemic 1-58 and enantiopure 1-60. 
 
1.4 Conclusion 
In summary, we have developed and shown the utility of 5-(p-
methoxybenzylthio)-1-phenyl-1H-tetrazole (PMB-ST, 1-23) as a new reagent for PMB 
etherification. The functional group tolerance of the reagent system was studied over a 
range of alcohols. Even sensitive substrates and functionality survived the PMB-
ST/AgOTf/DTBMP conditions, thereby, in certain cases, allowing a full recovery of 
precious starting material. While costly for large scale protections, we envisage this 
reagent system to find utility in the PMB protection of advanced, multifunctional 
substrates. Applications to other protecting modalities, such as to the NAP, MOM, 








1. (a) Gudmundsdottir, A. V.; Nitz, M. Org. Lett. 2008, 10, 3461. (b) Lainchbury, 
M. D.; Medley, M. I.; Taylor, P. M.; Hirst, P.; Dohle, W.; Booker-Milburn, K. I. 
J. Org. Chem. 2008, 73, 6497. (c) Baran, P. S.; Maimone, T. J.; Richter, J. M. 
Nature 2007, 446, 404. (d) McFadden, R. M.; Stoltz, B. M. J. Am. Chem. Soc. 
2006, 128, 7738. (e) Heim, R.; Wiedemann, S.; Williams, C. M.; Bernhardt, P. 
V. Org. Lett. 2005, 7, 1327. 
2. (a) Hoffmann, R. W. Synthesis 2006, 21, 3531-3541. (b) Schelhaas, M.; 
Waldmann, H. Angew. Chem, Int. Ed. 1996, 35, 2056. 
3. Example of NAP-protection versus benzyl ethers: Inoue, M.; Uehara, H.; 
Maruyama, M.; Hirama, M. Org. Lett. 2002, 4, 4551. 
4. (a) Wuts, P. G. M.; Greene, T. W. Protective groups in Organic Synthesis, 4th 
ed.; Wiley and Sons, New York, 2006. (b) Kocienski., P. Protecting groups, 3rd 
ed.; Thieme, Stuttgart, 2005. 
5. (a) Sartori, G.; Ballini, R.; Bigi, F.; Bosica, G.; Maggi, R.; Righi, P. Chem. Rev. 
2004, 104, 199. (b) Sharma, G. V. M.; Mahalingam, A. K. J. Org. Chem.  1999, 
64, 8943. 
6. (a) Wright, J. A.; Yu, J. Q.; Spencer, J. B.  Tetrahedron Lett.  2001, 42, 4033. 
(b) Plante, O. J.; Buchwald, S. L.; Seeberger, P. H.  J. Am. Chem. Soc.  2000, 
122, 7148. 
7. (a) Yan, L.; Kahne, D.  Synlett 1995, 523. (b) Oikawa, Y.; Yoshioka, T.; 
Yonemitsu, O. Tetrahedron Lett. 1982, 23, 885; 
8. Marco, J. L.; Huesorodriguez, J. A.  Tetrahedron Lett. 1988, 29, 2459.  
 23
9. Nakajima, N.; Horita, K.; Abe, R.; Yonemitsu, O. Tetrahedron Lett. 1988, 29, 
4139.  
10. The Chemical Synthesis of Natural Products, ed. Hale, K. CRC Press, Boca 
Raton, Florida, 2000. 
11. Poon, K. W. C.; Dudley, G. B. J. Org. Chem. 2006, 71, 3923. 
12. Ager, D. J. Org. React. 1990, 38, 1. 
13. (a) Lopez, S. S.; Dudley, G. B. Beilstein J. Org. Chem. 2008, 4; 
doi:10.3762/bjoc.4.44. (b) Nwoye, E. O.; Dudley, G. B. Chem. Commun. 2007, 
1436. 
14. Hanessian, S.; Huynh, H. K. Tetrahedron Lett. 1999, 40, 671. 
15. Marcune, B. F.; Karady, S.; Dolling, U. H.; Novak, T. J. J. Org. Chem. 1999, 
64, 2446. 
16. Lear, M. J.; Yoshimura, F.; Hirama, M. Angew. Chem. Int. Ed. 2001, 40, 946. 
17. Ren, F.; Hogan, P. C.; Anderson, A. J.; Myers, A. G. J. Am. Chem. Soc. 2007, 
129, 5381. 
18. Yan, L.; Kahne, D.  Synlett  1995,  523. 
19. Tsuboyama, K.; Takeda, K.; Torii, K.; Ebihara, M.; Shimizu, J.; Suzuki, A.; 
Sato, N.; Furuhata, K.; Ogura, H. Chem. Pharm. Bull. 1990, 38, 636. 
20. (a) Lee, J. I.; Park, H.  Bull.  Korean Chem.  Soc.  2001, 22, 421. (b) Takeda, K.; 
Tsuboyama, K.; Takayanagi, H.; Shirokami, R.; Takeura, M.; Ogura, H. Chem. 
Pharm. Bull. 1989, 37, 2334.  
21. Smith, A. B.; Wan, Z. H. J. Org. Chem.  2000, 65, 3738. 
 24
22. The dual action of both “soft” Lewis acids or π-acids” and “hard” Brønsted 
bases are gaining importance in organic synthesis: (a) Duschek, A.; Kirsch, S. F. 
Angew. Chem. Int. Ed. 2008, 47, 5703 (b) A. S. K. Hashmi, Chem. Rev. 2007, 
107, 3180; (c) Y. Yamamoto, J. Org. Chem. 2007, 72,7817. 
23. Blakemore, P. R.; Cole, W. J.; Kocienski, P. J.; Morley, A. Synlett. 1998, 26. 
24. Wong, C. H.; Ye, X. S.; Zhang, Z. Y. J. Am. Chem. Soc.  1998, 120, 7137. 
25. Yu, C. Z.; Liu, B.; Hu, L. Q. J Org. Chem.  2001, 66, 5413. 
26. Denmark, S. E.; Regens, C. S.; Kobayashi, T. J. Am. Chem. Soc., 2007, 129, 
2774. 
27. Peterson, D. J. J. Org. Chem. 1968, 33, 780. 
28. Hauser, C. R.; Hance, C. R. J. Am. Chem. Soc. 1952, 74, 5090. 
29. Carpino, L. A.; Han, G. Y. J. Org. Chem. 1972, 37, 3404. 
30. Vishwakarma, R. A.; Ali, A.; Gowda, D. C. Chem. Commun.  2005, 519. 
31. Karmi, B.; Golshani, B. J. Org. Chem.  2000, 65, 7228. 









TOTAL AND ANALOGUE SYNTHESIS 
OF ANTIMALARIAL PEPTIDES 















Chapter 2: Introduction 
 
 
Before we discuss the synthesis of new antimalarial peptides and chloroquine 
probes, it is important to provide background on malaria. In this chapter, we shall 
discuss the biology of malaria, problems associated with this disease, and the current 
strategies in antimalarial chemotherapy. Due to resistance being developed to drugs 
currently being used, it is important to develop new agents that are active against new 
targets. The next sections shall cover information on selected new targets that can be 
used for developing better drugs against malaria, for example, falcipain-2 and also give 
examples of compounds currently active against these targets. We also shall briefly 
summarize the methods and reagents currently employed in peptide synthesis, as 
preparation for our total and analogue synthesis of a new antimalarial peptide, N1266, 
which was isolated at MerLion Pharma during a falcipain-2 screening campaign. Later, 
we shall discuss the synthesis of chloroquine probes to study drug resistance and to 
track concentration-dependent differences in drug localization in Plasmodium 
falciparum (Pf).  
 
2.1 Malaria background 
Malaria is one of the three most devastating infectious diseases along with 
tuberculosis and AIDS. It remains a major health problem in Africa, South America and 
major parts of Asia. Around 300-500 million of the world population suffer from the 
disease every year resulting in more than a million deaths.1 The word “malaria” comes 
from the Italian word “mal’aria” meaning “bad airs” as it was thought to arise from foul 
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air in marshy areas and swamps.  Alphonse Laveran, a French researcher, was the first 
to discover the malarial parasite in the human blood.2,3 He was awarded the Nobel Prize 
for his work along with other discoveries into the protozoan diseases. In 1902, Sir 
Ronald Ross was awarded the Nobel Prize in Medicine for his pioneering work on 
malaria.4 He demonstrated that the malarial parasite was injected into the human 
bloodstream through the bite of an infected female anopheles mosquito.  
Malaria in humans is caused by protozoan Plasmodium species, namely P. falciparum, 
P. vivax, P. malariae and P. ovale.5 P. knowlesi, a malaria parasite that infects 
monkeys, is the latest addition to the list in humans as reported by Singh and Cox-
Singh.6 Of these, P. falciparum is the most lethal species contributing to the majority of 
deaths. This parasite produces specific proteins that are transported to and embedded in 
the cell membrane of the infected erythrocytes. As a result, the erythrocytes stick to the 
pre-venous capillaries causing obstruction of blood vessels. Cerebral malaria, a 
condition where the infected erythrocytes accumulate in brain vessels, leading to loss of 
consciousness and ultimately death, is the most severe case of malaria caused by P. 
falciparum.7 Common symptoms of malaria are high temperature (fever), chills, 
headache, sweats, tiredness (fatigue), nausea and vomiting. It is estimated that over 40% 
of the world’s population lives in malaria endemic areas (Figure 2-1), namely 
throughout the tropics and subtropical regions. 
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Figure 2-1: Global malaria distribution and endemicity, 2003 
(Source http://commons.wikimedia.org/wiki/File:Malaria_map.PNG) 
 
2.1.1 Life cycle of the malarial parasite 
The life cycle of malarial parasites8 (Figure 2-2) consists of two hosts. The primary host 
is the female anopheles mosquito, where the sexual cycle takes place.  The secondary 
host is man, where the asexual cycle takes place. Sporozoites are released into the 
human blood through the bite of an infected female anopheles mosquito. Sporozoites 
find their way into human liver cells and begin their asexual division (10000-30000 fold 
multiplication), resulting in the formation of several thousands of merozoites. The 
released merozoites invade the erythrocytes and grow through the stages of rings, 
trophozoites and schizonts by feeding on the host cell hemoglobin. Within the 
erythrocytes, the asexual reproduction occurs in a 48 hour cycle. Each schizont typically 
divides into 16 erythrocytic merozoites and is released by lysis of the erythrocyte. The 
released merozoites attack the new erythrocytes. It is the cyclic release of parasites from 
the red blood cells (RBC), which causes the intermittent symptoms of fever, shivering 
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and anemia that are characteristic of malaria. During this stage, small proportions at the 
blood stages undergo differentiation into female and male gametocytes.  
 
Figure 2-2: Life cycle of Plasmodium falciparum 
 
 
The male and female gametocytes enter the mosquito when it bites the infected man.  
They reach the mid-gut of the mosquito, where the female gametocytes develop into 
macro gametes and the male gametocytes divide to micro gametes. The male and 
female gametes fuse to form a zygote. The zygote transforms into motile ookinete 
which penetrates the gut wall and becomes oocyst. Asexual reproduction inside the 
oocyst produces thousands of sporozoites, which reach the salivary glands by the 
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rupture of oocyst. These sporozoites are transmitted to the humans by the bite of the 
mosquito at this juncture.  
 
2.1.2 Hemoglobin degradation pathway 
Hemoglobin degradation is an essential step for the survival of the parasite.9 The 
malaria parasite ingests and degrades most of the host cell hemoglobin10 to amino acids 
for use in protein synthesis11 and as an energy source12 during the morphologically 
different growth phases inside the erythrocyte (ring, trophozoite and schizont stages).13 
Figure 2-3 shows the degradation of hemoglobin in an orderly pathway through the 
action of aspartic and cysteine proteases in P. falciparum.14  Four aspartic proteases, 
namely the plasmepsin (PM) I, II, IV and histo-aspartic protease participate in 
hemoglobin degradation. PM I and II have been proposed to initiate hemoglobin 
degradation by hydrolyzing the peptide bond15-16 followed by further degradation by 
other PMs,17 the cysteine proteases namely, falcipains-2, 2’ and 3,18-21 a metalloprotease 
called falcilysin22 and the dipeptidyl aminopeptidase 1 (DPAP1).23 The precise 
sequence of events, particularly whether a plasmepsin or a falcipain catalyses the initial 
degradation step is still under debate.9 It has been proposed that inhibition of cysteine 
proteases turns out to be lethal for parasites. Cysteine protease inhibitors irreversibly 
block the rupture of host cell membrane preventing the parasites to attack fresh 
erythrocytes.24 The metalloprotease falcilysin can cleave small polypeptides, up to 20 
amino acids producing shorter oligopeptides.22 DPAP1 cleaves dipeptides from 
hemoglobin-derived oligopeptides in the food vacuole.23 
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Finally, small peptides are pumped out of the food vacuole into the cytoplasm and 
aminopeptidase activity provides amino acids essential for parasite survival.24-25 The 
large amount of heme generated through the massive degradation of hemoglobin causes 
membrane damage due to its peroxidative properties.26 The heme is almost entirely 
oxidized from the ferrous (+2) state to ferric (+3) hematin.27 The released hematin is 
detoxified to a cyclic dimer, β-hematin. These dimers crystallize to form hemozoin (an 
insoluble malaria pigment), which is non-toxic to the parasite. 
 
Figure 2-3: Hemoglobin degradation pathway14 
2.2 Antimalarial drugs 
A number of antimalarial drugs have been developed and are still under 
development due to the severe spread of malaria. Figure 2-4 summarizes the list of 
available antimalarial drugs. The first attempts to treat malaria dates back to the 18th 
century by the use of the bark of cinchona trees. In 1820, the active component (quinine 
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2-1) from the bark of cinchona trees was isolated for the treatment against malaria. 
Malaria was among the first diseases to be treated by a pure chemical compound28 and 
also by a synthetic drug, methylene blue (2-2).29 Later, several aminoquinolines 
(pamaquine 2-3, mepacrine 2-4, chloroquine 2-5, etc.) were developed by modification 








































































Tetracycline (2-12)    
Figure 2-4: Available antimalarial drugs in the market31 
As a result of overuse, resistance quickly developed against these synthetic 
aminoquinolines. New drugs were thus sought from traditional chinese medicine. 
Artemisinin was isolated as an active ingredient from the Chinese herb, Artemisia 
annua, which showed antimalarial activity.30 At present, artemisinin and its derivatives 
are routinely administered for the treatment of malaria. 
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The mechanism of action or biological targets of most antimalarial drugs in use 
today is not clear. They have been proposed to act either by preventing heme 
polymerization or inhibiting dihydrofolate/dihydropteroate synthase. Other antimalarial 
drugs which are in clinical development include lumefantrine-artemether, atovaquone-
proguanil, chlorprogaunil-dapsone, pyronaridine, tafenoquine, fosmidomycin (Figure 
2-5).28 Most of these drugs are limited in use owing to resistance developed by the 
malarial parasite. Recently, resistance has also been observed to the artemisinins, which 
are currently the major players in the treatment of malaria.35 It is therefore important to 
control or eliminate this primitive infectious disease owing to the resistance developed 
by the parasites to existing antimalarials. Table 2-1 summarizes the list of old and new 
antimalarial compounds along with their target of action.31  
 





2.3 Antimalarial drug resistance32-33 
One of the major drawbacks in the treatment of malaria is the emergence of resistance 
to antimalarial drugs. The development of resistance, particularly in P. falciparum, has 
been a major contributor to the global increase in the number of malaria cases over the 
last three decades.34 Previously, resistance was observed in all classes of antimalarial 
drugs with the notable exception of the artemisinins. Today, there have been reports of 
plasmodium species developing resistance to artemisinins, which currently are our last 
line of defense against malaria.35 
Target Pathway or mechanism 
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Mitochondria Electron transport Cytochrome c oxidoreductase 



























Extracellular Erythrocyte invasion Subtillisin serine protease 
 Protease inhibitors 
Table 2-1: Antimalarial drugs with their targets 
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Antimalarial drug resistance has been defined as the “ability of a parasite strain 
to survive and / or multiply despite the administration and absorption of a drug given in 
doses equal to or higher than those usually recommended but within tolerance of the 
subject”.32 In general, resistance is proposed to develop through spontaneous mutations 
that result in the parasite showing reduced sensitivity to a given drug or class of drugs. 
Single point mutation or multiple mutations (depending on the drug) may result in 
developing resistance, provided the mutations are not harmful to the survival of the 
parasite. The frequency at which the mutations occur and the speed at which resistance 
develops is influenced by a variety of factors related to the pharmacological 
characteristics of the drugs used, the local epidemiological context in which they are 
used, and the manner in which the drugs are deployed and used operationally. The 
biochemical mechanism of resistance has been well described for chloroquine, the 
antifolate combination drugs and atovaquone. Chloroquine resistance in P. falciparum 
may be multigenic and is conferred by mutations on genes that encode transport 
proteins localized in the membrane of digestive vacuole. The transporters involved in 
quinoline resistance are Pf chloroquine resistance transporter PfCRT, P-glycoprotein 
homologue 1 (Pgh1) and multidrug resistance protein (PfMRP).36-37 
2.4 Approaches to antimalarial chemotherapy 
A number of different approaches are being pursued to control malaria. It is still 
necessary to develop new drugs against malaria as most of the established antimalarials 
are developing resistance to malaria. Approaches to antimalarial chemotherapy39-40 are 
described next. 
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2.4.1 Optimization of therapy with existing agents 
  There is a growing consensus that drug combinations are essential to the optimal 
control of malaria in developing countries. Combination therapies offer a number of 
improved advantages over single agents. First, they provide improved efficacy. 
Artemisinin derivatives and atovaquone have unacceptable failure rates when used as 
single agents due to their short half-lives, but were highly effective when used in 
combination with other antimalarials.40 Second, drug combinations help in the treatment 
of malaria, even if one of the agents develops resistance, as the other is still active 
(amodiaquine/sulfadoxine/pyrimethamine). Third, and the most important of drug 
combination therapy, is the slow progression of parasite resistance 
(artesunate/mefloquine).   
2.4.2 Development of analogues of existing agents  
Chemical modifications to the existing antimalarials provide new analogues 
which may show better efficacy over the parent ones. Chloroquine, primaquine, and 
mefloquine, for example, have been developed through chemical synthesis to improve 
upon quinine. Several analogues and derivatives of artemesinins have been synthesized 
by simple chemical modifications and are being used as antimalarials.41-42 
Another strategy towards antimalarial chemotherapy is to identify agents that are 
developed as treatments for other diseases. These compounds might act against 
orthologs of their targets in other systems or by other mechanisms against malarial 
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parasites. Folate antagonists, tetracyclines and other antibiotics initially developed for 
their antibacterial properties were found to be active against the malarial parasites.43 
2.4.3 Drug resistance reversers 
Compounds which reverse the parasite drug resistance when administered with 
the antimalarials previously reported to show drug resistance is another approach 
towards antimalarial chemotherapy. Verapamil,44 an antihypertensive drug, notably 
reverses the resistance of P. falciparum to chloroquine in vitro. Desipramine,45 
chlorpheniramine46 and trifluperazine47 have also been shown to reverse drug 
resistance. Efforts to design new reversers48 of chloroquine are underway. 
2.4.4 Compounds active against new targets  
Another approach towards the development of antimalarial drugs is to identify 
new targets and develop drugs aimed at these targets. Various potential biochemical 
targets31 in the parasite have been identified (Figure 2-7). Data from the malaria 
genome project49-50 has greatly assisted in the identification of a number of potential 
drug targets. The important targets for drug design include protease enzymes,51 
respiratory chain and mitochondria,52 apicoplast53 consisting of isoprenoid 
biosynthesis,54 fatty acid metabolism55 and protein farnesyl transferase,56 polyamine 
metabolism, protein kinases,57 helicases,58 nucleic metabolism involving purine, 
pyrimidine and folate metabolism, topoisomerases and the glycolysis pathway.59 
Among these new targets, the cysteine (falcipains)60 and aspartic proteases 
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(plasmepsins)51 are the most attractive and promising target enzymes, which play a key 
role in hemoglobin degradation during the trophozoite stages of growth in Plasmodium.  
2.4.4.1 Plasmepsins  
The plasmodium aspartic proteases are referred to as plasmepsins. Most of the 
plasmepsins belong to the pepsin family. The cleavage of hemoglobin is also mediated 
by plasmepsins along with the falcipains.  Plasmepsins I, II and IV have been proposed 
to be involved in this process.61-62 Most of the plasmepsin inhibitors identified to date 
have been peptidomimetic in nature. Specific plasmepsin II inhibitors have been 
obtained by modification of the available inhibitors of cathepsin D, a lysosomal 
protease in mammalian cells.63 Small compound libraries have been iteratively 
synthesized, which has led to the identification of 2-21 with an IC50 of 4.3 nM against 
plasmepsin-II (Figure 2-6). The crystal structure of plasmepsin-II has led the 
modification of inhibitors known for the homologue, renin. The de novo design of 
inhibitors gave compound 2-22, highly active against plasmepsin-II. Compound Ro 42-
1118 (2-23) originally identified as plasmepsin-II inhibitor, was found to show a 16-80 
fold higher potency against plasmepsin-IV.64 
 
Figure 2-6: Examples of plasmepsin inhibitor 
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2.4.4.2 Falcipains and Falcipain-2 inhibitors 
Cysteine proteases65-66 are proteolytic enzymes which contain a cysteine-
histidine pair at the catalytic centre. They hydrolyze the peptide bond through a 
nucleophilic attack on the amide carbonyl group.67 The well characterized P. falciparum 
cysteine proteases are the falcipains. Falcipains belong to the papain family of cysteine 
proteases and share similar sequence identity. 
 
Figure 2-7: Intra-erythrocytic P. falciparum trophozoite highlighting new targets31 
Facipain-1 (FP-1),18 falcipain-2, falcipain-2’ (FP-2 and FP-2’ also known as FP-
2A and FP-2B)19,68 and falcipain-3  (FP-3)20 are all expressed during the erythrocytic 
stage of Plasmodium life cycle (Figure 2-7).69   FP-2 and FP-3 are primarily located in 
the food vacuole and are responsible for the degradation of the host hemoglobin 
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required for sustaining the metabolic needs of a rapidly growing parasite.19 Both 
falcipains are synthesized during the erythrocytic cycle as membrane bound proforms 
that are processed to soluble mature forms. Genetic ablation studies of FP-2 gene has 
underscored the importance of this protease in hemoglobin degradation,70 the prime 
target for discovery of novel antimalarial drugs. FP-2 is also involved in the degradation 
of erythrocyte membrane skeletal proteins, including ankyrin and the band 4.1 protein71 
during the late trophozoite and schizont stages. Falcipains are also involved in the 
conversion of pro-plasmepsins72 into their active forms with the exception of FP-1. 
Thus, studies on developing antimalarial drugs should focus on FP-2 and FP-3. Mature 
FP-2 is a single polypeptide chain of 241 amino acids, synthesized during the 
trophozoite stage as a membrane bound proenzyme comprising 484-amino acid 
residues.19 The crystal structure of the free FP-2, and in complex with cystatin,73 has 
been deposited in the protein data bank. More recently, the crystal structures of FP-2 in 
complex with natural epoxysuccinate E-64 (2-31; Figure 2-8) and FP-3 with aldehyde 
leupeptin has been reported.74  
Peptide based FP-2 inhibitors 
Numerous peptide based falcipain-2 inhibitors that can form covalent bonds 
with the thiol group of cysteine in the catalytic domain have been identified. These 
include vinyl sulfones, ketones and aldehyde based inhibitors. They tend to exhibit high 
antimalarial activity. Due to their limited utility as therapeutic agents, several 
peptidomimetic and non-peptide inhibitors have thus been developed (Figure 2-8, 2-9, 
2-10 and 2-11).  
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The fluoromethyl ketones75 are highly reactive and selective irreversible 
inhibitors of falcipain-2. They show high activity at pico to nanomolar ranges; for 
example, the benzyloxy carbonyl peptide 2-24 is a potent inhibitor of FP-2 at picomolar 
concentration.76 The IC50 values of benzyloxycarbonyl Phe-Arg-CH2F peptide along 
with other effective inhibitors are shown (Figure 2-8). Vinyl sulfones are well known to 
be covalent inhibitors of falcipain-2 which show activity via the irreversible addition of 
the thiol group of active site Cys42 to the electrophilic vinyl sulfone moiety, which 
behaves as Michael acceptor.77 Peptidyl aldehydes and α-ketoamide derivatives inhibit 
falcipain-2 activity at the low nanomolar range.78 The natural product E-64 (2-31) is an 
irreversible inhibitor of papain-like cysteine proteases, which has IC50 values of 0.015 
µM and 0.075 µM toward FP-2 and FP-3, respectively.79 E-64 (2-31) contains a trans 
(2S, 3S) configured epoxide ring80-81 with an amino acid part having the L-
configuration. A cis configuration leads to total loss of inhibition activity. 
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Figure 2-8: Peptide-based inhibitors of falcipain-2 
 
Peptidomimetic FP-2 inhibitors 
The utility of peptide based FP-2 inhibitors as therapeutic agents is limited due 
to their susceptibility to protease degradation and their poor absorption through cell 
membranes. A common strategy to improve pharmacokinetic and pharmacodynamic 
parameters is to adopt peptidedomimetic methodology. The benzodiazepine nucleus is a 
motif to mimic β-turns82-83 and possesses good oral bioavailability as a drug class. 
Novel FP-2 inhibitors have been designed on the 1,4-benzodiazepine scaffold.84 These 
peptidomimetic inhibitors, displayed a significant inhibition of falcipain-2 and 
falcipain-2’. Compound 2-32 was found to be the most active. 
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Figure 2-9: Peptidomimetic inhibitors with 1,4-benzodiazepine scaffold  
The pyridone core of the most potent compound is also recognized as a valuable 
peptidomimetic scaffold85 (Figure 2-10). 
 
Figure 2-10: Peptidomimetics with pyridine ring 
Chalcones,86-88 isoquinoline derivatives89-90 and thiosemicarbozone derivatives91-93 are 
further examples of non-peptidic inhibitors of falcipain-2 (Figure 2-11). 
 
Figure 2-11: Non-peptidic inhibitors of falcipain-2 
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It has been suggested that the simultaneous inhibition of different classes of 
proteases that participate in hemoglobin degradation may result in increasing the 
efficiency and also slow the development of resistance to new antimalarial drugs. A 
synergistic effect has also been observed with the compounds active against both 
cysteine and aspartic proteases.94  
2.4.5 Natural products active against new targets 
Natural products have been and will remain an everlasting source of compounds 
for medicine.95 The most important drugs currently available to treat severe falciparum 
malaria, quinine and artemisinin derivatives, are derived from natural products.95 A 
number of promising lead compounds showing antimalarial activity are being isolated 
from plants, bacteria and fungi. Bielschowskysin, 2-42 a highly oxygenated hexacyclic 
diterpene isolated from the Caribbean gorgonian octocoral Pseudopterogorgia kallos 
shows moderate antimalarial activity.96 The total synthesis of this molecule 2-42 is 
underway in our group. Peptides N1266 (3-1) and N1708 (2-43), showing antimalarial 
activity have also been isolated from Streptomyces and Myxobacterium species by 
MerLion Pharmaceuticals in Singapore. The activities reported are based on whole cell 
assays while that reported for N1266 is against cysteine protease enzyme, falcipain-2. 
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Figure 2-12: New natural products showing antimalarial activity. 
 
2.5 Strategies of peptide synthesis 
Before we move on to the synthesis of the antimalarial natural tetrapeptide, it is 
important to discuss the strategies involved in peptide synthesis. The peptide or amide 
bond is the structural component of peptides and proteins, which plays a major role in 
all biological systems. The amide functionality is also an important feature of other 
biologically active molecules. Peptides can be synthesized either in solid or solution 
phase. Each has its own advantages and disadvantages.  
 
Scheme 2-1: General strategy for peptide bond formation 
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2.5.1 Common protecting group strategies in peptide chemistry 
The successful synthesis of peptides typically requires protecting group 
methodology. Because each amino acid consists of an acid and basic groups, 
polymerization of amino acids is common in reactions they are not protected. Most 
common protection strategies involve benzyloxycarbonyl (Cbz), tert-butoxycarbonyl 
(Boc), 9-fluorenylmethyloxycarbonyl (Fmoc) and N-allyloxycarbonyl (Alloc) 
functionalities. 
 
Figure 2-13: Protecting groups common to peptide synthesis 
2.5.2 Peptide coupling methods and reagents 
  
Figure 2-14: Activation of carboxylic group 
For amide formation, it is necessary to first activate the carboxylic acid by 
converting the hydroxyl group (-OH) into a good leaving group. Carboxylic 
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components can be activated as acyl halides, acyl azides, acylimidazoles, anhydrides, 
and esters (Figure 2-14). A plethora of methods and coupling reagents have been 
developed to achieve amide formation in a chemoselective, mild manner. Figure 2-15 
shows the commonly used reagents for the generation of acyl halides, acyl azides, 
acylimidazoles, and anhydrides. Acid halogenating reagents include cyanuric chloride,97  
2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT),98 and bis(trichloromethyl) carbonate 
(BTC).99 Tetramethyl-α-chloroenamine100 developed by Ghosez et al. enables the 
conversion of carboxylic acids into the corresponding chlorides under strictly neutral 
conditions suitable for acid sensitive substrates. Racemization and side reactions may be 
avoided by the use of acid fluorides.101 Carpino reported 
tetramethylfluoroformamidinium hexafluorophosphate (TFFH), bis(tetramethylene) 
fluoroformamidinium hexafluorophosphate (BTFFH) and 1,3-dimethyl-2-fluoro-4,5-
dihydr-1H-imidazolium hexafluorophosphate (DFIH) as new fluorinating agents 
(Figure 2-15), which act via the in situ generation of amino acid fluorides in peptide 
coupling reactions.102 Diphenylphosphonic azide (DPPA) is a useful reagent to generate 
acyl azides.103 Carbonyl diimidazole (CDI)104 is a useful coupling reagent that allows 
the one-pot formation of amides. Chloroformates such as ethylchloroformate105, 
isobutylchloroformate (IBCF)106 have been used in peptide coupling reactions via 
mixed carbonic anhydride.  
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Figure 2-15: Reagents to convert carboxylic acids to acyl halides, azides and 
acylimidazoles 
In peptide synthesis the most commonly used activating groups are HOBt, p-
nitrophenol (PNP)107 and pentafluorophenol moiety (PFP).108 2,4,5-Trichlorophenol 
derived esters are more reactive than both PNP esters, N-hydroxy-5-norbornene-2,3-
dicarboximide (HONB) esters and N-hydroxysuccinimide (HOSu) esters.109-111 
1-hydroxy-7-azabenzotriazole (HOAt) has been reported to be more effective than 
1-hydroxybenzotriazole (HOBt) in some difficult cases such as coupling with hindered 
substrates. The increased efficiency might be due to additional chelation or neighboring 
effects as provided by the pyridine nitrogen during the amide bond formation.112  
One-pot coupling conditions have been developed for peptide synthesis where 
the active ester is prepared in situ as an intermediate and subsequently reacts with the 
desired amine. Various types of phosphonium, uronium, and immonium type coupling 
reagents have been developed, which have found wide applicability in organic 
synthesis, especially peptide synthesis (Figure 2-16). The special need for rapid and 
highly efficient coupling reagents led to the development of new reagents based on 
HOBt. Gross introduced 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
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hexafluorophosphate (HBTU) as the progenitor of uronium reagents in 1978.113 After 
that, various analogues of HBTU have been prepared and investigated by Knorr.114 
Carpino disclosed the true structure of the active HBTU and its family as the N- 
guanidium rather than the O-uronium salt.115 The structural modification of HBTU 
provided several similar peptide coupling reagents with good activity.116-117 2-(7-Aza-
1H–benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexa fluorophosphate (HATU), the 
aza analogue of HBTU can be considered as today’s gold standard for peptide 
couplings. It has been used for difficult amide bond formation in both solution and solid 
phase synthesis.118 
 
Figure 2-16: Reagents to generate active esters 
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Scheme 2-2: Mechanism using uronium based coupling reagents 
 
2.6 Isolation and biological activity 
Bioassay-guided isolation of an extract from Myxobacterium Y23 strain using 
the falcipain screen at Merlion Pharma led to the isolation of 0.5 mg of a new peptide 
inhibitor N1266. The peptide showed an IC50 of 6 µM against falcipain-2. Selectivity 
studies against PM2, PM2FP (aspartic proteases) and tryptase (serine protease) were 
evaluated, giving IC50 values of ~6 µM against Falcipain, ~50 µM against plasmepsin 2, 
~66 µM against PM2FP and 91 µM against tryptase. 
2.6.1 Aims of the present study 
During a screening campaign by MerLion Pharmaceuticals for inhibitors against 
the Plasmodium falciparum cysteine protease falcipain-2, a natural peptide lead N1266 
(3-1) was identified. The peptide has an m/z of 546.3467 by (-)-ESI that corresponds to 
a molecular formula of C27H45N7O5. Examination of the NMR indicated that the 
compound consists of histidine, isoleucine, valine, proline and an isovaleric acid unit. 
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The peptide was sequenced at Merlion Pharma by MS/MS, which unambiguously 
determined proline to be the terminal amino acid unit. In addition, the mass of the 
remaining fragments were in accordance with the proposed gross structure (Figure 2-
17). As the natural product could not be obtained from the natural source in appreciable 
quantity, our aim was to synthesize the natural product and identify its stereochemistry. 
If active, synthetic analogues would be developed by structural modifications on the 
peptide unit or incorporation of peptidomimetic units. A fluorescent-tagged probe of the 
tetrapeptide could also be synthesized to help in target validation studies. 
 





Chapter-3: Total Synthesis of a Natural Antimalarial Tetrapeptide 
3.1 First and second generation approaches 
As the stereochemistry of the natural tetrapeptide N1266 was unknown, we initially 
targeted the all L-amino acid version of proline, valine, isoleucine and histidine (Figure 
3-1). Our initial plan was to apply a linear synthetic strategy using Boc chemistry 
starting from L-isoleucine to target tetrapeptide (Scheme 3-2). Our initial synthetic 
approach utilized the mixed anhydride method using chloroformates (ethyl/isobutyl 
chloroformate) to form the tripeptide 3-7, and then coupling agents would be used to 
prepare the target compound 3-1.   
 
Figure 3-1: Structure and components of the natural antimalarial peptide, N1266 (3-1) 
isolated at MerLion Pharma. 
3.1.1 First generation synthesis of tetrapeptide 
The N-terminal of L-isoleucine was initially protected by the tert-
butoxycarbonyl group (Boc) under standard conditions using di-tert-butyldicarbonate 
(Scheme 3-2). Dipeptide 3-4 was prepared via formation of the mixed anhydride 
method of chloroformate. In this method, the carboxyl and the amino groups of valine 
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were protected by the trimethylsilyl group (TMS).119 The TMS group serves both to 
temporarily protect the carboxyl group and to generate an activated amino group. The 
bis-TMS valine 3-3 was generated in situ by treatment with trimethylsilyl chloride and 
triethylamine. The α-amino protected, N-Boc-isoleucine 3-2 was first converted into its 
activated anhydride by using isobutylchloroformate and N-methylmorpholine; however, 
this did not provide satisfactory yields in our hands. Better yields were obtained by 
employing ethylchloroformate and N-methylmorpholine. The bis-TMS valine 3-3 
generated in situ was then added to the activated anhydride of N-Boc-isoleucine 3-2 to 
give the dipeptide 3-3. The unreacted N-Boc-isoleucine was recovered. 
 
Scheme 3-1: Synthesis of tripeptide 3-7 
There were difficulties in separating compounds 3-4 and 3-2 by column 
chromatography due to the presence of polar carboxyl groups. Under similar conditions, 
we prepared the tripeptide 3-6. The anhydride of dipeptide 3-4 was thus reacted with the 
bis-TMS proline 3-5 generated in situ. This reaction did not go to completion. Attempts 
to obtain the pure tripeptide 3-6 by column chromatography were complicated due to 
co-elution of compound 3-4 with polar side products and unreacted starting materials. 
The mixture was thus used crude for the next step. The carboxyl group of the tripeptide 
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3-5 was converted into its amide using a similar protocol. After generating the mixed 
anhydride of 3-6, aqueous NH3 was added to give tripeptide 3-7.  
 
Scheme 3-2: Synthesis of all L-configured tetrapeptide 3-10 from tripeptide 3-7 
The Boc group of tripeptide 3-7 was then cleaved using trifluoroacetic acid 
(TFA) and then coupled to Boc-His (Trt)-OH 3-8 using the peptide coupling agent 2-(7-
aza-1H–benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) 
in the presence of 1-hydroxy-7-azabenzotriazole (HOAt) and diisopropyl ethylamine 
(DIPEA) to give the tetrapeptide 3-9 (Scheme 3-2).120 Completion of the synthesis of 
the target peptide was achieved by TFA facilitated removal of the tert-butyloxycarbonyl 
(Boc) and trityl groups in 3-9 and coupling with isovaleric acid using HATU/HOAt. 
Concomitant cleavage of the trityl group under these conditions led to side reactions 
giving a poor yield of the final tetrapeptide 3-10. The overall yield for this synthesis 
was 2% over 6 steps.  
3.1.2 Second generation synthesis of tetrapeptide 
In order to improve the synthesis and practical difficulties associated with 
purification, we devised another approach where the N-Boc-proline 3-11 would first be 
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converted to amide121 3-12 and then coupled to the dipeptide 3-4 to give the tripeptide 
3-7 (Scheme 3-3). The tripeptide 3-7 was then coupled to Fmoc-His(Trt)-OH 3-13 to 
generate the Fmoc-tetrapeptide, 3-14. The Fmoc group was removed from tetrapeptide 
3-14 using piperidine to give the free amine122 3-15, which was then coupled to 
isovaleric acid to afford the tetrapeptide 3-16. Employing diethylamine for the Fmoc 
removal took more than 12 hours for the reaction to complete, whereas the reaction 
completed in 30 minutes using piperidine. Coupling with isovaleric acid followed by 
the removal of the trityl group of compound 3-16 with TFA in the presence of 
triisopropylsilane gave the target tetrapeptide 3-10 in good yield.123 The overall yield 
for this scheme was 10% over 6 steps.  
 
Scheme 3-3: Second generation synthesis of tetrapeptide 3-10 
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3.2 Convergent approach to the synthesis of tetrapeptide 
To optimize our approach further, we adopted a convergent strategy to obtain 
the target tetrapeptide 3-10 and proposed to couple fragments 3-7 and 3-19.  
 
Fragment 3-16 was prepared by coupling His (Trt)-OH with isovaleric acid 3-20 using 
the mixed anhydride protocol. The carboxyl group of isovaleric acid was converted to 
the activated anhydride of ethylchloroformate 3-21 and then treated with the bis-TMS 
of His (Trt)-OH 3-18 to give fragment 3-19 (Scheme 3-4). Fragment 3-7 was prepared 
according to the method described in Scheme 3-3. 
 
Scheme 3-4: Convergent synthesis of 3-10 by coupling fragments 3-6 and 3-19 
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The Boc-group of tripeptide 3-7 was removed using trifluoroacetic acid (TFA) and 
coupled to fragment 3-19 using the HATU/HOAt to obtain the tetrapeptide compound 
3-16. The trityl group of 3-15 was cleaved using TFA to form the target tetrapeptide 3-
10 (Scheme 3-4). This convergent approach gave an overall yield of 24%. Although, 
the molecular weight and MS-MS fragmentation patterns of the synthetic tetrapeptide 3-
10 matched that of 3-1, the NMR spectra did not correlate with the natural peptide, 








Figure 3-2: NMR comparison of (a) synthetic tetrapeptide (3-10) and (b) natural 
product N1266. 
HPLC analysis also showed different retention times on co-elution of the synthetic and 
natural materials (Figure 3-3). These findings suggest that the structural differences 
between the synthetic and the natural peptide residues in the stereochemistry of the 
constituent amino acids. Theoretically, we could synthesize 25 compounds and compare 




Figure 3-3: Co-HPLC injection of natural peptide N1266 and synthetic 3-10 
This would be an arduous task. When we compared the NMR spectra of the synthetic 
with that of natural one, we found suspected differences in the splitting pattern of 
isoleucine signals, which overlapped with the signals from valine and isovaleric acid. 
The δ methyl signals of isoleucine of natural product N1266 and synthetic 3-10 were 
found to be at 0.70 and 0.81 ppm and the γ methylene protons of isoleucine were found 
to be δ 1.23 ppm in the natural product and at δ 1.03 and 1.39 ppm in synthetic 3-10. 
We thus decided to synthesize the peptide using the allo isomer of isoleucine. Using our 
preferred convergent approach, tripeptide 3-22 was synthesized using D-allo-isoleucine 
and then coupled to the histidine fragment 3-19 (Scheme 3-5). The NMR spectrum of 
this synthetic peptide 3-27 also did not match that of the natural product N1266.  
Scheme 3-5: Synthesis of tetrapeptide 3-27 using D-alloisoleucine 













Synthetic peptide (3-10) Natural peptide, N1266  
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3.3 Determination of stereochemistry of the tetrapeptide, N1266 
In order to determine the amino acid configurations, we proposed to hydrolyze 
and compare the amino acids of the natural peptide with known amino acid derivatives. 
To this end, we had to be certain of our strategy, especially since only 0.3 mg of the 
natural material was available. Both direct and indirect methods have been reported in 
the literature for the analysis and determination of absolute configuration of amino 
acids. Direct methods require no chemical derivatization prior to the separation process. 
For example, ligand-exchange chromatography (LEC) employs chiral stationary phases 
(CSP) and chiral selector additives for the mobile phase. For a clear amino acid 
determination, the use of a chiral stationary phase in GC requires achiral derivatizations 
to produce appropriately volatile analytes. Possible thermal degradation, racemization 
and enantiomer selectivity bias have been the main weaknesses of this approach. Direct 
approaches are also complicated chromatographically. 
Indirect methods employing chiral derivatizing agents and subsequent HPLC 
analyses are standard for the determination of the absolute configuration or 
enantiomeric purities of amino acids. Such an indirect approach requires pre-column 
derivatization to produce a greater resolution (Rs) and separation factor (α) over most 
direct methods. Marfey et al. first reported the use of an ortho-fluoro nitro-aromatic 
reagent for derivatization of amino acids in enantiomeric purity analysis in 1984.124-125 
Marfey’s reagent or 1-fluoro-2-4-dinitrophenyl-5-L-alanine amide (FDAA) 3-28 has a 
chiral center in its L-form of alanine group. FDAA derivatives of D-amino acids tend to 
exhibit stronger intramolecular bonding, which reduces their polarity relative to the 
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corresponding L-amino acid derivatives. Consequently, the D-derivatives are selectively 
retained on reverse phase columns and elute after their corresponding L-derivatives. 
 
  Marfey’s reagent 
Marfey’s reagent typically reacts within 1 hour under alkaline conditions by 
nucleophilic substitution of the aromatic fluorine. This produces diastereomers that can 
be separated and evaluated (in the nanomolar range) by reverse-phase HPLC due to the 
added chromophoric unit. Generally, the derivatized L-amino acids elute before their 
respective D-diastereomer, with the exception of histidine. These derivatives can be 
detected by simple UV and by mass spectrometry simultaneously. 
Keeping this in mind and our scarce availability of the natural material, we 
adopted Marfey’s method for the determination of the absolute stereochemistry of the 
natural product. To this end, we gathered genuine samples of all possible L and D amino 
acids present in the natural peptide (isoleucine, valine, proline and histidine). These 
amino acids were then derivatized with Marfey’s reagent and analyzed by reverse phase 
HPLC-MS. All the L and D diastereomers of the amino acids separated distinctly under 
a linear gradient elution of acetonitrile/water. As expected, the L-diastereomers of 
isoleucine, valine, and proline eluted first, compared to their D-diastereomers, with the 





Figure 3-4: LC-MS profile of a standard mixture of L and D amino acids 
After LC-MS analysis was optimized, we decided to optimize the hydrolysis conditions 
for the synthetic peptide 3-10 (all L-configured) due to the limited amounts of the 
natural peptide N1266 (~0.3 mg). Conventional hydrolysis of the synthetic peptide by 
refluxing in 6N HCl for 24 hours under argon followed by derivatization with Marfey’s 
reagent was successful on a 1 mg scale. Here, we achieved a clear separation of all the 
constituent amino acids on the LC-MS chromatogram (Figure 3-5a). When we reduced 
the scale to 0.3 mg, the method was not reproducible. The chromatogram was not clear 
and showed several partially hydrolyzed fragments along with impurities. We then 
decided to perform peptide hydrolysis under microwave conditions126-127 (Table 3-1). 
The component amino acids of the synthetic peptide were clearly detected at 170 
oC for 20 min of microwave irradiation (Entry 7, Table 3-1, Figure 3-5a). The 
conditions showed good enough reproducibility for us to use our natural peptide sample 
N1266. Exposure of 0.2 mg of the natural peptide to 0.2 ml 6N HCl at 170 oC for 20 
min and the direct derivatization with Marfey’s reagent gave the HPLC-MS 
chromatogram as shown in Figure 3-5b. On analysis, we observed that the natural 


































sample differed with the synthetic sample in the retention time of histidine. On co-
injection of the natural material with that of synthetic one, we found all the peaks 
merged except that of L-histidine (Figure 3-5c). 
Entry Scale (mg) Conditions Remarks 
1 0.3 0.3 mL 6N HCl, 110 oC, 20 min  
2 0.3    0.2 mL 6N HCl, 160 oC, 4 min  
3 0.3    0.2 mL 6N HCl, 160 oC, 8 min  No trace of amino acids on derivatization 
4 0.3    0.3 mL 6N HCl, 170 oC, 4 min  
5 0.3 0.3 mL 6N HCl, 170 oC, 10 min  
6 0.3 0.3 mL 6N HCl, 170 oC, 20 min Component amino acids detected. 
7 0.2 0.2 mL 6N HCl, 170 oC, 20 min Amino acids detected 
Table 3-1: Optimization of MW conditions for the hydrolysis of tetrapeptide 3-10 
Figure 3-5: (a) LC-MS profile of a synthetic all L-version 3-10 (b) LC-MS profile of 
the natural peptide N1266 (c) Co-elution of both the synthetic 3-1 and natural N1266. 
 
 





















































































3.4 Synthesis of the natural antimalarial peptide N1266 
Based on this analysis, L-histidine should be replaced by the D-isomer. We thus 
synthesized the peptide according to our protocol discussed in the previous section by 
replacing L-histidine with that of D-histidine (Scheme 3-6).  
 
Scheme 3-6: Total synthesis of tetrapeptide N1266 (3-1) using D-histidine 
HPLC co-injection of the synthetic material 3-1 with that of the natural peptide N1266 
showed a single peak corresponding to a molecular weight of 548. NMR and HPLC co-
injection data were identical to that of the natural product confirming the structure and 
















Figure 3-6: NMR comparison of (a) synthetic 3-1 and (b) natural product, N1266 and 
(c) HPLC co-injection of natural N1266 and synthetic peptide 3-1. 

















Chapter-4: Synthesis and Biological Evaluation of N1266 Analogues  
4.1 Background  
The synthetic peptide 3-10 showed moderate activity at 1.2 µM against the P. 
falciparum 3D7 strain. With the aim of achieving better antimalarial activity, we 
synthesized various analogues of this antimalarial agent. Our synthesis of analogues 
was based on three key modifications. (i) by deleting a particular amino acid of the 
parent peptide; (ii) by replacing the isovaleric acid unit with alternative hydrogen bond 
acceptors and donors; and (iii) by replacing histidine with a triple bond analogue to 
enable diversification to a set of triazole analogues via ‘click-type’ chemistry.128  
4.2 Synthesis of N1266 analogues 
We have initially synthesized analogue 4-2 lacking a proline unit and the 
analogue 4-3 lacking a histidine unit. The synthesis adopted our general coupling 






















i) TFA , CH2Cl2














54 %3-4 4-1 4-2
3-19  
Scheme 4-1: Synthesis of analogue 4-2 (lacking proline) 
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Scheme 4-2: Synthesis of analogue 4-3 (lacking histidine) 
 
Analogues with structural modification to the isovaleric acid portion (Figure 4-1) were 
then targeted. Since α-keto derivatives60 have been shown to bind to falcipain enhancing 
antimalarial activity, we decided to synthesize analogues 4-5 and 4-9, by coupling the 
tetrapeptide with pyruvic acid and Boc-indole-3-glyoxylic acid 4-7 (Schemes 4-3 and 
4-4).  Indole-3-glyoxylic acid 4-6 was Boc-N-protected followed by coupling to the 
tetrapeptide unit 3-15 under HATU conditions. Analogue 4-5 could not be isolated in 
our hands and analogue 4-9 was isolated in pure form after removing the trityl and Boc 
groups by using TFA.  
 




































R= Trt  
Scheme 4-3: Synthesis of pyruvate analogue 4-5  
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Scheme 4-4: Synthesis of indole-3-glyoxyl analogue 4-9. 
Incorporation of a trifluoromethyl group into peptide and protein structures is 
emerging as an attractive strategy for improving biological activity and modifying 
physicochemical properties.129-130 We synthesized an analogue with a trifluoromethyl 
moiety 4-12 by coupling the tetrapeptide with α-trifluoromethyl, α-methoxy phenyl 
acetic acid 4-10 (Scheme 4-5).  To determine the effect of introducing hydrogen-bond 
donors, we synthesized analogues 4-14 and 4-17 possessing α-hydroxyl groups adjacent 
to the terminal amide (Scheme 4-5 and 4-6). 
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Scheme 4-5: Synthesis of α-trifluoromethyl, α-methoxyphenylacetyl analogue 4-12 and 
α-hydroxy-2-methylpropanyl analogue 4-14 
It has also been reported that hydrogen-bond donors enhance the efficiency 
towards aspartic proteases and may produce synergistic effect along with falcipain 
activity. Although the analogues 4-5 and 4-14 could not be isolated after removal of the 
trityl group by column chromatography, the trityl precursors 4-4 and 4-13, as well as the 
indole-3-glyoxyl analogue 4-9, α-trifluoromethyl derivative 4-12 and mandelic acid 









































Scheme 4-6: Synthesis of mandelic derivative 4-17 
 Griffith et al. have reported 2-methoxy cinnamic acid131 as an antimalarial 
pharmacophore. We thus decided to target analogue 4-20 with a histidine-cinnamic acid 
unit. The tripeptide 3-16 was thus coupled to the pre-synthesized histidine fragment 
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Scheme 4-7: Synthesis of cinnamic acid analogue 4-20 
4.3 Histidine surrogates via click chemistry 
1,2,3-Triazoles are an important class of heterocycles that have been 
incorporated into various therapeutic agents. These heterocycles are generally prepared 
by the 1,3-dipopar cycloaddition of azides and alkynes (so called ‘click chemistry’).132 
Towards this end, we planned to replace histidine with a 1,2,3-triazole moiety. To 
introduce this moiety we have developed the alkyne analogue 4-24 of the peptide by 
coupling the tripeptide to Fmoc-propargyl glycine 4-21 to give the tetrapeptide 4-22. 
Fmoc removal of compound 4-22 gave the free amine compound 4-23, which on 
coupling to isovaleric acid gave the alkyne analogue 4-24 (Scheme 4-8).  
 69
 
Scheme 4-8: Synthesis of alkyne analogue 4-24 
 We then tested various click conditions using CuI on this peptide to form 1,2,3-
triazole analogue. Selected preliminary results are shown (Scheme 4-9). No products 
have been isolated due to the small scales employed (ca. 1 mg scales of 4-24) and 
amount of time remaining. Further work is required to expand this study. 
 
Scheme 4-9: Synthesis of click-based D-histidine surrogates. 
4.4 Synthesis of a coumarin-tagged tetrapeptide probe 
Fluorescent molecules provide important tools for the observation of molecular 
pathways once a molecule enters a cell. We decided to tag our antimalarial peptide lead 
at the carboxyl position of the proline, so as to maintain the amide functionality similar 
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to that of the parent peptide. Dimethylaminocoumarin-4-acetic acid (DACA)133 4-31 
was chosen as the fluorescent tag based on its lack of biological activity, water 
solubility, small size, availability, photostability and photophysical properties (λex = 370 
nm, ε = 22 000 M-1 cm-1, λem = 459 nm, Φ = 0.1-0.4). By further possessing 
immunoaffinity-fluorescent (IAF) properties, one additional facet of this fluorophore is 
that it allows biomolecule (typically protein) identification and isolation by co-
immunoprecipitation with its own specific antibody partner. We synthesized the 
coumarin according to the reported procedure,133 and attached the mono Boc-
ethylenediamine 4-32 as a linker portion to 4-31 (Scheme 4-11). 
 
Scheme 4-10: Synthesis of coumarin with linker 
The Boc-group of the coumarin tag 4-33 was cleaved using TFA and coupled to the free 
carboxylic group of Boc-proline 3-11 to give compound 4-34. Compound 4-34 was 
converted to the labeled peptide probe 4-37 by following our optimized coupling 
procedures (Scheme 4-11).  
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Scheme 4-11: Synthesis of coumarin-tagged tetrapeptide probe 4-37 
4.5 Biological evaluation of N1266 analogues 
The natural peptide N1266 and its synthetic analogues have all been tested for 
their antimalarial activity against the 3D7 drug sensitive strain of P. falciparum at the 
Department of Microbiolgy under the direction of Dr Kevin Tan. The drug assay was 
performed based on a previously described technique.134 The effects of the synthesized 
compounds on live cultures of P. falciparum were determined by treating parasites with 
the selected compounds at 10h after invasion (ring stage). Parasites were grown to 2% 
parasitemia after synchronization. Cultures were treated with serial dilutions of each 
compound diluted in DMSO for a final concentration of 0.5% DMSO and were 
harvested after 48 h of treatment. The new parasitemia after reinvasion was measured 
by flow cytometry, using Hoechst as a DNA stain. Synchronous 0.5% DMSO-treated 
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cultures and chloroquine treated cultures were used as controls. The results from the 
two sets of dilutions from the malarial assays were then combined into a single graph. 
The curve of the graph was fitted using a 3 variable sigmoidal curve and the IC50 values 
were derived from that curve.  
Table 4-1 shows the IC50 values of the peptide based inhibitor 3-1 along with 
other analogues. The data reveals that compounds possessing a free imidazole NH 
proton displayed lesser activity, as compared to ones N-protected with a trityl group. 
While it is conceivable that the trityl groups may be hydrolyzed under acidic cytosolic 
conditions, this disparity in activity may reflect the greater permeability of trityl 
analogues through plasma membranes and not structure-function activities per se. The 
analogue with the CF3 group showed the best activity at 136 nM. 
4.6 Conclusion 
Through total synthesis, we confirmed the structure of the naturally scarce peptide 
inhibitor N1266 as 3-1 and produced quantities (60 mg) beyond those achieved through 
the fermentation of Myxobacterium species. A diverted total synthesis campaign then 
led to the development of the trifluoromethyl analogue 4-11 that showed an IC50 (Pf) 
activity of 136 nm. Possibly through peptidomimetic modifications, these compounds 
represent potential antimalarial drug leads. Falcipain-2 target validation studies are 
ongoing with the peptide-probe 4-37. 
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Table 4-1: IC50 values of antimalarial peptides against P. falciparum (3D7). 
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Chapter 5: Design and Synthesis of Chloroquine Probes 
5.1 Background 
Before the emergence of drug resistance in the 1960s, chloroquine (CQ, 5-1) 
was a life-saving tool in the control of malaria due to its efficacy, low toxicity and 
affordability. It was effective in preventing and treating the disease with minimal side 
effects.135-136 The degradation pathway of hemoglobin in the parasitic food vacuole has 
been described in Chapter 2. It is believed that CQ interferes with heme detoxification 
by binding to heme (ferriprotoporphyrin, Fe(III)FPIX) released inside Plasmodium-
infected erythrocytes during hemoglobin digestion.137-138 A drug-hematin complex is 
thus formed, impairing hematin sequestration and destruction, leading to the build up of 
toxic hematin, thereby resulting in parasitic death.  
 
The misuse of the drug has given rise to resistant strains, which have since 
proliferated across the globe.139 Today, only artemisinin-based drug combinations140 
can effectively combat all parasitic forms of the disease. However, recent reports 
indicate that Plasmodium species are even developing resistance to artemisinins.141 We 
still do not fully understand the mode of action and the mechanism of resistance to most 
antimalarial agents. Even the detailed molecular basis for chloroquine resistance is not 
fully elucidated. In particular, the biomolecular mechanisms of drug-resistance between 
differing strains of Plasmodium parasites and differing types of antimalarial agents are 
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poorly understood.142 The growing widespread resistance to current drugs is thus 
prompting the development of new antimalarial agents that have new biological targets. 
While identification of new drug targets could facilitate the development of 
effective antimalarials, new targets can be difficult to identify. We reasoned that the 
determination of cellular accumulation of antimalarials such as chloroquine could help 
understand drug action and may lead to the identification of new targets. Furthermore, a 
means to rapidly identify drug resistance in the field could lead to a more accurate 
diagnosis and the administration of an appropriate chemotherapy. Therefore, a need 
exists to develop methods to examine the interaction of antimalarials within the 
Plasmodium parasite in order to elucidate new pathways that can be exploited for the 
successful treatment of malaria. In collaboration with the group of Dr. Kevin Tan at 
NUS Microbiology, we decided to tackle this need in the preliminary context of 
studying programmed cell death (PCD) in P. falciparum. 
The existence of PCD features in unicellular organisms including Blastocystis, 
Leishmania, trypanosomes, Saccharomyces cerevisiae and Trichomonas vaginalis143 
have been reported in the literature. Indeed, accounts of PCD in P. falciparum144 and 
the rodent malaria parasite P. berghei145 are featured by the fragmentation of DNA and 
a loss of mitochondrial potential. However, other reports suggest that P. falciparum 
does not undergo PCD.146-147 Identifying PCD modulators in P. falciparum may thus 
lead to new chemotherapeutic directions. We chose to use chloroquine for this purpose 




Cancer Clinical Trials Phase 
Glioblasto mamultiforme III 
Breast cancer I, II 
Lung cancer I, II 
Prostate cancer II 
Non-Small Cell lung cancer I, II 
Cancer I 
Unspecified adult solid  tumor I 
Brain and central nervous system 
tumour I, II 
Multiple myeloma and plasma cell 
neoplasm I, II 
 
Table 5-1: CQ and its analogues in cancer therapy 
 
Bacteria Fungi Viruses 
Coxiella burnetii Histoplasma capsulatum HIV 
Bacillus anthracis Cryptococcus neoformans SARS-CoV 
Legionella pneumophila Penicillium marneffei Influenza viruses 
Mycobacterium 
tuberculosis Aspergillus fumigatus HAV 
Salmonella Typhi  HBV 
Staphylococcus aureus  HCV 
Tropheryma whipplei  Herpes simplex viruses 
 
Table 5-2: CQ and its analogues active against bacteria, fungi and viruses 
 
 CQ and its analogues have also shown promise as effective and safe sensitizers 
in several cancer clinical trials (Table 5-1),148 as well as an ability to inhibit the growth 
of several bacteria, viruses and fungi (Table 5-2).149 Synthesis of a fluorescent tagged 
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CQ-analogue may thus reveal their modes of action. These activities are presumed to 
result from the inherent lysosomotrophic property of CQ appears to increase efficacy 
and specificity of the chemotherapeutic treatment. 
5.2 Design of coumarin-tagged chloroquine probes 
 
In light of these observations, we decided to design new fluorescent-tagged 
antimalarials to help study the disease and identify new targets in collaboration with Dr. 
Kevin Tan. We first targeted to make a chloroquine probe to image the accumulation of 
the antimalarial within malaria infected red blood cells (RBC). Such a fluorophore-
tagged chloroquine analogue could then be used to image live cells to locate the 
antimalarial within or around the cell, screen and understand drug resistance. Further, it 
may help to identify growth-related pathways and new drug targets in Plasmodium 
species. In particular, the localization of the labeled drug may be predicted to be 
different between sensitive and resistant strains because CQ-resistant strains are 
expected to pump out the labeled CQ probe. We thus first targeted to design and 
synthesize coumarin-chloroquine probes (CM-CQ) that may distinguish between CQ-



































5-17, n=2  
Figure 5-1: Initial design of fluorescent-tagged chloroquine analogues 
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7-Dimethylaminocoumarin-4-acetic acid (DMAC) 4-31 as fluorescent tag for 
protein and antibody labeling has been reported by our group.150 DMAC 4-31 was again 
chosen as a valid tag due to its desirable photophysical properties for confocal work, 
lack of biological (cytotoxic) activity, small-size and water solubility. The coumarin 
fluorophore, being an immunoaffinity fluorescent (IAF) tag would also allow the 
possibility of biomolecules to be identified through co-immunopreciptation (co-IP) 
studies.151 
Apart from the 7-chloro-4-amino quinoline pharmacophore that defines binding 
to free heme,152 structure-function studies for quinoline antimalarial drug design suggest 
that the terminal tertiary amino group and basicity of the quinolyl nitrogen to be the key 
elements responsible for potent antimalarial activity.153 Our aim was therefore to 
develop fluorescent probes of chloroquine without disturbing these functionalities. 
Varying the aliphatic side chain of CQ has also been shown to alter activity against 
Plasmodium strains (especially towards CQ resistant strains).  
We initially designed the fluorescent probes of chloroquine analogues by linking 
the coumarin to chloroquine with amide linker portion. Here, the coumarin fluorophore 
would be attached at the ethyl group termini of CQ as studies have shown that extension 
at this position would not alter the pKa essential for parasitic vacuolar localization.154 
We also designed probes without any linker portion so as to study subtle alterations and 
to provide clues of important structure-function properties. Omission of the methyl 
group in our CQ-probes was expected to present no major alteration in antimalarial 
activity (as compared to the parent drug, CQ). 
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5.3 Synthesis of coumarin-tagged chloroquine probes 
The coumarin carboxylic acid derivative 5-3 (an immunoaffinityfluorescent 
label, IAF) was prepared by the Von Pechmann reaction by mixing freshly purified m-
dimethylaminophenol and diethyl 1,3- acetonedicarboxylate with zinc chloride in 
anhydrous ethanol,155 refluxing the mixture for 15 h and then hydrolyzing with lithium 
hydroxide provided the carboxylic acid 3 (Scheme 4-10). N-Boc removal with TFA of 
tert-butyl 2-(2-bromoacetamido)ethyl carbamate 5-2 followed by coupling to 5-3 gave 
the coumarin linked derivative 5-4. The bromoacetamide 5-2 was prepared by HATU 
coupling of N-Boc-ethylene diamine with bromoacetic acid (Scheme 5-1).  
 
Scheme 5-1: Synthesis of coumarin fluorophore with α-bromo linker 5-4. 
 
Fluorescent analogues were prepared in two steps from 4,7-dichloroquinoline 5-
5 and the diamines 5-6 or 5-7153 by heating at 110 oC for 6 h and then amidation with 
the coumarin carboxylic acid derivative 5-3 (Scheme 5-2). It is important to note that 
these amide analogues were designed to neutralize the basicity of the tertiary free amine 




Scheme 5-2: Synthesis of coumarin-tagged chloroquines (directly amide coupled) 
 
Mono-desethyl analogues of chloroquine 5-12 and 5-13 were synthesized by 
alkylation in the presence of ethyl bromide and cesium carbonate (Scheme 5-3).153 N-
alkylation of monodesethyl analogues of chloroquine 5-12, 5-13 with coumarin-bromo 
derivative 5-4 in the presence of potassium carbonate156 gave the fluorescent probes 5-
16 and 5-17 (Scheme 5-3). 
 
 
Scheme 5-3: Synthesis of coumarin-tagged chloroquines with acetamide linkers 
 
As these analogues 5-16 and 5-17 showed 5 to 10-fold less activity compared to 
CQ, we thus synthesized another analogue 5-21 with an extended alkyl chain. N-Fmoc-
propanal 5-18 was synthesized from N-Fmoc-proponol 5-19 following the reported 
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procedure in 55% yield. Reductive amination of N-Fmoc-propanal 5-19 with the 
monodesethyl analogue of chloroquine derivative 5-12 using sodium 
triacetoxyborohydride157 gave carbamate 5-20 in 80% yield. The Fmoc group of 5-20 
was removed using piperidine to give the primary amine. The primary amine was then 
coupled to the coumarin acetic acid derivative 5-3 to give the chloroquine analogue 
5-21 in 65% yield over 2 steps (Scheme 5-4). 
 
Scheme 5-4: Synthesis of coumarin-tagged chloroquine 5-21. 
5.4 Biology of coumarin-tagged chloroquine probes 
To ascertain the antimalarial efficiency of the CM-CQ probes, the β-hematin 
assay was assessed and IC50 values were measured. The CM-CQ probes 5-17 and 5-21 
showed a clear inhibition of β-hematin formation as characterized by reduction in the 
Soret absorption band of hematin at 400 nm (Figure 5-2). The activity of chloroquine 
was thus retained in these CM-CQ analogues by binding to hematin. However, 
analogues 5-10 and 5-11 did not show any reduction in the Soret absorption indicating 
the importance of the tertiary free amine functionality for hematin binding. The IC50 
values of CQ and CM-CQ analogues are listed in Table 5-1. The CM-CQ analogues 5-
16 and 5-21 show promise for future development. 
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Figure 5-2: Spectra of heme with CQ, CM-CQ at pH 5.5 (A) absorbance of heme at 0 
(control), 10, and 32 μM of CQ diphosphate (B) absorbance of heme at 0, 10, and 32 
μM of CQ analogue 5-15 (C) & (D) absorbance of CM-CQ 5-17, 5-21 analogues at 0, 
10 and 32 μM  
 
The directly amide-linked coumarin analogues 5-10 and 5-11 showed poor IC50 
values, presumably due to the absence of the tertiary free amine functionality that is 
important to CQ activity.  The IC50 of the fluorescent probe CM-CQ (5-17) was found 
to be 10-fold less compared to commercial chloroquine (5-1). The CM-CQ probe 5-17 
showed similar activity to that of commercial CQ. Our collaborator Dr. Kevin Tan 
further demonstrated that CM-CQ (5-17) behaves like CQ. They found 5-16 to induce 
mitochondria outer membrane permeabilization (MOMP) with ten-fold less 
efficiency.158 The similarity in the activities of CQ and CM-CQ (5-17) analogues also 


























































Plasmodium species. Confocal bioimaging assays were carried out with P. falciparum-
infected red blood cells (RBCs) exposed to increasing concentration of the CM-CQ 
probe 5-17. The drug was shown to accumulate in different cellular compartments 
depending on the concentration of 5-17 administered. Figure 5-3 shows the localization 
of 5-17 in the parasite food vacuole is similar to that of chloroquine. 
 
Compound IC50 (µM) (Plasmodium 3D7) 





0.13, 3.2 0.012, 0.018 
 
0.037, 0.200 0.013, 0.012 








Table 5-1: IC50 values of CQ and CM-CQ analogues 
 
JC-1 and CaspaTag assays were also performed by Kevin Tan’s group to 
investigate programmed cell death (PCD) features at different concentrations of CQ. 
JC-1 is a lipophilic cation probe, normally with green fluorescence. At a high 
transmembrane potential of functional mitochondria, it aggregates to emit an orange-red 
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fluorescence. At low nanomolar concentrations, basal levels of PCD features were 
observed; at micromolar concentrations of CM-CQ (5-16), there was a large increase in 
the proportion of cells displaying mitochondria outer membrane permeabilization 
(MOMP) and activation of caspase-like proteases. Confocal microscopy was then 
employed to assay for concentration-dependent differences in the cellular localization of 









Figure 5-3: Confocal images of a malaria-infected blood cell showing accumulation of 
the blue fluorescent drug 5-16 accumulating in the parasite food vacuole (blue) that is 
located within the parasite cytoplasm (green) and next to the parasite mitochondria 
(red). 
  
Figure 5-3 show the observation that 5-17 accumulated in the hemazoin 
containing food vacuole at nanomolar concentrations, which is in agreement with 
conventionally accepted mechanism of CQ antimalarial activity.158 At micromolar 
concentrations, however, the labeled drug accumulated non-specifically throughout the 
parasite's cytoplasm. Accumulation of 5-17 within the parasite is non-specific at 
concentrations exceeding 3 μM and localizes throughout the parasite’s cytoplasm. At 
these concentrations, 5-17 also induced MOMP resulting in mitochondria that were not 
clearly defined. Thus, the fluorescent-labeled analogue of chloroquine 5-16, showed a 
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shift in localization from the food vacuole at nanomolar concentrations to the cytoplasm 
of the parasite at micromolar concentrations. This suggests that the PCD features 
observed are brought about by CQ accumulation and by the subsequent activation of 
PCD mediators in the cytoplasm. 
To assess the usefulness of CM-CQ probes in differentiating between CQ 
sensitive and resistant strains, the ratio of CM-CQ (5-17) positive erythrocytes after 8 
hrs of incubation and Hoechst-positive erythrocytes were investigated; DNA-binding 
stains like Hoechst and DAPI provide an accurate determination of the percentage of 
parasitized erythrocytes. As such, the ratio of CM-CQ versus DNA staining should 
clearly indicate the proportion of parasites that are CM-CQ (5-17) positive. As shown in 
Figure 5-4 the proportion of CM-CQ-positive parasites was evidently different between 
the CQ-sensitive (3D7) and CQ-resistant (7G8 and K1) strains of P. falciparum (even at 
3 and 6 µM of 5-17). This suggests that CM-CQ is able to distinguish between CQ 
sensitive and resistance strains without the need for tedious genetic analysis or lengthy 
IC50 determination. 




























Figure 5-4: Flow cytometric analysis of CM-CQ (5-17) sensitive (3D7) and resistant 
(7G8, K1) P. falciparum strains.  
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5.5 Conclusion 
In conclusion, CM-CQ probes like 5-17, 5-16 and 5-21 are anticipated to have 
utility in the elucidation of drug-resistance and growth-related pathways, as well as to 
advance and highlight the differences between differing plasmodium species and related 
parasitic diseases. The use of a novel fluorophore-linked chloroquine 5-17 revealed that 
the differences in PCD features at low versus high CQ doses were associated with 
differential localization of the CM-CQ probe 5-17 at varying concentrations.159 CM-CQ 
probes like 5-16 and 5-21 also have a potential beyond malaria as reports suggest that 
chloroquine is also effective in treating other diseases, such as HIV, cancer, influenza 
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                           Experimental: Chapter 1 
General experimental procedures: Solvents were purified according to standard 
procedures, and reagents used were of highest purity available. All reactions were 
performed in flame-dried glass apparatus under nitrogen atmosphere unless mentioned 
otherwise. Anhydrous solvents like CH2Cl2, Et2O, THF, CH3OH, CH3CN, DMF, 
pyridine, and Et3N were freshly dried using standard methods. NMR measurements (1H, 
13C) were recorded on a 300 and 500 MHz spectrometer (Bruker) fitted with a pulse-
field gradient probe, and trimethylsilane (TMS) or the residual resonance of deuterated 
solvent were used as internal reference. 13C NMR spectra were broadband 1H 
decoupled. Chemical shifts are expressed in parts per million  (ppm) and coupling 
constants or J in Hz. Mass-spectra (ESI) and high resolution mass-spectra (HRMS) 
were obtained on quadrupole and LC-ITTOF (time of flight) spectrometers respectively 
using acetonitrile-water (1:1) as the mobile phase. Analytical TLC was performed on 
Merck Kieselgel 60 F254 plates, and compounds were typically visualized by 
ammonium molybdate/ceric-sulfate developing reagent after UV inspection. Silica 
column chromatography was carried out with silica gel 60 (60-120 mesh) or flash silica 
gel (230-400 mesh). The enantiomeric purity of products was determined by chiral 
HPLC analysis, using a Daicel Chiralcel OD-H column (250 x 4.6 mm). 
One pot preparation of 5-(p-methoxybenzylthio)-1-phenyl-1H-tetrazole (1-23): 
Trichloromethyl chloroformate (0.6 mL, 5 mmol) was added drop-wise to a solution 
mixture of 1-phenyl-1H-tetrazole-5-thiol 1-21 (3.6 gm, 20 mmol) and triethylamine (3.1 
mL, 22.5 mmol) in freshly distilled dichloromethane (40 mL) at 0°C. The reaction 
mixture was allowed to warm up slowly to room temperature and left to stir overnight. 
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The reaction mixture was cooled to 0°C, and p-methoxybenzyl alcohol (0.9 mL, 7.5 
mmol) and triethylamine (3.1 mL, 22.5 mmol) was added to the cooled mixture. The 
reaction mixture was allowed to warm up slowly to room temperature and left to stir 
overnight. The reaction mixture was evaporated to dryness in vacuo, followed by 
precipitation in ethyl acetate. The suspension obtained was filtered through celite and 
the filtrate was evaporated to dryness in vacuo. The crude product was purified by silica 
gel column chromatography using n-hexane/ethyl acetate (16/1) as eluent to obtain 5-
(p-methoxybenzylthio)-1-phenyl-1H-tetrazole 1-23 (2.2 gm, 99%). Rf = 0.30 (Hexane 
/EtOAc 4:1); 1H NMR (300 MHz, CDCl3): δ 7.52 (m, 5H), 7.34 (d, J = 8.7 Hz, 2H), 
6.84 (d, J = 8.8 Hz, 2H), 4.59 (s, 2H), 3.79 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
159.4, 153.9, 133.6, 130.5, 129.7, 127.0, 123.7, 114.2, 55.2, 37.3; MS-EI [M+] calcd for 
C15H14N4OS: 298.0888, found 298.089. 
Preparation of 5-(p-methoxybenzylthio)-1-phenyl-1H-tetrazole via Mitsunobu 
reaction (1-23): p-Methoxybenzyl alcohol 1-16 (0.7 mL, 5.6 mmol) was dissolved in 
25 mL of THF with 1-phenyl-1H-tetrazole-thiol 1-21 (2.0 gm, 11.2 mmol) and diethyl 
azodicarboxylate (1.6 mL, 10.1 mmol). A 25 mL solution of triphenylphosphine (2.2 
gm, 8.4 mmol) in THF was added dropwise to the reaction mixture and allowed to stir 
for 1 hour. The reaction mixture was added to 100 mL of saturated sodium bicarbonate 
and extracted 3 times with diethyl ether. The combined organic extract was dried in 
magnesium sulphate and the crude mixture was purified under silica gel 
chromatography using n-hexane/ethyl acetate (16/1) as eluent to obtain 5-(p-
methoxybenzylthio)-1-phenyl-1H-tetrazole 1-23 (1.58 gm, 95%). 
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Preparation of 5-(p-methoxybenzylthio)-1-phenyl-1H-tetrazole via thio-ether 
synthesis (1-23): 1-phenyl-1H-tetrazole-thiol 1-21 (0.59 gm, 3.4 mmol) and 
triethylamine (0.5 mL, 3.7 mmol) were dissolved in 20 mL of THF. The reaction 
mixture was cooled to 0oC and p-methoxybenzyl chloride (0.6 mL, 4.36 mmol) was 
added dropwise to the reaction mixture and allowed to stir overnight. The solvent was 
evaporated in vacuo and diluted in ethyl acetate. The suspension obtained was filtered 
through celite and the filtrate was evaporated in vacuo. The crude mixture was purified 
by silica gel chromatography using n-hexane/ethyl acetate (16/1) as eluent to obtain 5-
(p-methoxybenzylthio)-1-phenyl-1H-tetrazole 1-23 (0.92 gm, 92%).  
General procedure for p-methoxybenzylation of alcohols: A solution of 5-(p-
methoxybenzylthio)-1-phenyl-1H-tetrazole 1-23 (0.095 gm, 0.32 mmol, 1.60 equiv.) 
and DTBMP (0.05 gm, 0.25 mmol, 1.25 equiv.) in freshly distilled anhydrous 
dichloromethane (1.5 mL) was added to the alcohol (0.20 mmol, 1 equiv.). The solution 
mixture was cooled to 0°C and transferred to a suspension of silver triflate (0.08 gm, 
0.32 mmol, 1.60 equiv.) in freshly distilled anhydrous dichloromethane (0.5 mL). The 
reaction mixture was allowed to warm up slowly to room temperature and left to stir 
overnight. Ethyl acetate was added to the reaction mixture and the suspension obtained 
was filtered through celite. The filtrate obtained was evaporated to dryness in vacuo. 
The crude product was purified by silica gel column chromatography. Side product (1-
27): 1H NMR (300 MHz, CDCl3): δ 7.29 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 




p-methoxybenzyl bis-ether (1-27): 1H NMR (300 MHz, CDCl3): δ 7.30 (d, J= 8.7 Hz, 
2H), 6.91 (d, J = 8.7 Hz, 2H), 4.48 (s, 2H), 3.81 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
159.1, 130.4, 129.3, 113.7, 71.4, 55.2. 
 
p-methoxybenzyl-2-phenylethylether (1-28): Rf = 0.55 (Hexane/EtOAc 4:1); 1H NMR 
(300 MHz, CDCl3): δ 7.16-7.28 (m, 7H), 6.85 (d, J = 9.0 Hz, 2H), 4.45 (s, 2H), 3.80 (s, 
3H), 3.64 (t, J = 7.2 Hz, 2H), 2.92 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 
159.1, 138.9, 130.4, 129.4, 128.8, 128.2, 126.1, 113.7, 72.6, 70.9, 55.2, 36.3; MS-EI 
calcd for C16H18O2: 242.1307, found 242.130. Rf: 0.55 
 
p-methoxybenzyl-cyclohexylether (1-26): Rf = 0.65 (Hexane/EtOAc 4:1); 1H NMR 
(300 MHz, CDCl3): δ  7.27 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.47 (s, 2H) 
3.80 (s, 3H), 3.34 (m, 1H), 1.93 (m, 2H), 1.75 (m, 2H), 1.28 (m, 6H); 13C NMR (75 
MHz, CDCl3): δ  158.9, 131.3, 128.9, 113.7, 69.2, 55.2, 32.2, 25.8, 24.1; MS-EI [M+] 
calcd for C14H20O2: 220.1463, found 220.146. 
 
p-methoxybenzyl-2-chloroethylether (1-29): Rf = 0.50 (Hexane/EtOAc 4:1); 1H NMR 
(300 MHz, CDCl3):  δ 7.27 (d, J = 9.0 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 4.52 (s, 2H), 
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3.81 (s, 3H), 3.69 (m, 2H), 3.67 (m, 2H);  MS (EI): m/z 200.0605. MS-EI [M+] calcd for 
C10H13ClO2: 200.0604, found 200.06. 
OPMB
1-30  
 p-methoxybenzyl-2-phenyl-2-propanyl ether (1-30): 1H NMR (300 MHz, CDCl3): δ 
7.51 (m, 5H), 7.26 (d, J = 6.5 Hz, 2H), 6.89 (d, J = 6.5 Hz, 2H), 4.18 (s, 2H), 3.80 (s, 
3H), 1.64 (s, 6H); 13C NMR (75 MHz, CDCl3): δ 158.8, 146.2, 131.4, 128.9, 128.2, 
126.9, 125.8, 113.7, 64.7, 55.2, 28.5.  
 
p-methoxybenzyl-2-methylprop-2-enyl ether (1-31): 1H NMR (300 MHz, CDCl3): δ 
7.27 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 4.99 (s, 1H), 4.91 (s, 1H), 4.42 (s, 
2H), 3.90 (s, 2H), 3.80 (s, 3H), 1.82 (s, 3H);  MS-EI [M+] calcd for C12H16O2: 192.1150, 
found 192.115. 
 
tert-butyl-3-(p-methoxybenzyloxy)propyl carbamate: 1H NMR (300 MHz,  CDCl3): 
δ 7.23 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.39 (s, 2H), 3.79 (s, 3H), 3.43 (m, 
2H), 3.25 (m, 2H), 1.72 (m, 2H), 1.43 (s, 9H).  
 
(4-(p-methoxybenzyloxy)butyl)triethylsilane (1-41): 1H NMR (300 MHz, CDCl3): δ 
7.26 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.43 (s, 2H), 3.80 (s, 3H), 3.61 (t, J = 
6.1 Hz, 2H), 3.46 (t, J = 6.2 Hz, 2H), 1.68-1.60 (m, 4H), 0.95 (t , J = 7.9 Hz, 9H), 0.59 
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(q, J = 7.9 Hz, 6H); 13C NMR (75 MHz, CDCl3): δ 159.0, 130.7, 129.1, 113.7, 72.4, 
69.9, 62.6, 55.2, 29.5, 26.2, 6.7, 4.3. 
 
(9H-fluoren-9-yl)methyl 1-(4-methoxybenzyloxy)-2-methylpropan-2-ylcarbamate 
(1-42): 1H NMR (300 MHz, CDCl3): δ 7.67 (d, J = 7.2 Hz, 2H), 7.51 (d, J = 7.4 Hz, 
2H), 7.33-7.19 (m, 4H), 7.15 (d, J = 8.4 Hz, 2H), 6.78  (d, J = 8.4 Hz, 2H), 4.94 (s, 1H), 
4.37 (s, 2H), 4.25 (d, 2H), 4.12 (t, J = 6.7 Hz, 1H), 3.70 (s, 3H), 3.29 (s, 2H), 1.23 (s, 
6H); 13C NMR (75 MHz, CDCl3): δ 159.1, 144.0, 141.2, 130.2, 129.1, 127.5, 126.9, 
125.0, 119.8, 113.7, 75.9, 72.8, 66.0, 55.2, 53.0, 47.2, 24.1. 
 
p-methoxybenzyl-p-bromophenylether (1-43): Rf = 0.58 (Hexane/EtOAc 4:1); 1H 
NMR (300 MHz, CDCl3): 7.37 (d, J = 9.0 Hz, 2H), 7.33 (d, J = 9.0 Hz, 2H), 6.91 (d, J 
= 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.96 (s, 2H), 3.82 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 159.5, 157.8, 132.2, 129.1, 128.5, 116.7, 114.0, 112.9, 70.0, 55.2, 30.8, 30.1. 
MS-EI [M+] calcd for C14H13BrO2: 292.0099, found 292. 
 
p-methoxybenzyl-prop-2-yn-1-ylether (1-44): 1H NMR (300 MHz, CDCl3): δ 7.29 (d, 
J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.55 (s, 2H), 3.81 (s, 3H), 2.47 (s, 1H); 13C 




(2-(4-methoxybenzyloxy)-2-phenylethyl)trimethylsilane (1-45): 1H NMR (300 MHz, 
CDCl3): δ 7.40 (m, 5H), 7.24 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 4.47 (t, J = 
7.6 Hz, 1H), 4.31 (d, J = 11.0 Hz, 1H), 4.20 (d, J = 11.0 Hz, 1H), 3.84 (s, 3H), 1.40-
1.11 (m, 2H), -0.05 (s, 9H). 13C NMR (75 MHz, CDCl3): δ 158.9, 144.4, 130.8, 129.7, 
129.3, 128.4, 127.4, 126.6, 113.6, 79.4, 69.7, 55.2, 27.8, -1.0.  
 
Allyl-3-O-(p-methoxybenzyl)-4,6-O-benzylidene-α-D-mannopyranoside (1-53): 1H 
NMR (300 MHz, CDCl3): δ 7.52-7.36 (m, 5H), 7.29 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 
Hz, 2H), 5.97-5.84 (m, 1H), 5.62 (s, 1H), 5.32-5.20 (m, 2H), 4.91 (s, 1H), 4.80 (d, J = 
11.3 Hz, 1H), 4.65 (d, J = 11.3 Hz, 1H), 4.28-3.85 (m, 9H), 3.80 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 159.3, 137.5, 133.4, 130.0, 129.5, 128.8, 128.1, 126.0, 117.7, 113.8, 
101.5, 99.1, 78.8, 77.4, 77.0, 76.5, 75.3, 72.7, 69.9, 68.8, 68.1, 63.3, 55.2.  
 
Allyl-2,3-di-O-carbonyl-6-O-(p-methoxybenzyl)-α-D-mannopyranoside (1-54): 1H 
NMR (300 MHz, CDCl3): δ  7.29 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 5.97-
5.84 (m, 1H), 5.38-5.26 (m, 2H), 5.16 (s, 1H), 4.77-4.65 (m, 2H), 4.59 (d, J = 11.7 Hz, 
1H), 4.51 (d, J = 11.7 Hz, 1H), 4.26-4.20 (m, 1H), 4.09-4.03 (m, 1H), 3.93-3.67 (m, 
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7H); 13C NMR (75 MHz, CDCl3): δ 159.4, 153.6, 132.5, 130.0, 129.4, 118.6, 113.9, 
94.2, 78.8, 75.3, 69.0, 68.9, 68.4, 67.7, 55.2.  
 
Allyl-2,3-di-O-carbonyl-4-O-(p-methoxybenzyl)-6-O-dichloroacetyl-α-D-mannopyr 
anoside (1-55): 1H NMR (300 MHz, CDCl3): δ  7.19 (d, J = 8.4Hz, 2H), 6.83 (d, J = 
8.4Hz, 2H), 5.85-5.72 (m, 2H), 5.26-5.17 (m, 3H), 4.84-4.79 (m, 1H), 4.72-4.69 (m, 
1H), 4.61-4.57 (m, 1H), 4.49-4.43 (m, 1H), 4.30-4.35 (m, 1H), 4.16-4.10 (m, 1H), 3.98-
3.86 (m, 2H), 3.74-3.49 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 164.0, 159.7, 153.0, 
132.3, 130.0, 128.3, 118.9, 114.0, 114.0, 94.1, 79.3, 76.1, 73.3, 72.7, 68.3, 65.4, 65.4, 




(S)-Methyl 3-(p-methoxybenzyloxy)-2-methylpropionate (1-60): 1H NMR (500 
MHz, CDCl3): δ  7.22 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 4.44 (m, 2H), 3.80 
(s, 3H), 3.69  (s, 3H), 3.61 (m, 1H), 3.44 (m, 1H) 2.78 (m, 1H), 2.70 (d, J = 6.9 Hz, 3H); 
13C NMR (125 MHz, CDCl3): δ 175.3, 159.1, 130.2, 129.1, 113.7, 72.7, 71.6, 55.2, 
51.6, 40.1, 13.9.  The ee value was 97%, tR (major) = 7.29 min, tR (minor) = 8.08 min 
(Chiralcel AD-H, λ = 254 nm, 15% iPrOH/hexanes, flow rate = 1.0 mL/min). 
Triethylsilyl monoprotection of butane-1,4-diol (1-32): To an ice-cooled solution of 
butane-1,4-diol (0.96 mL, 10.9 mmol) and pyridine (1.2 mL, 15.2 mmol) in anhydrous 
dichloromethane (20 mL) was added chlorotriethylsilane (1.6 mL, 9.9 mmol). The 
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reaction mixture was allowed to stir overnight. The reaction mixture was quenched with 
50 mL of saturated sodium bicarbonate and extracted three times with diethyl ether. The 
combined organic extracts were washed with brine, dried over anhydrous sodium 
sulphate and the ether layer was evaporated in vacuo to give 4-O-(triethylsilyl)butan-1-
ol 1-33 which was purified using n-hexane/ethyl acetate (5/1) as eluent. 1H NMR (300 
MHz, CDCl3): δ 3.66 (m, 4H), 1.66 (m, 4H), 0.97 (t, J = 8.0 Hz, 9H), 0.62 (q, J = 8.0 
Hz, 6H); 13C NMR (75 MHz, CDCl3): δ 62.9, 62.8, 30.3, 29.9, 6.6, 4.3. 
Preparation of 2-(trimethylsilyl)-1-phenylethanol (1-35): Into a flame-dried round 
bottom flask with magnesium turnings (0.2 gm, 8.4 mmol) was added a solution of 
chloromethyl trimethylsilane 1-34 (0.6 mL, 4.2 mmol) in THF (1.5 mL). The reaction 
mixture was warmed to 50oC and two drops of bromobutane was added to initiate the 
reaction. Upon formation of a cloudy solution, a solution of benzaldehyde (0.4 mL, 3.6 
mmol) in THF (1.5 mL) was added and the mixture was refluxed for 4.5 hours. The 
reaction mixture was then poured into an ice cold solution of ammonium chloride which 
was then diluted with diethyl ether, washed twice with saturated sodium bicarbonate 
and dried over anhydrous sodium sulphate. The dried organic extract was evaporated in 
vacuo and crude 1-35 was used for protection without further purification. 1H NMR 
(300 MHz, CDCl3): δ 7.35 (m, 5H), 4.85 (m, 1H), 1.23 (m, 2H), -0.07 (s, 9H); 13C NMR 
(75 MHz, CDCl3): 146.3, 128.3, 127.4, 125.8, 72.7, 28.3, -1.1. 
Fmoc protection of 2-amino-2-methyl-1-propanol (1-38).29 To the solution of 2-
amino-2-methyl-1-propanol 1-36 (0.1 mL, 1.0 mmol) in dichloromethane (0.6 mL) was 
added, dropwise, Fmoc chloride (0.3 gm, 1.1 mmol) in dichloromethane (1.4 mL). 
Sodium bicarbonate (168 mg, 2.0 mmol) was added and the reaction mixture was 
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allowed to stir overnight. The reaction mixture was filtered and the filtrate was 
concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
using n-hexane/ethyl acetate (3/2) to obtain (9H-fluoren-9-yl)methyl1-hydroxy-2-
methylpropan-2-yl carbam ate 1-38. (192 mg, 62%). 1H NMR (300 MHz, CDCl3) : δ 
7.85 (d, 2H), 7.60 (d, 2H), 7.43-7.30 (m, 4H), 4.83 (s, 1H), 4.42 (d, J = 6.2 Hz, 2H), 
4.20 (t, J = 6.4 Hz, 1H), 3.57 (s, 2H), 1.25 (s, 6H); 13C NMR (75 MHz, CDCl3) : δ 
156.1, 143.8, 141.3, 127.6, 127.0, 119.9, 70.0, 66.2, 54.4, 47.2, 24.4. 
Preparation of 2-hydroxyethyl 3-(2-methyl-1,3-dithiolan-2-yl)propanoate (1-40). 2-
hydroxyethyl 3-(2-methyl-1,3-dioxolan-2-yl)propanoate 1-39 (150 mg, 0.74 mmol) and 
iodine (19 mg, 0.074 mmol) were dissolved in chloroform (3.7 mL). Ethane-1,2-dithiol 
(0.07 mL, 0.088 mmol) was added dropwise to the reaction mixture and was allowed to 
stir overnight. The reaction was quenched with saturated sodium thiosulphate solution, 
10% sodium hydroxide and diluted with chloroform. The organic layer was washed 
with water, brine and dried over anhydrous sodium sulphate. The solvent was removed 
in vacuo and the crude mixture was purified via silica gel chromatography (3/2) to give 
2-hydroxyethyl 3-(2-methyl-1,3-dithiolan-2-yl)propanoate 1-40 (30 mg, 17%). 1H NMR 
(300 MHz, CDCl3): δ 4.23-4.20 (m, 2H), 3.84-3.81 (m, 2H), 3.39-3.25 (m, 4H), 2.67-
2.62 (m, 2H), 2.27-2.22 (m, 2H), 1.78 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 173.6, 
66.1, 61.1, 40.2, 39.5, 32.9, 31.8.  
Preparation of Allyl-4,6-O-benzylidene-α-D-mannopyranoside (1-48).30 D-Mannose 
1-47 (5 gm , 27.8 mmol) was refluxed at 80oC for 4 h in presence of BF3·Et2O (0.25 
mL, 1.95 mmol) in allyl alcohol (29 mL). After neutralization with triethylamine, the 
excess of allyl alcohol was evaporated and the residue purified by silica column 
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chromatography using CH2Cl2/MeOH (8/1) to give allyl-α-D-mannopyranoside (5.13 
gm, 83%). 1H NMR (500 MHz, DMSO-d6): δ 5.92-5.84 (m, 1H), 5.27-5.13 (m, 2H), 
4.71 (t, J = 4.5 Hz, 2H), 4.63 (s, 1H), 4.55 (d, J = 5.7 Hz, 1H), 4.45 (t, J = 5.8 Hz, 1H), 
4.14-4.08 (m, 1H), 3.94-3.88 (m, 1H), 3.68-3.62 (m, 2H); 13C NMR (125 MHz, DMSO-
d6): δ 134.80, 116.46, 99.08, 74.09, 71.00, 70.29, 67.04, 66.63, 61.28. A solution of 
allyl-α-D-mannopyranoside (5.13 gm, 23 mmol), benzaldehyde-dimethylacetal (5.35 
mL, 5.42 mmol) and camphor sulphonic acid (0.675 gm, 4.43 mmol) in anhydrous 
acetonitrile (219 mL) was stirred at room temperature for 18 h. After neutralization with 
triethylamine and the reaction mixture was concentrated, diluted with ethyl acetate. The 
organic layer was washed with saturated sodium bicarbonate, water and brine. The 
organic layer was dried over sodium sulphate, concentrated and the residue was purified 
by silica column chromatography (hexane/EtOAc, 6/4) to give compound allyl-4,6-O-
benzylidene-α-D-mannopyranoside 1-48 (4.67 gm, 65%). 1H NMR (300 MHz, CDCl3): 
δ 7.51-7.36 (m, 5H), 5.98-5.86 (m, 1H), 5.57 (s, 1H), 5.34-5.21 (m, 2H), 4.92 (d, J = 1.0 
Hz, 1H), 4.29-3.79 (m, 8H); 13C NMR (75 MHz, CDCl3) : δ 137.1, 133.4, 129.2, 128.3, 
126.2, 117.7, 102.1, 99.4, 78.8, 70.9, 68.7, 68.5, 68.2, 63.1. 
3-O-trimethylsilylation of allyl-4,6-O-benzylidene-D-mannopyranoside: 1,1,1,3,3,3-
hexamethyldisilazane (0.06 mL, 0.312 mmol) was added dropwise to a solution mixture 
of allyl-4,6-O-benzylidene-D-mannopyranoside (200 mg, 0.649 mmol) and iodine (0.1 
mg, 0.0039 mmol) in dichloromethane (3 mL). At the end of 1 hour, the reaction was 
quenched with 1gm of finely powdered sodium thiosulphate. The suspension was 
allowed to stir for another 1 hour before filtering off excess sodium thiosulphate. The 
filtrate was concentrated and purified by silica gel chromatography using n-
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hexane/ethylacetate (4/1) to obtain allyl-3-O-trimethylsilyl-4,6-benzylidene-D-manno 
pyranoside as a mixture of anomers (α:β = 3: 1) (12 mg, 5%). 1H NMR (300 MHz, 
CDCl3) : δ 7.49-7.35 (m, 5H), 5.98-5.85 (m, 1H), 5.55 (m, 1H), 5.33-5.21 (m, 2H), 4.94 
(s, 1H), 4.26-3.81 (m, 8H), 0.13 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 137.5, 133.6, 
128.8, 128.1, 126.2, 126.1, 116.7, 101.8, 98.9, 78.8, 72.1, 69.5, 68.8, 68.2, 63.2, 0.3. 
Preparation of allyl-2,3-O-bis(dichloroacetyl)-4,6-O-benzylidene-α-D-mannopyra 
noside (1-49). A solution of allyl-4,6-O-benzylidene-α-D-mannopyranoside 1-48 (0.2 
gm, 0.649 mmol), 4-dimethylaminopyridine (0.008 gm, 0.0649 mmol) and pyridine 
(0.16 mL, 1.947 mmol) was dissolved in dichloromethane (13 mL) and cooled to -20oC. 
Dichloroacetyl chloride (0.2 mL, 1.9 mmol) was added dropwise and the reaction 
mixture was allowed to warm to room temperature and stirred overnight. The reaction 
was diluted with 20 mL of ethyl acetate and quenched with 20 mL of saturated sodium 
bicarbonate solution. The organic layer extracted with saturated sodium bicarbonate, 
brine and dried over sodium sulphate. The solvent was removed in vacuo and the crude 
mixture was purified via silica gel chromatography using n-hexane/ethyl acetate (9/1) to 
obtain allyl-2,3-O-bis(dichloroacetyl)-4,6-O-benzylidene-α-D-mannopyranoside 1-49 
(0.203 gm, 65%). 1H NMR (300 MHz, CDCl3): δ 7.46-7.35 (m, 5H), 6.07 (s, 1H), 6.03-
5.85 (m, 2H), 5.64-5.58 (m, 2H), 5.49-5.48 (m, 1H). 5.38-5.27 (m, 2H), 4.94 (d,  J = 1.3 
Hz, 1H), 4.36-3.86 (m, 6H).   
Preparation of allyl-2,3-di-O-carbonyl-α-D-mannopyranoside (1-50).32 To an 0oC 
solution of allyl-4,6-O-benzylidene-α-D-mannopyranoside 1-48 (2.06 gm, 6.67 mmol) 
and pyridine (4.3 mL, 53.36 mol) in dichloromethane (40 mL) was added 
trichloromethyl chloroformate (1.2 mL, 10.0 mol). The reaction was stirred for 1 hour 
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and saturated sodium bicarbonate solution was added dropwise to the reaction mixture 
until effervescence ceases. The mixture was diluted with ethyl acetate and the organic 
layer was washed with sodium bicarbonate, brine and dried over anhydrous sodium 
carbonate. The solvent was evaporated and the crude mixture was purified by silica gel 
chromatography using n-hexane/ethyl acetate (4/1) to obtain allyl-2,3-di-O-carbonyl-
4,6-O-benzylidene-α-D-mannopyranoside 1-50 (1.45 gm, 66%). 1H NMR (300 MHz, 
CDCl3) : δ 7.53-7.37 (m, 5H), 5.96-5.83 (m, 1H), 5.60 (s, 1H), 5.36-5.20 (m, 3H), 4.87 
(t, J = 7.2 Hz, 1H), 4.72 (d, J = 6.9 Hz, 1H), 4.38-4.34 (m, 1H). 4.35-4.18 (m, 1H), 
4.09-4.02 (m, 1H), 3.90-3.76 (m, 3H); 13C NMR: δ 153.1, 136.4, 132.5, 129.3, 128.3, 
126.0, 118.8, 101.9, 94.9, 78.6, 76.5, 75.1, 68.5, 59.4. p-Toluene sulphonic acid (0.476 
gm, 2.5 mmol) and allyl-2,3-di-O-carbonyl-4,6-O-benzylidene-α-D-mannopyranoside 
(0.846 gm, 2.5 mmol) in a 1:1 dichloromethane/methanol mixture (17 mL) was allowed 
to react for 4 hours before quenching the reaction with triethylamine. The solvent was 
evaporated in vacuo and the crude product was purified by silica gel chromatography 
using n-hexane/ethyl acetate (2/3) to obtain allyl-2,3-di-O-carbonyl-α -D-
mannopyranoside (0.492 gm , 80%).  IR: 3454cm-1 (OH stretch), 1808cm-1 (C=O 
stretch); 1H NMR (300 MHz, Acetone-d6): δ 5.97-5.89 (m, 1H), 5.36-5.16 (m, 3H), 
4.82-4.74 (m, 2H), 4.31-4.24 (m, 1H), 4.12-4.05 (m, 1H), 3.89-3.62 (m, 5H), 13C NMR 
(300 MHz, Acetone-d6): δ 133.6, 116.7, 94.1, 79.8, 76.2, 69.7, 67.8, 67.4, 60.9.  
Preparation of allyl-2,3-di-O-carbonyl-6-O-dichloroacetyl-α-D-mannopyranoside 
(1-49). Allyl-2,3-di-O-carbonyl-α-D-mannopyranoside (74 mg, 0.3 mmol), pyridine 
(0.036 mL, 0.45mmol) and 4-dimethylaminopyridine (4 mg, 0.03 mmol) were dissolved 
in dichloromethane (6 mL) and cooled to -20oC. Dichloroacetyl chloride (0.032 mL, 
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0.33 mmol) was added dropwise to the reaction mixture and the reaction was allowed to 
stir overnight. The reaction was quenched with saturated sodium bicarbonate and 
diluted with ethyl acetate. The organic layer was washed with saturated sodium 
bicarbonate, water, brine and dried over anhydrous sodium sulphate. The solvent was 
removed in vacuo and the crude mixture was purified via silica gel chromatography 
using n-hexane/ethyl acetate (7/3) to yield allyl-2,3-di-O-carbonyl-6-O-dichloroacetyl-
α-D-mannopyranoside (61 mg, 57%). 1H NMR (300 MHz, MeOH-d4): δ 4.48 ppm (s, 
1H), 6.00-5.87 (m, 1H), 5.36-5.17 (m, 3H), 4.77-4.73 (m, 2H), 4.66-4.62 (m, 2H), 4.45-
4.39 (m, 1H), 4.30-4.24 (m, 1H), 4.11-4.05 (m, 1H), 3.90-3.88 (m, 1H), 3.69-3.64 (M, 
1H); 13C NMR (MeOH-d4): δ 165.8, 155.5, 134.5, 118.4, 95.5, 81.2, 77.9, 69.3, 68.9, 
68.3, 66.8, 65.6. 
Preparation of allyl-2,3-di-O-carbonyl-4,6-O-di-O-tosyl-α-D-mannopyranoside (1-
52). Allyl-2,3-di-O-carbonyl-α-D-mannopyranoside (74 mg, 0.3 mmol), triethylamine 
(0.21 mL, 1.5 mmol) and 4-dimethylaminopyridine (catalytic) were dissolved in 
anhydrous dichloromethane and cooled to 0 oC. p-toluenesulphonyl chloride (86 mg, 
0.45 mmol) was added and the reaction was allowed to stir overnight. The reaction was 
quenched with saturated sodium bicarbonate and diluted with ethyl acetate. The organic 
layer was washed with saturated sodium bicarbonate, brine and then dried over 
anhydrous sodium sulfate. The solvent was removed in vacuo and the crude mixture 
was purified via silica gel chromatography using n-hexane/ethyl acetate (7/3) to obtain 
allyl-2,3-di-O-carbonyl-4,6-O-di-O-tosyl-α-D-mannopyranoside 1-52 (57 mg, 38%). 1H 
NMR (300 MHz, CDCl3): δ 7.80-7.75 (4H, m), 7.39-7.35 (4H, m), 5.89-5.76 (1H, m), 
5.32-5.22 (m, 2H), 5.04 (s, 1H), 4.71-4.64 (m, 1H), 4.56-4.53 (m, 1H), 4.43-4.30 (M, 
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2H), 4.19-3.91 (m, 4H), 2.46 (s, 3H), 2.44 (s, 3H); 13C NMR (75 MHz, CDCl3) : δ 
151.8, 146.0, 145.1, 132.4, 132.2, 131.9, 130.0, 129.8, 129.1, 127.9, 119.3, 93.7, 75.7, 





















Experimental: Chapter 3 and Chapter 4 
General Procedure for the synthesis of Boc-Aminoacids: 2-(tert-
butoxycarbonylamino)-3-methylpentanoic acid: Aminoacid (1 mmol) was dissolved 
in a mixture of dioxane and water (1:1). To this solution, sodium carbonate (1.1 mmol) 
and Boc-anhydride (1.5 mmol) were added at 0 oC and stirred for 12 hours. The solvent 
was removed in vacuo. The residue was extracted with sodium bicarbonate solution and 
acidified with citric acid. The aqueous layer was extracted with ethyl acetate. The 
organic layer was washed with brine and then dried over Na2SO4. 
 
Boc-L-Isoleucine (3-2): Isoleucine (5 gm, 38.1 mmol) was treated with 1M solution of 
sodium carbonate (42 mmol) followed by Boc-anhydride (13.2 mL, 57.2 mmol). Flash 
chromatography of the crude product  on silica gel (hexane/ethylacetate, 5/1) gave the 
desired compound 3-2 (8.6 gm, 37.2 mmol, 98%) as a white crystalline solid. 1H NMR 
(500 MHz, DMSO-d6): δ 0.80 (m, 6H), 1.14 (m, 1H), 1.38 (s, 9H), 1.73 (m, 1H), 3.81 
(t, 1H), 6.89 (d, J = 8.2 Hz, 1H), 12.4 (brs, 1H); 13C NMR (125 MHz, DMSO-d6): δ 
11.2, 15.5, 24.7, 28.2, 35.9, 58.0, 77.9, 155.6, 173.5; ESI-MS, calcd for C11 H24 NO4 
231.15, found [M+Na]+ 
General procedure for coupling of amino acids via the mixed anhydride method: 
(a) Preparation of Bis-TMS amino acid: To the solution of amino acid (1.6 gm, 13.6 
mmol, 1 equiv.) in dichloromethane, triethyl amine (6.7 mL, 48 mmol, 3.5 equiv.) and 
trimethylsilylchloride (6.1 mL, 48 mmol, 3.5 equiv.) were added. The mixture was 
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refluxed for 2 hours. The mixture was then used in situ for coupling to the anhydride. 
(b) Preparation of mixed anhydride using chloroformate: Boc-amino acid (2.0 gm, 8.65 
mmol, 1 equiv.) was dissolved in THF. Then, N-methyl morpholine (1.2 mL, 10.3 
mmol, 1.2 equiv) was added at -20 oC followed by the addition of ethyl chlorofomate 
(1.0 mL, 10.3 mmol, 1.0 equiv). The mixture was stirred at -20 oC for 15 minutes to 20 
minutes. At this point, Bis-TMS amino acid was added to the anhydride solution and 
stirred for 10 h at room temperature. After completion, the reaction mixture was 
concentrated under rotary evaporation. The residue obtained was dissolved in sat. 
NaHCO3. The aqueous layer was washed with n-hexane. n-Hexane layers were 
removed. The aqueous bicarbonate layer was acidified with citric acid and then 
extracted with ethyl acetate. The organic layer was then brine washed, dried using 
anhydrous Na2SO4 and removed by rotary evaporation to give white solid. 
General procedure for cleavage of Boc group and coupling using HATU coupling 
agent: Boc protected amino acid or peptide compound was dissolved in 
dichloromethane. To this, trifluoroacetic acid was added slowly at 0 oC and left to room 
temperature for 30 min. After completion of the reaction, excess TFA was removed 
under rotary evaporator. To this, diethylether was added. Solid compound precipitated 
out. Supernant diethylether layer was then removed and the solid was dissolved in 
dichloromethane. α- amino protected amino acid or peptide with free carboxylic acid 
was then added to the reaction flask at 0 oC, followed by the addition of DIPEA, HATU 
and HOAt. A catalytic amount of DMAP was also added. The reaction was stirred for 5 
h at room temperature. After completion, the reaction mixture was evaporated in vacuo. 
The residue obtained was dissolved in ethyl acetate. The organic layer was washed with 
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saturated sodium bicarbonate solution, followed by brine solution. The organic layer 
was finally dried using sodium sulphate and evaporated in vacuo to give a solid residue. 
The residue was purified by column chromatography. 
General procedure for cleavage of Fmoc group: To the solution of Fmoc-protected 
amino acid or peptide (1 equiv.) in anhydrous dichloromethane, piperidine (5 vol.) was 
added and stirred overnight. After completion of the reaction, the solvent was removed 
in vacuo. The crude obtained was purified by silica gel column chromatography 
(DCM/MeOH) to give the free amine. 
General procedure for the removal of trityl group: To the solution of trityl-protected 
compound in dichloromethane, trifluoroacetic acid was added at 0 oC followed by the 
addition of triisopropylsilane. The reaction mixture was stirred at rt for 30 min. After 
completion of the starting material, the reaction mixture was concentrated on rotary 
evaporator to give oily residue. The residue was diluted with saturated NaHCO3 solution 
and extracted with ethyl acetate. The organic layer was washed with brine and dried 
over anhydrous sodium sulfate. Finally, the organic layer was removed in vacuo and the 
crude obtained was purified over silica gel column chromatography to afford the target 
compounds. 
 
Preparation of Dipeptide: (S)-2-((2S,3S)-2-(tert-butoxycarbonylamino)-3-
methylpentan amido)-3-methylbutanoic acid (3-4): To the solution of Boc-Isoleucine 
3-2 (2.0 gm, 8.65 mmol) in THF, N-methyl morpholine (1.2 mL, 10.3 mmol) and 
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ethylchloroformate (1.0 mL, 10.3 mmol) were added at 0 oC followed by the addition of 
Bis-TMS-Valine. Bis-TMS-Valine (3-3) was prepared by dissolving valine (1.6 gm, 
13.6 mmol) in 60 mL dichloromethane. Triethyl amine (6.7 mL, 48 mmol) and 
trimethylsilylchloride (6.1 mL, 48 mmol) were then added. The residue was purified by 
column chromatography (hexane/ethyl acetate, 3/1) to give the compound 3-4 (2.5 gm, 
7.5 mmol, 88 %) as a white crystalline solid. 1H NMR  (300 MHz, DMSO-d6): δ 0.77 
(m, 6H), 0.87 (m, 6H), 1.08 (m, 1H), 1.37 (s, 9H), 1.58 (m, 1H), 1.98 (m, 2H), 3.84 (t, J 
= 8.2 Hz, 1H), 4.13 (dd, J = 5.7, 8.4 Hz, 1H), 6.73 (d, J = 9.0 Hz, 1H), 7.74 (d, J = 8.4 
Hz, 1H), 12.56  (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 10.8, 15.3, 17.9, 18.9, 24.3, 
28.1, 29.9, 36.3, 56.9, 58.7, 77.9, 155.8, 171.6, 172.7; ESI-MS: m/z calcd for C16 
H30N2O5  330.2, found 330.9, [M+Na]+ 353.1  
 
Preparation of Tripeptide: tert-butyl (2S,3S)-1-((S)-1-((S)-2-carbamoylpyrrolidin-
1-yl)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxopentan-2-ylcarbamate (3-7): 
L-Bocproline amide 3-12 (350 mg, 1.6 mmol) was coupled to the dipeptide 3-4 (647 
mg, 1.95 mmol) according to the general procedure for peptide coupling using 
HATU/HOAt to give the desired compound 3-7 as white solid (368 mg, 0.86 mmol, 
53%) after silica gel column purification with chloroform/methanol (15/1) as eluents. 
1H NMR  (500 MHz, DMSO-d6) :  δ 0.77 (m, 6H), 0.85 (m, 6H), 1.04 (m, 1H), 1.37 (s, 
9H), 1.65 (m, 1H), 1.75 (m, 2H), 1.82 (m, 4H), 3.54 (m, 1H), 3.70 (m, 1H), 3.81 (t, J = 
8.2 Hz, 1H),  4.20 (1H, m), 4.33 (t, J = 8.2 Hz, 1H), 6.82 (brs, 2H), 7.24 (s, 1H), 7.72 (d, 
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J = 8.8 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ 10.8, 15.3, 18.1, 19.1, 24.4, 28.1, 
29.2, 30.1, 36.5, 46.9, 58.8, 78.0, 79.1, 155.2, 169.6, 171.2, 173.3; ESI-MS: m/z (%) 
calcd for C21H38N4O5  426.3, found 427.0, [M+Na]+ 449.2 
 
Preparation of Boc–Tetrapeptide: tert-butyl (S)-1-((2S,3S)-1-((S)-1-((S)-2-
carbamoyl pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxopenta 
n-2-ylamino)-1-oxo-3-(1-trityl-1H-imidazol-4-yl)propan-2-ylcarbamate (3-9): Tri 
peptide 3-7 (297 mg, 0.7 mmol) was coupled to Nα-Boc-N(im)-trityl-L-histidine 3-8 (436 
mg, 0.77 mmol) to give the desired compound 3-9 as a white solid (456 mg, 0.5 mmol, 
70% yield) after silica gel column purification using chloroform/methanol (15/1). 1H 
NMR  (300 MHz, DMSO-d6) : δ 0.79 (m, 6H), 0.84 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.7 
Hz, 3H), 1.06 (m, 2H), 1.35 (s, 9H), 1.73 (m, 6H), 2.69 (m, 2H), 3.58 (m, 2H), 3.73 (m, 
1H), 4.11 (m, 2H), 4.27 (t, J = 8.5 Hz, 1H), 6.70 (s, 1H), 6.86 (s, 1H), 7.00 (d, J = 7.7 
Hz, 1H), 7.08 (m, 5H), 7.25 (m, 2H), 7.41 (m, 8H), 7.58 (d, J = 8.5 Hz, 1H), 8.1 (d, J = 
7.9 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 11.6, 14.4, 15.9, 17.4, 17.6, 19.2, 19.3, 
24.6, 28.2, 29.0, 29.7, 30.7, 36.0, 46.6, 53.3, 55.9, 58.5, 59.4, 75.3, 80.2, 119.6, 128.0, 
128.1, 129.6, 136.3, 138.6, 142.0, 156.0, 171.0, 173.0, 173.9; ESI-MS, calcd for 
C46H59N7O6  805.5, found 806.4 
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Preparation of Tetrapeptide:  (S)-1-((S)-2-((2S,3S)-2-((S)-3-(1H-imidazol-4-yl)-2-
(3-methylbutanamido)propanamido)-3-methylpentanamido)-3-methylbutanoyl) 
pyrrolidine -2-carboxamide (3-10): Compound 3-9 (57 mg, 71µmol ) was dissolved in 
dichloromethane and then TFA solution was added and then coupled to isovaleric acid 
using HATU/HOAt. After the reaction was complete, the solvent was removed in vacuo 
and the reaction was worked up by adding saturated sodium bicarbonate. The aqueous 
layer was extracted with ethyl acetate. The residue was purified on Prep HPLC to give 
3-10 (31 mg 0.057 mmol, 79%), as a gummy residue by preparative HPLC using Luna 
C18, 50x3.0mm, 5µm;  (linear gradient: 0 to 100% B, 0.1% formic acid, 70 min). 1H 
NMR  (500 MHz, DMSO-d6) : δ 0.80 (m, 6H), 0.89 (d, 6H) 0.9 (m, 6H), 1.06 (m, 1H), 
1.39 (m, 1H), 1.7 (m, 1H), 1.80 (m, 1H), 1.91 (m, 7H) 2.84 (m, 1H), 3.01 (m, 1H), 3.59 
(m, 1H), 3.76 (m, 1H), 4.23 (m, 2H), 4.3 (t, J = 8.5 Hz, 1H), 4.62 (m, 1H), 6.86 (s, 1H),  
7.06 (s, 1H), 7.28 (s, 1H), 7.76 (d, J = 8.2 Hz, 1H), 8.1 (m, 2H), 8.25 (brs, 1H); 13C 
NMR (125 MHz, DMSO-d6): δ 10.6, 14.9, 17.8, 18.5, 21.9, 23.8, 24.9, 28.7, 29.4, 36.5, 
44.1, 46.6, 52.6, 55.5, 56.4, 59.1, 132.1, 134.1, 167, 168.5, 169.8, 170.8, 171.0; ESI-

















1H NMR  (500 MHz, DMSO-d6):  δ 0.70 (m, 18H), 1.23 (m, 2H), 1.65 (m, 1H), 1.77 
(m, 1H), 1.91 (m, 5H), 2.72 (m, 1H), 2.86 (m, 1H), 3.54 (m, 1H), 3.74 (m, 1H), 4.20 (m, 
2H), 4.25 (t, J = 8.5 MHz, 1H), 4.55 (m, 1H), 6.80 (s, 1H), 6.84 (s, 1H),  7.22 (s, 1H), 
7.48 (s, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.96 (m, 2H);  13C NMR (125 MHz, DMSO): δ 
10.6, 14.9, 17.8, 18.5, 21.9, 23.8, 24.9, 28.7, 29.4, 36.5, 44.1, 46.6, 52.6, 55.5, 56.4, 




imidazo l-4-yl)propanoic acid (3-19): Isovaleric acid 3-20 (60 mg, 0.59 mmol) was 
coupled to N(im)–trityl-L-histidine 3-17 (353 mg, 0.9 mmol) by using the anhydride 
method described in the general procedure. The crude product was purified by silica gel 
column chromatography (dichloromethane/methanol, 10/1) to give the desired fragment 
3-19 (215 mg, 0.45 mmol, 76%) as a white crystalline solid. 1H NMR (500 MHz, 
DMSO-d6) :  δ 0.77 (d, J = 6.3 Hz, 3H), 0.80 (d, J = 6.3 Hz, 3H), 1.84 (m, 2H) 2.70 (m, 
1H), 2.86 (dd, J = 5.1, 14.0 Hz, 1H), 4.35 (m, 1H), 6.67 (s, 1H), 7.04 (m, 6H), 7.23 (s, 
1H), 7.35 (m, 9H), 7.89 (d, J = 7.5 Hz, 1H); 13C NMR (125 MHz,CDCl3): δ 19.0, 22.3, 
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25.8, 45.7, 52.4, 76.1, 120.1, 127.8, 129.6, 137.1, 141.5, 171.8; ESI-MS, calcd for 
C30H31N3O3  481.2, found 482.0, [M+Na]+ 504.1. 
 
Preparation of Fmoc–tetrapeptide: (9H-fluoren-9-yl)methyl (S)-1-((2S,3S)-1-((S)-1-
((S)-2-carbamoylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxo 
pentan-2-ylamino)-1-oxo-3-(1-trityl-1H-imidazol-4-yl)propan-2-ylcarbamate(3-14): 
Tripeptide 3-7 (297 mg, 0.7 mmol) was coupled to Nα-Fmoc-N(im)-trityl-L-histidine 3-13 
(436 mg, 0.77 mmol) to give the desired compound 3-14 as a white solid (456 mg, 0.5 
mmol, 70% yield) after silica gel column purification using chloroform/methanol 
(10/1). 1H NMR  (300 MHz, CDCl3) δ 0.80 (m, 12 H), 1.05 (m, 1H), 1.39 (m, 1H), 1.92 
(m, 4H), 2.2 (m, 2H),  3.02 (m, 2H), 3.45 (m, 1H), 3.57 (m, 1H), 4.19 (m, 1H), 4.29 (m, 
6H), 6.66 (m, 2H), 6.99 (m, 7H), 7.30 (m, 17H), 7.56 (m, 2H), 7.72 (m, 2H); 13C NMR 
(125 MHz, pyridine-d5) δ 11.1, 16.0, 18.8, 19.6, 25.2, 25.3, 29.3, 31.2, 32.0, 37.7, 47.7, 
47.9, 55.0, 56.3, 56.9, 58.0, 60.3, 67.0, 75.4, 119.7, 120.3, 123.3, 125.8, 127.4, 127.5, 
128.0, 128.2, 128.4, 130.1, 138.5, 138.9, 141.6, 143.1, 144.6, 144.7, 157.2, 171.6, 

















Preparation of tetrapeptide: (S)-1-((S)-2-((2S,3S)-2-((S)-2-amino-3-(1-trityl-1H-
imidazol-4-yl)propanamido)-3-methylpentanamido)-3-methylbutanoyl)pyrrolidine 
-2-carboxamide (3-15): Fmoc-tetrapeptide 3-14 (107 mg, 0.1 mmol) was cleaved using 
the general procedure for the removal of Fmoc group to give compound 3-15 as a white 
solid (70 mg, 0.1 mmol, 86%)  after purification by column chromatography using 
DCM/methanol/TEA (6/1+0.1%TEA).   1H NMR  (500 MHz, CDCl3): δ 0.83 (m, 6H), 
0.88 (d, 6H), 1.05 (m, 1H), 1.43 (m, 1H), 1.85 (m, 7H), 2.27 (m, 1H),  2.67 (m, 1H), 
3.06 (dd, J = 4.4, 14.5 Hz, 1H), 3.59 (m, 2H), 3.76 (m, 1H), 4.35 (dd, J = 2.5, 8.8 Hz, 
1H), 4.57 (m, 2H), 6.66 (s, 1H), 7.03 (brs, 1H), 7.10 (m, 6H), 7.16 (d, J = 8.8 Hz, 1H), 
7.30 (m, 9H), 7.36 (brs, 1H), 8.12 (d, J = 9.4 Hz, 1H); 13C NMR ( 125 MHz, CDCl3):  δ 
11.3, 15.9, 17.8, 19.3, 24.5, 25.0, 27.2, 31.3, 33.1, 47.7, 55.6, 55.7, 57.5, 59.3, 75.2, 
119.4, 128.0, 129.7, 138.0, 138.7, 142.3, 171.4, 171.6, 173.2, 175.0; ESI-MS: calcd for 
C41H51N7O4 705.4, found 706.2, [M+Na]+ 728.4  
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Coupling with Isovaleric acid: (S)-1-((S)-3-methyl-2-((2S,3S)-3-methyl-2-((S)-2-(3-
methylbutanamido)-3-(1-trityl-1H-imidazol-4-yl)propanamido)pentanamido)buta 
noyl)pyrrolidine-2-carboxamide (3-16): Tetrapeptide 3-15 (70 mg, 0.1 mmol) was 
coupled to isovaleric acid (40 mg, 0.39 mmol) to give the desired compound 3-16 as a 
white solid (57 mg, 0.07 mmol, 72 %) after column purification using chloroform 
/methanol (8/1). 1H NMR (500 MHz, CDCl3) : δ 0.85 (m, 18H), 1.05 (m, 1H), 1.41 (m, 
1H), 1.82 (m, 2H), 1.88 (m, 6H), 2.34 (m, 1H), 3.01 (m, 2H), 3.53 (m, 1H), 3.82 (m, 
1H), 4.39 (m, 1H), 4.47 (t, J = 8.2 Hz, 1H), 4.53 (dd, 1H), 4.62 (brm, 1H), 6.72 (s, 1H), 
6.88 (brs, 1H), 7.09 (m, 6H), 7.29 (m, 11H), 7.46 (brm, 2H), 7.82 (brm, 1H); 13C NMR 
( 125 MHz, CDCl3): δ 11.6, 15.8, 18.3, 19.2, 22.4, 22.5, 25.0, 26.0, 26.6, 29.6, 30.0, 
30.8, 36.5, 45.8, 47.7, 53.5, 58.5, 59.2, 75.2, 119.8, 128.1, 129.7, 142.2, 171.1, 171.2, 
173.1, 173.3; ESI-MS: calcd for C46H59N7O5 789.5, found 790.1, [M+Na]+  812.4 
Preparation of Tetrapeptide:  (S)-1-((S)-2-((2S,3S)-2-((S)-3-(1H-imidazol-4-yl)-2-
(3-methylbutanamido)propanamido)-3-methylpentanamido)-3-methylbutanoyl) 
pyrrolidine -2-carboxamide (3-10): Compound 3-16 (57 mg, 71µmol) was dissolved 
in dichloromethane and then TFA solution was added followed by triisopropylsilane. 
After one hour, the reaction was complete. The solvent was removed in vacuo and the 
reaction was worked up by adding saturated sodium bicarbonate. The aqueous layer was 
extracted with ethyl acetate. The residue was purified on preparative HPLC to give 3-
10, (31 mg, 0.057 mmol, 79%) as a gummy residue using Luna C18 column, 
50x3.0mm, 5µm;  (linear gradient: 0 to 100% B, 0.1% formic acid, 70 min). 1H NMR  
(500 MHz, DMSO-d6) : δ 0.80 (m, 6H), 0.89 (d, 6H) 0.9 (m, 6H), 1.06 (m, 1H), 1.39 
(m, 1H), 1.7 (m, 1H), 1.80 (m, 1H), 1.91 (m, 7H) 2.84 (m, 1H), 3.01 (m, 1H), 3.59 (m, 
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1H), 3.76 (m, 1H), 4.23 (m, 2H), 4.3 (t, 1H), 4.62 (m, 1H), 6.86 (s, 1H),  7.06 (s, 1H), 
7.28 (s, 1H), 7.76 (d, J = 8.2 Hz, 1H), 8.1 (m, 2H), 8.25  (brs, 1H). 13C NMR (125 MHz, 
DMSO-d6): δ 10.6, 14.9, 17.8, 18.5, 21.9, 23.8, 24.9, 28.7, 29.4, 36.5, 44.1, 46.6, 52.6, 
55.5, 56.4, 59.1, 132.1, 134.1, 167, 168.5, 169.8, 170.8, 171.0; ESI-MS: calcd for 
C27H45N7O5  547.3, found 548.3, [M+Na]+ 570.4 
 
(2R,3S)-2-Amino-3-methylpentanoic acid (3-22) : D-Alloisoleucine (500 mg, 3.8 
mmol) was prepared using the general procedure for Boc protection to give the desired 
compound as a white solid in nearly quantitative yield (858 mg, 3.71 mmol, 97%). 1H 
NMR  (500 MHz, DMSO-d6): δ 0.80 (m, 6H), 1.09 (m, 1H), 1.23 (m, 1H), 1.32 (s, 9H), 
1.75 (m, 1H), 3.97 (m, 1H), 6.79 (d, J = 8.85 Hz, 1H); 13 C NMR (125 MHz, CDCl3): δ 
11.4, 14.7, 25.6, 28.1, 36.0, 56.7, 77.9, 155.8, 173.7; ESI-MS, calcd for C11H21NO4 








noic acid  (3-24): Boc-D-alloisoleucine (730 mg, 3.15 mmol) was coupled to L-valine 
(500 mg, 4.27 mmol) using the method described above. The crude was purified using 
column chromatography (hexane/ethylacetate, 3/1) to give the desired compound as a 
white solid (716 mg, 2.17 mmol, 69%). 1H NMR  (500 MHz, DMSO-d6): δ 0.76 (m, 
12H), 1.08 (m, 2H), 1.29 (s, 9H), 1.75 (m, 1H), 1.98 (m, 1H), 4.01 (m, 1H), 4.12 (m, 
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1H), 6.57 (d, J = 9.0 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 12.57 (brs, 1H); 13C NMR (125 
MHz, CDCl3): δ 11.3, 14.2, 18.0, 19.1, 25.7, 28.1, 29.8, 36.9, 56.9, 59.4, 78.0, 155.4, 
172.9;  ESI-MS, calcd for C16H30N2O5 330.2, found 330.9, [M+Na]+ 353.1 
 
tert-butyl (2R,3S)-1-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-methyl-1-oxobutan-
2-yl a mino)-3-methyl-1-oxopentan-2-ylcarbamate (3-25) : L-Boc proline amide 3-12 
(350 mg, 1.6 mmol) was coupled to the dipeptide 3-24 (647 mg, 1.95 mmol) to give the 
desired compound as a white solid 3-25 (368 mg, 0.86 mmol, 53%) after silica gel 
column purification with chloroform/methanol (15/1) as eluents. 1H NMR  (500 MHz, 
DMSO-d6):  δ 0.78 (m, 12H), 1.11 (m, 2H), 1.41 (s, 9H), 1.81 (m, 6H), 3.57 (m, 1H), 
3.73 (m, 1H), 3.98 (m, 1H), 4.26 (m, 1H), 4.34 (t, J = 8.2 Hz, 1H), 6.85 (brs, 2H), 7.17 
(d, J= 8.8 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.95  (d, J = 8.8 Hz, 1H); ESI-MS, calcd 
for C21H38N4O5 426.3, found 427.1, [M+Na]+ 449.2  
 
(S)-1-((S)-2-((2R,3S)-2-((S)-3-(1H-imidazol-4-yl)-2-(3-methylbutanamido)propana 
mido)-3-methylpentanamido)-3methylbutanoyl)pyrrolidine-2-carboxamide (3-27) :  
The tripeptide 3-25 (112 mg, 0.26 mmol) was coupled to the fragment 3-19 (126 mg, 
0.26 mmol) using the standard coupling agent, HATU as described in the general 
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procedure followed by the removal of trityl group by following the general procedure 
described above gave compound 3-27 as a gummy solid (158 mg, 0.2 mmol, 77%) after 
silica gel column chromatography (chloroform/methanol, 8/1). 1H NMR  (500 MHz, 
DMSO-d6) : δ 0.68 (d,  J = 6.9 Hz, 3H), 0.77 (m, 12H), 0.89 (d, J = 6.9 Hz, 3H), 0.96 
(m, 1H), 1.10 (m, 1H), 1.74 (m, 1H), 1.90 (m, 8H) 2.74 (m, 1H), 2.89 (m, 1H), 3.55 (m, 
1H), 3.73 (m, 1H), 4.22 (m, 1H), 4.28 (t, J = 8.2 Hz, 1H), 4.38 (m, 1H), 4.64 (m, 1H), 
6.81 (brs, 1H),  6.90 (brs, 2H), 7.23 (brs, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.92 (brs, 1H), 
8.01 (d, J = 7.5 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H); ESI-MS, calcd for C27H45N7O5 547.3, 
found 548.3, [M+Na]+ 570.4. 
Determination of absolute stereochemistry of tetrapeptide, N1266 (3-1): Hydrolysis 
of tetrapeptide N1266 (3-1, 0.2 mg) was achieved by heating under microwave 
irradiation in 6N HCl (0.2 mL) at 170 °C for 20 min. After cooling, the solution was 
evaporated to dryness and dissolved in H2O (50 µL). To the acid hydrolyzate solution 
was added a 1% (w/v) solution (100 µL) of 2,4-dinitro-5-fluorophenyl)-L-alaninamide 
(FDAA) in acetone. After addition of NaHCO3 solution (1 M; 20 µL) the mixture was 
incubated for 1 h at 40 °C. The reaction was stopped by the addition of HCl (2 N; 10 
µL), the solvents were evaporated to dryness and the residue was dissolved in 
MeOH/H2O (1:1; 1 mL). An aliquot of this solution (30 µL for 3-1 and 10 µL for the 
standards) was analyzed by HPLC-MS (IT-TOF, Phenomenex C18, 50x3.0mm, 5µm; 
linear gradient: 1 to 100% B, 45 min; 1 mL min-1; 25 °C). Retention times (min) of the 
FDAA amino acid derivatives used as standards were as follows: D-His (13.72), L-His 
(14.54), L-Pro (17.26), D-Pro (17.62), L-Val (19.10), D-Val (20.45) L-Ile (20.46) and 
D-Ile (21.75). Retention times (min) of the observed peaks in the HPLC trace of the 
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FDAA derivatized hydrolysis product of 3-1 were as follows: D-His (13.15) L-Pro 

















-1H-im idazol-4-yl)propan-2-ylcarbamate (3-30): Tripeptide 3-7 (160 mg, 0.37 
mmol) was coupled to Nα-fmoc-N(im)-trityl-D-histidine 3-29 (256 mg, 0.41 mmol) using 
the general procedure for coupling by HATU coupling reagent. The desired compound 
3-30 (262 mg, 0.28 mmol, 75%) was obtained as a white solid after column purification 
using chloroform/methanol (9/1).  1H NMR  (300 MHz, CDCl3), δ 0.75 (m, 12H), 1.02 
(m, 1H), 1.18 (m, 1H), 1.41 (m, 1H), 1.87 (6H, m),  3.0 (d, J = 6.2 Hz, 2H), 3.61 (m, 
1H),  3.77 (m, 1H), 4.19 (m, 3H), 4.51(m, 3H), 6.54 (brs, 1H), 6.66 (s, 1H), 7.06 (m, 
7H), 7.14 (brs, 1H), 7.28 (m, 14H), 7.56 (m, 2H), 7.64 (brd, 1H), 7.72 (m, 2H), 7.79  
(brd, 1H);  13C NMR ( 75 MHz, CDCl3) : δ 11.3, 15.8, 17.9, 19.2, 24.4, 25.0, 27.7, 31.2, 
47.0, 47.7, 55.1, 55.8, 57.8, 59.3, 67.2, 75.3, 119.3, 119.8, 125.1, 125.2, 127.0, 127.6, 
128.0, 129.6, 138.5, 141.1, 141.2, 142.2, 143.7, 143.9, 171.2, 171.3, 171.7, 173.5; ESI-





tetrapeptide 3-30 (140 mg, 0.15 mmol) was cleaved using piperidine to give the desired 
compound 3-31 as a white solid (77 mg, 0.11 mmol, 70%) after silica gel column 
purification (dichloromethane/methanol, 6/1). 1H NMR  (300 MHz, CDCl3) 0.83 (m, 
12H),  1.10 (m, 1H), 1.40 (m, 1H), 1.93 (m, 6H),  2.82 (m, 2H), 3.62 (m, 1H), 3.85 (m, 
1H),  4.00 (m, 1H), 4.30 (m, 1H), 4.53 (m, 2H), 5.86 (s, 1H), 6.63 (s, 1H), 7.03 (brs, 
1H), 7.10 (m, 6H), 7.16 (d, 1H), 7.33 (m, 9H), 7.46 (s, 1H), 7.65 (d, J = 8.2 Hz, 1H), 
8.28 (d, J = 8.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) : δ 11.2, 15.7, 18.1, 19.1, 24.6, 
24.9, 28.2, 30.6, 32.2, 36.5, 47.6, 54.5, 55.9, 58.4, 59.5, 75.1, 119.5, 127.9, 129.5, 
136.7, 138.6, 142.0, 171.3, 171.5, 173.4, 173.7;  ESI-MS: calcd for C41H51N7O4  705.4, 


















(3-32): Tetrapeptide 3-31 (74 mg, 0.1 mmol) was coupled to isovaleric acid (10 µL, 0.1 
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mmol) using the general procedure for coupling using HATU coupling agent. The 
desired compound 3-32 (48 mg, 0.06 mmol, 58%) was obtained as a white solid after 
column purification on silica gel using chloroform/methanol (10/1). 1H NMR  (500 
MHz, CDCl3) δ 0.82 (m, 18H),  1.05 (m, 1H), 1.41 (m, 1H), 1.92 (m, 2H),  2.02 (m, 
6H), 2.29 (m, 1H), 2.92 (m, 1H), 3.02 (m, 1H), 3.57 (1H, m), 3.75 (1H, m),  4.36 (m, 
1H), 4.53 (m, 2H), 4.64 (q, J = 6.3 Hz, 1H), 6.67 (s, 1H), 6.94 (brs, 1H), 7.02 (brs, 1H), 
7.08 (6H, m), 7.32 (m, 11H), 7.98 (br, 1H); 13C NMR (125 MHz, CDCl3) : δ 11.4, 15.8, 
17.9, 19.3, 22.4, 22.5, 24.6, 25.0, 26.0, 27.1, 29.6, 29.7, 31.2, 36.8, 45.8, 47.7, 53.2, 
55.7, 58.3, 59.3, 75.5, 119.4, 128.1, 129.7, 138.1, 142.1, 171.1, 171.6, 171.7, 173.1, 




Trt-tetrapeptide 3-32 (40mg, 50.6 µmol) was treated with TFA to give the target 
compound. Pure compound 3-1 (14 mg, 0.02 mmol, 51%) was obtained as a gummy 
residue by preparative HPLC using Luna C18 column, 50x3.0mm, 5µm;  (linear 
gradient: 0 to 100% B, 0.1% formic acid, 70 min). 1H NMR  (500 MHz, DMSO-d6) :  δ 
0.74 (m, 18H), 1.27 (m, 2H), 1.67 (m, 1H), 1.79-1.82 (m, 1H), 1.91-2.02 (m, 5H), 2.73 
(m, 1H), 2.93 (m, 1H), 3.55 (m, 1H), 3.77 (m, 1H), 4.23 (m, 2H), 4.3 (m, 1H), 4.59 (m, 
1H), 6.79 (s, 1H), 6.84 (s, 1H),  7.26 (s, 1H), 7.53 (s, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.99 
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(m, 2H);  13C NMR (125 MHz, DMSO-d6): δ 11.0, 15.2, 18.4, 19.0, 22.1, 22.2, 24.0, 
24.4, 25.4, 29.2, 36.9, 44.4, 46.9, 52.6, 55.7, 56.2, 59.1, 134.5, 169.5, 170.7, 171.3, 
172.6, 173.3; ESI-MS: calcd for C27H45N7O5  547.3, found 548.1. 
 
Histidine-Cinnamicacid fragment: (S,E)-6-(2-methoxyphenyl)-4-oxo-2-((1-trityl-1 
H -imidazol-4-yl)methyl)hex-5-enoic acid (4-18): Cinnamic acid (30 mg, 0.17 mmol) 
was coupled to N(im) –trityl - L-histidine  3-17 (100 mg, 0.25 mmol) by using the 
anhydride method described in the general procedure. The crude product was purified 
by column chromatography using silica gel (chloroform/methanol, 9/1) to give the 
desired fragment 4-18 (81mg, 0.14 mmol, 86%) as a white crystalline solid. 1H NMR 
(500 MHz, DMSO-d6) :  δ 2.70 (m, 1H), 2.94 (m, 1H), 3.85 (s, 3H), 4.51 (m, 1H), 6.65 
(t, J = 8.2 Hz, 2H), 6.92 (m, 9H), 7.22 (m, 11H), 7.48 (dd, J = 7.6, 1.9 Hz, 1H), 7.61 (d, 
J = 15.7 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ 30.2, 
52.1, 55.5, 74.3, 111.6, 119.2, 120.6, 122.1, 123.2, 127.8, 128.0, 128.1, 129.1, 130.8, 






-2-carb oxamide (4-19): The tripeptide 3-7 was coupled to (50 mg, 0.1 mmol) was used 
to coupled to the fragment 4-19 (65 mg, 0.12 mmol) to give compound 4-19 as a white 
solid after purification by silica gel column chromatography (chloroform/methanol, 
9/1). 1H NMR  (500 MHz, CDCl3) : δ 0.78 (m, 6H), 0.86 (d, J = 6.9 Hz, 3H), 0.90 (d, J 
= 6.9 Hz, 3H), 1.02 (m, 1H), 1.18 (m, 1H), 1.40 (m, 1H), 1.72 (m, 3H), 1.90 (m, 3H), 
3.00 (m, 1H), 3.07 (d, J = 5.6 Hz, 1H), 3.57 (m, 1H), 3.73 (m, 1H), 3.82 (s, 3H), 4.05 
(m, 1H), 4.34 (m, 2H), 4.70 (m, 1H), 6.56 (d, J = 16.3 Hz, 1H), 6.67 (brs, 1H), 6.72 (s, 
1H), 6.88 (d, J = 8.2 Hz, 1H), 6.92 (t, J = 7.0 Hz, 1H), 7.01 (brm, 1H), 7.08 (m, 6H), 
7.28 (m, 11H), 7.36 (d, J = 16.3 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 5.6 Hz, 
1H), 7.75 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 15.8 Hz, 1H); 13C NMR (125 MHz, DMSO-
d6): δ 11.6, 15.8, 18.4, 19.1, 24.5, 25.0, 27.0, 30.1. 30.9, 36.6, 47.7, 54.1, 55.3, 55.6, 
56.2, 58.3, 59.0 111.0, 119.7, 120.6, 121.0, 123.7, 128.0, 128.8, 129.7, 130.8, 136.8, 
138.4, 142.1, 142.2, 158.2, 166.6, 171.3, 171.5, 171.7, 173.3; ESI-MS: calcd for 




boxamide (4-20): The trityl group of compound 4-19 was then removed by using TFA 
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to give the desired compound 4-20 as a white solid after column purification with 
chloroform/methanol (8/1). 1H NMR  (500 MHz, DMSO-d6) : δ 0.78 (m, 6H), 0.86 (d, 
J= 6.9 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H), 1.02 (m, 1H), 1.37 (m, 1H), 1.72 (m, 3H), 1.90 
(m, 3H), 2.82 (m, 1H), 2.93 (m, 1H), 3.54 (m, 1H), 3.73 (m, 1H), 3.85 (s, 3H), 4.20 (m, 
2H), 4.30 (t, J = 8.8 Hz, 1H), 4.66 (m, 1H), 6.72 (s, 1H), 6.75 (s, 1H), 6.76 (brs, 1H), 
6.96 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 7.19 (brs, 1H), 7.34 (m, 1H), 7.51 
(brs, 1H), 7.52 (d, J = 1.2 Hz, 1H), 7.62 (d, J = 15.7 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 
8.02 (d, J = 8.2 Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ 
11.0, 15.2, 18.2, 19.0, 24.1, 24.3, 29.1. 29.7, 36.7, 52.6, 55.4, 55.6, 56.6, 59.1, 111.6, 
120.5, 122.1, 123.1, 127.7, 130.7, 133.9, 134.5, 157.4, 165.1, 169.5, 170.7, 170.8, 
173.3; ESI-MS: calcd for C32H45N7O6 623.3, found 624.2, [M+Na]+ 646.4 
 
(S)-1-((S)-3-methyl-2-((2S,3S)-3-methyl-2-(3-methylbutanamido)pentanamido)but 
anoyl)pyrrolidine-2-carboxamide (4-3): Tripeptide 3-7 (100 mg, 0.23 mmol) was 
coupled to isovaleric acid ( 27.7 µL, 0.25 mmol) following the general procedure. to 
give the desired compound 4-3 as a white solid (60 mg, 0.15 mmol, 62%) after silica gel 
column chromatography (chloroform/methanol, 10/1). 1H NMR  (500 MHz, DMSO-d6) 
: δ 0.78 (m, 18H), 1.04 (m, 1H), 1.24 (m, 1H), 1.75 (m, 2H), 1.91 (m, 5H), 3.54 (m, 
1H), 3.72 (m, 1H), 4.22 (m, 1H), 4.30 (t, J = 8.1 Hz, 1H), 4.42 (m, 1H), 6.77 (s, 1H), 
7.19 (s, 1H), 7.61 (d, J = 9.4 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ 11.1, 16.0 17.6, 19.2, 19.3, 22.2, 22.3, 24.3, 25.0, 26.1, 28.3, 31.4, 38.0, 
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46.0, 47.7, 55.6, 57.0, 59.2, 171.0, 171.6, 172.7, 173.9; ESI-MS: calcd for C21H38N4O4  


















xamide (4-17): Tetrapeptide 3-15 (50 mg, 0.071 mmol) was coupled to mandelic acid 
4-15 (10.8 mg, 0.071 mmol) to give compound 4-16 which on removal of trityl group 
gave compound 4-17 (6 mg, 0.01 mmol) as a white solid after purification by silica gel 
column chromatography (chloroform/methanol, 6/1) in 14% yield after 2 steps. 1H 
NMR  (500 MHz, DMSO-d6) : δ 0.68 (m, 6H), 0.84 (d, J = 6.3 Hz, 3H), 0.89 (d, J =  6.3 
Hz, 3H), 1.22 (m, 1H), 1.66 (m, 1H), 1.75 (m, 2H), 1.88 (m, 4H), 2.87 (m, 2H), 3.58 
(m, 1H), 3.80 (m, 1H), 4.20 (m, 2H), 4.27 (m, 1H), 4.53 (m, 1H), 4.90 (d, J = 4.4 Hz, 
1H), 6.25 (s, 1H), 6.77 (s, 1H),  6.83 (s, 1H), 7.22 (m, 4H), 7.34 (s, 1H), 7.35 (s, 1H), 
7.57 (s, 1H), 7.77 (d, J = 7.6 Hz, 1H), 8.26 (d, J = 6.9 Hz, 1H), 8.32 (d, J = 7.5 Hz, 1H), 






tide 3-15 (45 mg, 0.064 mmol) was coupled to Boc-indole-3-glyoxylic acid 4-7 
(18.4mg, 0.064 mmol) according to the general protocol to give compound 4-8 as a 
white solid (33 mg, 0.034 mmol, 52%) after purification by column chromatography on 
silica gel (chloroform/methanol, 9/1).  1H NMR (500 MHz, CDCl3): δ 0.82 (m, 6H), 
0.89 (m, 6H), 1.11 (m, 1H), 1.44 (m, 1H), 1.69 (s, 9H), 1.86 (m, 5H), 2.30 (m, 1H), 3.14 
(m, 1H), 3.55 (m, 1H), 3.79 (q, J = 9.4 Hz, 1H), 4.39 (m, 1H), 4.50 (t, J = 8.8 Hz, 1H), 
4.56 (dd, J = 2.5, 8.1 Hz, 1H), 4.79 (m, 1H), 5.20 (brs, 1H), 6.72 (s, 1H), 6.95 (brs, 1H), 
7.10 (m, 6H), 7.30 (m, 11H), 7.37 (m, 2H), 7.46 (brs, 1H), 7.96 (m, 1H), 8.19 (dd, J = 
2.5, 7.6 Hz, 1H), 8.38 (dd, J = 1.9, 6.9 Hz, 1H) 8.82 (brs, 1H), 9.25 (s, 1H); 13C NMR 
(125 MHz, CDCl3): δ 11.5, 15.9, 18.1, 19.2, 24.8, 25.0, 26.8, 28.0, 29.6, 30.0, 30.9, 
36.5, 47.7, 53.3, 55.9, 58.8, 59.2, 85.6, 115.1, 115.3, 122.3, 124.7, 125.7, 127.9, 128.1, 
129.7, 138.4, 148.7, 161.6, 170.8, 171.2, 172.8, 173.2, 181.8; ESI-MS: calcd for 





mide (4-9): Compound 4-8 (33 mg, 0.034 mmol) on treating with TFA (5vol) gave 
compound 4-9 as a white solid (14 mg, 0.02 mmol, 63%) after purification by silica gel 
column chromatography (chloroform/methanol, 5/1). 1H NMR  (500 MHz, DMSO-d6) : 
δ 0.74 (m, 6H), 0.85 (d, J = 6.3 Hz, 3H), 0.88 (d, J = 6.3 Hz, 3H), 0.98 (m, 1H), 1.32 
(m, 1H), 1.70 (m, 3H), 1.88 (m, 1H), 1.96 (m, 2H), 2.92 (m, 1H), 3.01 (q, J = 7.5 Hz, 
1H), 3.54 (m, 1H), 3.72 (m, 1H), 4.19 (q, J = 4.4 Hz, 1H), 4.23 (m, 2H), 4.60 (m, 1H), 
6.83 (s, 2H), 7.24 (m, 3H),  7.52 (m, 1H), 7.60 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 8.16 (d, 
J = 8.1 Hz, 1H), 8.21 (d, J = 8.2 Hz, 1H), 8.74 (s, 1H), 8.94 (d, J = 7.5 Hz, 1H), 11.8 (s, 
1H), 12.2 (brs, 1H); 13C NMR (125 MHz, DMSO-d6): δ 11.3, 15.9, 18.8, 19.7, 25.9, 
26.0, 30.8, 31.6, 38.1, 54.6, 57.9, 59.2, 61.2, 113.1, 113.9, 122.9, 123.8, 124.8, 127.8, 
136.4, 137.9, 139.7, 165.2, 172.2, 172.9, 173.6, 176.8, 182.0; ESI-MS: calcd for 




dine-2-carboxamide (4-11): Tetrapeptide 3-15 (100 mg, 0.14 mmol) was coupled to 
(S)-(−)-α-methoxy-α-(trifluoromethyl)phenylacetic acid 4-10 (33.2 mg, 0.14 mmol) to 
give compound 4-11 as a white solid (116 mg, 0.012 mmol, 89%) after purification by 
silica gel column chromatography (chloroform/methanol, 9/1). 1H NMR (500 MHz, 
CDCl3): δ 0.78 (m, 12H), 0.95 (m, 1H), 1.32 (m, 1H), 1.82 (m, 5H), 2.26 (m, 1H), 3.04 
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(m, 2H), 3.34 (s, 3H), 3.55 (m, 1H), 3.79 (q, J = 7.7 Hz, 1H), 4.38 (q, J = 5.3 Hz, 1H), 
4.49 (m, 2H), 4.67 (q, J = 6.1 Hz, 1H), 6.74 (s, 1H), 6.88 (brs, 1H), 7.07 (m, 6H), 7.31 
(m, 14), 7.52 (m, 2H), 7.57 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 8.35 (d, J = 
6.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) : δ 11.5, 15.8, 18.1, 19.2, 24.6, 25.0, 26.9, 
30.3, 30.9, 36.6, 47.7, 53.3, 54.9, 56.0, 58.6, 59.2, 75.1, 119.6, 127.7, 128.1, 128.2, 
128.6, 129.3, 129.7, 132.2, 138.4, 142.1, 166.2, 170.7, 171.1, 171.7, 173.2; ESI-MS: 



















carboxamide (4-12):  Trityl group of compound 4-11 (60 mg, 0.065 mmol) was 
removed using TFA to give compound 4-12 (31mg, 0.045mg, 70%) as a white solid 
after purification by silica gel column chromatography (CHCl3/MeOH, 8/1). 1H NMR  
(500 MHz, DMSO-d6) : δ 0.73 (t, J = 7.5 Hz, 6H), 0.87 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 
6.9 Hz, 3H), 1.23 (m, 1H), 1.63 (m, 1H), 1.76 (m, 2H), 1.90 (m, 4H), 2.92 (m, 2H), 3.19 
(s, 3H), 3.56 (m, 1H), 3.77 (m, 1H), 4.20 (m, 2H), 4.28 (t, J = 8.2 Hz, 1H), 4.61 (m, 
1H), 6.82 (brs, 2H), 7.24 (s, 1H), 7.37 (m, 3H), 7.49 (d, J = 7.5 Hz, 2H), 7.54 (s, 1H), 
7.64 (d, J = 8.8 Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 8.54 (brs, 1H), 11.7 (brs, 1H);  13C 
NMR (125 MHz, MeOD) : δ 11.3, 15.8, 18.8, 19.7, 25.8, 26.0, 30.1, 30.8, 31.6, 38.1, 
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47.8, 54.4, 55.4, 57.8, 59.1, 61.2, 129.0, 129.5, 130.6, 134.0, 136.4, 168.3, 172.3, 172.7, 













-2-yl carbamate (4-22): Tripeptide 3-7 (165 mg, 0.38 mmol, 1 equiv.) was coupled to 
Fmoc-propargyl glycine (335 mg, 0.41 mmol, 1.1 equiv) under standard peptide 
coupling conditions using HATU/HOAt to give the desired compound as a white solid 
(150 mg, 60%) after silica gel column chromatography (chloroform/methanol, 9/1). 1H 
NMR (500 MHz, CDCl3):  δ 0.85 (m, 6H), 0.92 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 6.9 Hz, 
3H), 1.07 (m, 1H), 1.22 (m, 1H), 1.43 (m, 1H), 1.95 (m, 6H), 2.23 (m, 1H), 2.72 (m, 
2H), 3.48 (m, 1H), 4.01 (m, 1H), 4.21 (t, J =  6.9 Hz, 1H), 4.25 (m, 1H), 4.38 (m, 4H), 
4.49 (m, 1H), 5.78 (brs, 1H), 6.22 (brs, 1H), 6.65 (brs, 1H), 7.00 (d, J = 8.2 Hz, 1H), 
7.15 (brs, 1H), 7.28 (m, 2H), 7.37 (t, J = 6.9 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.74 (d, 
J = 7.5 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ 10.9, 15.3, 18.4, 19.0, 22.1, 22.2, 
24.1, 25.5, 29.2, 29.7, 36.8, 44.2, 46.9, 55.7, 56.3, 59.1, 72.6, 80.5, 169.5, 169.6, 170.6, 




amido)pentanamido)butanoyl)pyrrolidine-2-carboxamide (4-24): Fmoc group of 
compound 4-24 (144mg, 0.22 mmol) was cleaved using piperidine as described in the 
general procedure and coupled to isovaleric acid (29.8mg, 0.29 mmol) under standard 
peptide coupling conditions using HATU/HATU to give the desired compound as white 
solid after purification by silica gel column chromatography (chloroform/methanol, 8/1) 
in 45% yield after 2 steps. 1H NMR (500 MHz, DMSO-d6):  δ 0.76 (m, 6H), 0.85 (dd, J 
= 3.1, 6.3 Hz, 6H), 0.88 (d, J = 6.9 Hz, 6H), 1.01 (m, 1H), 1.36 (1H), 1.69-1.80 (m, 
3H), 1.88-2.05 (m, 3H), 2.39 (m, 1H), 2.52 (m, 1H), 2.77 (t, J = 2.5 Hz, 1H), 3.52 (m, 
1H), 3.73 (m, 1H), 4.19 (q, J = 4.4 Hz, 1H), 4.23 (m, 2H), 4.50 (q, J = 7.6 Hz, 1H), 6.80 
(brs, 1H), 7.22 (brs, 1H), 7.93 (m, 2H), 7.97 (d, J = 8.2 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ 10.9, 15.3, 18.4, 19.0, 22.1, 22.2, 24.1, 25.5, 29.2, 29.7, 36.8, 44.2, 46.9, 
55.7, 56.3, 59.1, 72.6, 80.5, 169.5, 169.6, 170.6, 171.4, 173.3; ESI-MS, calcd for 






Ethyl-7-dimethylaminocoumarin (4-30): Ethyl-7-dimethylaminocoumarin 4-30 was 
synthesized from m-dimethylaminophenol 4-28 and diethyl 1,3- acetonedicarboxylate 
4-29 by using freshly purified starting materials. m-Dimethylamino phenol (4 gm, 36.5 
mmol, 1 equiv.), diethyl 1,3-acetonedicarboxylate (6.49 gm, 40.1 mmol, 1.1 equiv.) and 
ZnCl2 (5.25 gm, 48.1 mmol, 1.2 equiv.) were dissolved in absolute ethanol (80 mL). 
The reaction mixture was heated at reflux for 15 h. The reaction mixture was then 
cooled to room temperature and the yellow precipitate formed was filtered and air-
dried. The product was recrystallized to give ethyl 7-dimethylaminocoumarin acetic 
acid ester 4-30 as orange needles (10.9 g, 45%). Rf (CH2Cl2/MeOH, 9/1, +0.1%TEA) = 
0.78. IR (pellet) /cm-1: 1604.8, 1720.5, 2916.37; 1H NMR (500 MHz, CDCl3): δ 1.22 (t, 
J = 5.0 Hz, 3H), 3.03 (s, 1H), 3.65 (s, 2H), 4.16 (q, J = 7.6 Hz, 2H), 6.02 (s, 1H), 6.48 
(d, J = 2.6 Hz, 1H), 6.59 (dd, J = 8.9, 2.5 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H); 13C NMR 
(500 MHz, CDCl3) δ 14.0, 38.2, 40.0, 61.5, 98.2, 108.4, 108.9, 110.6, 125.2, 148.4, 
152.8, 155.9, 161.7, 169.0; MS (ESI): m/z : 276 [M+]+. 
 
2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetic acid (4-31): Ethyl-7-dimethyl 
aminocoumarin 4-30 (10 gm, 181.6 mmol, 1 equiv.) was dissolved in THF/H2O (3:1) 
(120mL) and cooled to 0◦C. 2M LiOH solution (3.05 gm, 36.3 mmol, 2 eq.) was added 
dropwise. The reaction mixture was stirred at room temperature for 0.5 h. Water (60 
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mL) was added, the aqueous layer was extracted with Et2O (3 x50 mL). The aqueous 
layer was acidified to pH 3-5 by 2 M HCl solution. The precipitate formed was filtered 
and air dried to give coumarin 4-31 as a yellow solid (6.51 gm, 80%). Rf (9:1 
CH2Cl2/MeOH/0.1%TEA) = 0.07. IR (pellet)/cm-1: 1612.49, 1679.36, 2916.37;. 1H 
NMR (500 MHz, DMSO-d6): δ 3.01 (s, 1H), 3.75 (s, 2H), 6.03 (s, 1H), 6.52 (d, J = 8.8 
Hz, 1H), 6.71 (dd, J = 2.5, 8.8 Hz, 1H), 7.48 (d, J = 9.5 Hz, 1H); 13C NMR (500 MHz, 
DMSO-d6): δ 37.5, 39.8, 97.4, 108.1, 109.1, 109.6, 126.0, 150.5, 152.8, 155.4,160.7, 










ate (4-33) : Coumarin acetic acid 4-31 (47 mg, 0.19 mmol, 1.0 equiv.) was coupled to 
Boc-ethylenediamine (30 mg, 0.19 mmol, 1.0 equiv.) under standard coupling 
conditions using HATU/HOAt to give the desired compound 4-33 as pale yellow solid 
(56 mg, 77%) after purification by silica gel column chromatography 
(chloroform/methanol, 20/1). 1H NMR  (500 MHz, CDCl3): δ 1.40 (s, 9H), 3.04 (s, 6H), 
3.17 (m, 2H), 3.31 (m, 2H), 3.6 (s, 2H), 6.04 (s, 1H), 6.47 (d, 1H), 6.59 (dd, 1H), 6.68 
(brs, 1H), 7.46 (d, 1H); 13C NMR (125 MHz, DMSO-d6): δ 28.3, 39.2, 40.0, 40.2, 47.1, 
80.3, 98.1, 109.0, 110.4, 125.7, 149.7, 152.9, 155.9, 161.8, 168.7, ESI-MS, calcd for 




carbamoyl)pyrrolidine-1-carboxylate (4-34) :Boc group of compound 4-33 (56 mg, 
0.14 mmol, 1 equiv.) was cleaved using TFA and coupled to Boc-proline (31 mg, 0.14 
mmol, 1 equiv.) under standard coupling conditions using HATU/HOAt to give the 
desired compound 4-34 as pale yellow solid (60 mg, 86%) after purification by column 
chromatography on silica gel (chloroform/methanol, 20/1). 1H NMR  (300 MHz, 
CDCl3): δ 1.40 (s, 9H), 1.81 (m, 4H), 3.00 (s, 6H), 3.33 (m, 6H), 3.58 (s, 2H), 4.07 (m, 
1H), 6.04 (s, 1H), 6.42 (d, 1H), 6.56 (dd, 1H), 6.86 (brs, 1H), 7.14 (brs, 1H), 7.46 (d, 
1H); 13C NMR (75 MHz, CDCl3):  28.3, 39.2, 40.0, 40.2, 47.1, 77.4, 80.3, 98.1, 109.0, 
110.4, 125.7, 149.7, 152.9, 155.9, 161.8, 168.7; ESI-MS, calcd for C25H34N4O6  486.2, 




hyl-1-oxopentan-2-ylcarbamate (4-35) : Boc group of compound 4-34 (60 mg, 0.12 
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mmol, 1 equiv.) was cleaved using TFA and coupled to dipeptide 3-4 (44 mg, 0.12 
mmol, 1 equiv.) under standard coupling conditions using HATU/HOAt to give the 
desired compound 4-35 as pale yellow solid (66 mg, 77%) after purification by silica 
gel column chromatography (chloroform/methanol, 15/1).  1H NMR (500 MHz, CDCl3): 
δ 0.83 (m, 12H), 1.03 (m, 2H), 1.34 (s, 9H), 1.84 (m, 6H), 3.00 (s, 6H), 3.08 (m, 7H), 
3.93 (m, 3H), 4.43 (t, 1H), 5.47 (d, 1H), 6.28 (s, 1H), 6.45 (d, 1H), 6.56 (m, 2H), 7.16 
(brs, 1H), 7.43 (d, 1H), 7.57  (d, 1H); 13C NMR (75 MHz, CDCl3): 11.0, 15.5, 18.0, 
18.3, 18.9, 24.4, 25.2, 28.2, 28.4, 31.0, 37.4, 38.7, 39.1, 39.9, 40.9, 48.0, 56.2, 59.3, 
60.6, 79.3, 98.0, 108.5, 109.1, 110.7, 125.9, 150.0, 152.9, 155.9, 162.7, 168.3, 168.6, 























l-4-yl)pro panamido)pentanamido)butanoyl)pyrrolidine-2-carboxamide (4-36) :  
Boc group of compound 4-35 (40 mg, 0.06 mmol, 1 equiv.) was cleaved using TFA and 
coupled to histidine-isovaleric fragment 3-19 (29 mg, 0.06 mmol, 1 equiv.) under 
standard coupling conditions using HATU/HOAt to give the desired compound 4-36 as 
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pale yellow solid (43 mg, 70%) after purification by silica gel column chromatography 
(chloroform/methanol, 9/1). 1H NMR  (500 MHz, CDCl3): δ 0.83 (m, 12H), 1.03 (m, 
2H), 1.34 (s, 9H), 1.84 (m, 6H), 3.00 (s, 6H), 3.08 (m, 7H), 3.93 (m, 3H), 4.43 (t, 1H), 
5.47 (d, 1H), 6.28 (s, 1H), 6.45 (d, 1H), 6.56 (m, 2H), 7.16 (brs, 1H), 7.43 (d, 1H), 7.57 
(d, 1H); 13 C NMR (75 MHz, CDCl3): 11.0, 15.5, 18.0, 18.3, 18.9, 24.4, 25.2, 28.2, 
28.4, 31.0, 37.4, 38.7, 39.1, 39.9, 40.9, 48.0, 56.2, 59.3, 60.6, 79.3, 98.0, 108.5, 109.1, 
110.7, 125.9, 150.0, 152.9, 155.9, 162.7, 168.3, 168.6, 171.4, 172.0, 172.4; ESI-MS, 






















2H-chromen-4-yl)acetamido)ethyl)pyrrolidine-2-carboxamide (4-37) : Trityl group of 
compound 4-36 was removed using TFA as described in the general procedure to give 
the desired compound as a pale yellow solid (31 mg, 51%) after purification by silica 
gel column chromatography (chloroform/methanol, 8/1). 1H NMR  (500 MHz, MeOH-
d4) δ 0.83-0.90 (m, 12H), 0.90 (dd, 6H), 1.12 (m, 1H), 1.28 (m, 2H), 1.49 (m, 1H), 1.80 
(m, 8H), 2.86 (m, 2H), 3.05 (s, 6H), 3.63 (m, 3H), 3.94 (m, 1H), 4.21 (m, 2H), 4.39 (m, 
1H), 4.64 (m, 1H), 4.8 (m, 1H), 6.07 (d, 1H), 6.55 (m, 1H), 6.74 (m, 1H), 6.84 (brs, 
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1H), 7.56 (m, 2H); 13C NMR (125 MHz, MeOH-d4): 11.0, 15.5, 18.0, 18.3, 18.9, 24.4, 
25.2, 28.2, 28.4, 31.0, 37.4, 38.7, 39.1, 39.9, 40.9, 48.0, 56.2, 59.3, 60.6, 79.3, 98.0, 
108.5, 110.7, 125.9, 150.0, 152.9, 155.9, 162.7, 168.3, 168.6, 171.4, 172.0, 172.4; ESI-




1-(tert-butyloxycarbonyl) ethyldiamine (4-32): To the solution of the ethylenediamine 
(3gm, 49.9 mmol, 5equiv.) in dry dichloromethane (100 mL) dilute solution (100mL) of 
ditert-butyldicarbonate (2.18 gm, 9.99 mmol, 1equiv.) was added drop wise under 
rigorous stirring at 0 oC over a period of 40min under argon atmosphere. The reaction 
was stirred at rt for 12h. After completion of the starting material, the reaction mixture 
was diluted with 50 mL of dichloromethane and then washed with distilled water 
followed by brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (CHCl3/MeOH, 9/1 
+0.1%TEA) to afford compound 4-32 as viscous oil (50%). Rf (9:1 
CH2Cl2/MeOH/0.1% TEA) = 0.22.  IR (KBr)/ cm-1: 1172.7, 1527.6, 1697.4, 2931.8, 
2978.1, 3363.9; 1H NMR (500 MHz, CDCl3): δ 1.43 (s, 9H), 2.79 (t, J = 5.0 Hz, 2H), 
3.20 (t, J = 5.0 Hz, 2H), 4.92 (brs, 1H); 13C NMR (500 MHz, CDCl3): δ 28.3, 41.8, 
43.3, 79.5, and 156.2.  
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General experimental procedure for the synthesis of N-(7-Chloro-4-quinolyl)-1,n-
diaminoalkanes: A mixture of 4,7-dichloroquinoline 5-5 and diamines  was heated to 
110 °C for 6 h under argon atmosphere. After completion of the starting materials, 
aqueous NaOH (1 N, 10mL) was then added and the mixture was extracted with 
CH2Cl2.The organic layer was washed with water followed by brine solution. The 
organic layer was then dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to afford the respective diaminoalkanes.  
 
N-(7-Chloro-4-quinolyl)-1,2-diaminoethane (5-8): Following the general procedure 
described above, N-(7-Chloro-4-quinolyl)-1,2-diaminoethane 5-8 (2.9 gm, 87% yield) 
was obtained as pale-yellow crystals.  Rf (CH2Cl2 /MeOH/(9:1+0.1%TEA) = 0.09. IR 
(KBr)/cm-1: 1581.6, 2916.4, 3248.1; 1H NMR (500 MHz, MeOH-d4): δ 2.99 (t,  J = 6.3 
Hz, 2H), 3.45 (t, J = 6.3 Hz, 2H), 6.56 (d,  J = 5.7 Hz, 1H), 7.38 (dd, J = 2 Hz, 1H), 
7.76 (d, J = 2.5Hz, 1H), 8.04 (d, J = 9.4 Hz, 1H), 8.35 (d, 1H); 13C NMR (500 MHz, 
MeOH-d4): δ 44.2, 50.3, 99.7, 118.8, 124.2, 126.1, 127.6, 136.4, 149.7, 152.4, 152.6; 
MS (ESI): m/z : 222.1 [M+H]+. 
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N-(7-Chloro-4-quinolyl)-1,4-diaminobutane (5-9): Employing 3.0 g (15.2 mmol, 1 
equiv.) of 4,7-dichloroquinoline following the general procedure described above gave 
5-9 (3.09 g 8.4 mmol, 80% yield) as pale-yellow crystals. Rf (CH2Cl2/MeOH 
:9:1+0.1%TEA) = 0.03 IR (KBr)/cm-1: 1581.6, 2931.8, 3255.8; 1H NMR (500 MHz, 
MeOH-d4): δ 1.62 (m, 2H), 1.78 (m, 2H),  2.71 (t, J = 6.9 Hz, 2H), 3.38 (t, J = 7.6 Hz, 
2H), 6.52 (d,  J = 5.7 Hz, 1H), 7.39 (d, J = 2.5 Hz, 1H), 7.77 (d, J = 2.5 Hz, 1H), 8.10 
(d, J = 9.5 Hz, 1H), 8.34 (d,  J = 5.1 Hz, 1H); 13C NMR (500 MHz, MeOH-d4): δ 26.8, 
31.3, 42.3, 43.9, 99.6, 118.8, 124.3, 125.8, 127.6, 136.2, 149.7, 152.4, 152.7; MS (ESI): 
m/z 250.1 [M+H]+. 
General experimental procedure for the synthesis of N-(7-chloro-4-quinolyl)-N′,N′-
diethyl-1,(n)-diaminoalkanes and N-(7-chloro-4-quinolyl)-N′-ethyl-1,n-diamino 
alkanes: To the solution of N-(7-chloro-4-quinolyl)-1,2-diaminoethane (1.0 gm, 4.5 
mmol, 1 equiv.) in anhydrous DMF, caesium carbonate (4.4 gm, 13.5 mmol, 3 equiv.) 
was added and the resulting solution was stirred at rt for 30 min. Then, ethyl bromide 
(0.49 gm, 4.5 mmol, 1 equiv.) was added and stirred at room temperature for 24 h. After 
completion of the starting material, DMF was removed in vacuo. The residue obtained 
was dissolved in CH2Cl2 and washed with water followed by brine solution. The 
organic layers were dried over anhydrous Na2SO4, and concentrated under reduced 
pressure to give the crude materials. The crude was purified by column chromatography 
on silica gel (CH2Cl2/MeOH: 8/1+0.1% TEA) to afford 0.21 gm (16.8% yield) of N-(7-
chloro-4-quinolyl)-N′,N′-diethyl-1,2-diaminoethane and 0.38 gm (33.7% yield) of N-(7-
chloro-4-quinolyl)- N′-ethyl-1,2-diaminoethane as pale-yellow crystals. 
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N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-diaminoethane (5-12): Rf (CH2Cl2/MeOH: 
(9/1+0.1% TEA) = 0.23 . IR (KBr)/cm-1: 1581.6, 2846.9 2962.6, 3271.3. 1H NMR (500 
MHz, MeOH-d4): δ 1.16 (t, J = 7.6 Hz, 3H), 2.72 (q, J = 7.0 Hz, 2H),  2.96 (t, J = 7.0 
Hz, 2H), 3.51 (t,  J = 6.3 Hz, 2H), 6.56 (d, J = 5.7 Hz, 1H), 7.41 (dd,  J = 2.5 Hz, 1H), 
7.78 (d, J = 2.6 Hz, 1H), 8.10 (d, J = 8.8 Hz, 1H), 8.37 (d, J = 5.7 Hz, 1H); 13C NMR  
(500 MHz, MeOH-d4): δ 14.6, 43.2, 44.7, 99.7, 118.8, 124.3, 126.1, 127.6, 136.4, 
149.7, 152.5, 152.8; MS (ESI): m/z 250.1 [M+H]+. 
 
N-(7-Chloro-4-quinolyl)-N′,N′-diethyl-1,2-diaminoethane (5-14): Rf = 0.3 (CH2Cl2/ 
MeOH, 9/1+0.1%TEA) IR (KBr)/cm-1: 1581.6, 2970.4, 3232.7; 1H NMR (500 MHz, 
MeOH-d4): δ 1.34 (t,  J = 7.6 Hz, 6H), 2.67 (q,  J = 7.0 Hz, 4H),  2.82 (t, J = 7.0 Hz, 
2H), 3.48 (t, J = 6.3 Hz, 2H), 6.55 (d, J = 5.1 Hz, 1H), 7.41 (dd, J =2.0 Hz, 1H), 7.78 (d,  
J = 2.0 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.37 (d, J = 5.1 Hz, 1H); 13C NMR (500 MHz, 
MeOH-d4): δ 11.6, 41.4, 48.1, 49.5, 99.7, 118.8, 124.1, 126.1, 127.7, 136.4, 149.7, 
152.5, 152.6 . MS (ESI): m/z: 278.1 [M+H]+. 
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N-(7-Chloro-4-quinolyl)-N′-ethyl-1,4-diaminobutane (5-13): Employing 1.5 gm (6.02 
mmol, 1 equiv.) of N-(7-chloro-4-quinolyl)-1,4-diaminobutane following the procedure 
described gave 0.3 gm (18% yield) of compound 5-13 after purification by column 
chromatography on silica gel (CH2Cl2/MeOH, 6/1+0.1%TEA) as pale-yellow crystals. 
Rf (CH2Cl2 /MeOH, 9/1+0.1%TEA) = 0.2; IR (KBr)/cm-1: 1581.6, 2931.8, 3278.9; 1H 
NMR (500 MHz, MeOH-d4): δ 1.13 (t, J = 7.0 Hz, 3H), 1.66 (m, 2H), 1.79 (m, 2H), 
2.67 (q, J = 7.0 Hz, 4H), 3.30 (t, J = 7.0 Hz, 2H) 6.52 (d, J = 5.7 Hz, 1H), 7.39 (dd, J = 
2.0 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.9 Hz, 1H), 8.34 (d, J = 5.1Hz, 1H); 
13C NMR (500 MHz, MeOH-d4): δ 14.5, 27.2, 27.9, 43.8, 44.5, 49.9, 99.6, 118.8, 124.3, 
125.9, 127.6, 136.2, 149.7, 152.4, 152.7; MS (ESI): m/z: 278.1 [M+H]+. 
 
N-(7-Chloro-4-quinolyl)-N′,N′-diethyl-1,4-diaminobutane (5-14): Employing 1.5 gm 
(6.02 mmol, 1 equiv.) of N-(7-chloro-4-quinolyl)-1,4- diaminobutane following the 
general procedure described above afforded 0.42 gm (23% yield) of compound 5-14 
after purification by column chromatography on silica gel (CH2Cl2/MeOH, 9/1+0.1% 
TEA) as pale-yellow crystals. Rf (CH2Cl2/MeOH, 9/1+0.1%TEA) = 0.36; IR (KBr)/cm-
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1: 1581.6, 2792.9, 2931.8, 3217.3; 1H NMR (500 MHz, CDCl3): δ 1.05 (t,  J = 7.0 Hz, 
6H), 1.69 (m, 2H), 1.84 (m, 2H), 2.53 (t,  J = 7.0 Hz, 2H),  2.60 (q, J = 7.0 Hz, 4H), 
3.30 (t, J = 6.3 Hz, 2H),  6.00 (s, 1H), 6.38 (d, J = 5.1 Hz, 1H), 7.34 (dd, J = 2.0 Hz, 
1H), 7.73 (d,  J = 9.5 Hz, 1H), 7.94 (d, J = 2.0 Hz, 1H), 8.51 (d, J = 5.7 Hz, 1H); 13C 
NMR (500 MHz, MeOD): δ 11.1, 24.9, 27.5, 43.8, 47.8, 53.5, 99.7, 118.8, 124.3, 125.9, 
127.6, 136.3, 149.7, 152.4, 152.7; MS (ESI): m/z: 306.1 [M+H]+ 
 
N-tert-Butyloxycarbonyl aminoethyl-2-bromoacetamide (5-2): To the solution of 
bromoacetic acid (44 mg, 0.31 mmol, 1 equiv.) in dichloromethane (10 mL) under 
argon atmosphere, diisopropylethylamine (81 mg, 0.62 mmol, 2 eq.) was added at -10 
oC followed by the addition of (2-(7-Aza-1H-benztriazole-1-yl))-1,1,3,3,-tetra methyl 
ammoniumhexafluoro phosphate (HATU) (142 mg, 0.37 mmol, 1.2 eq.) and 3H-
[1,2,3]triazolo [4,5-] pyridine-3-ol (HOAt) (51 mg, 0.37 mmol, 1.2 equiv). After 10min 
of stirring, 1-(tert-butyloxy carbonyl) ethyldiamine (50 mg, 0.31 mmol, 1 equiv) was 
added at -10 oC. The reaction was allowed to room temperature gradually and stirred for 
4h. After completion of the starting material, the reaction mixture was diluted with 
water and extracted with dichloromethane. The organic layer was washed with saturated 
sodium bicarbonate solution followed by brine solution. The organic layer was dried 
over anhydrous sodium sulfate and concentrated in vacuo. The crude residue obtained 
was purified by column chromatography on silica gel to give compound 5-2 ( 
CHCl3/MeOH, 15/1+ 0.1% TEA) in 80% yield. Rf (CH2Cl2/MeOH, 9/1+/0.1%TEA) = 
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0.33; 1H NMR  (500 MHz, CDCl3): δ 1.45 (s, 9H), 3.29 (m, 2H), 3.40 (m, 2H), 3.86 (s, 
2H), 4.88 (brs, 1H), 7.09 (brs, 1H); 13C NMR (500 MHz, CDCl3): δ 28.4, 28.9, 39.8, 
41.6, 79.9, 157.8, 166.3; MS (ESI): m/z: 304.9 [M+Na]+.HRMS (m/z) calc. 303.0314, 
observed 303.0314. 
 
(7-Coumarin-acetamide)aminoethyl-2-bromoacetamide (5-4): To the solution of N-
(tert-butyloxy carbonyl)aminoethyl-2-bromoacetamide (60 mg, 0.21 mmol, 1 equiv.) in 
anhydrous dichloromethane (1 mL), TFA (243 mg, 2.13 mmol, 10 equiv.) was added at 
0 oC under argon atmosphere. After completion of the starting material, the reaction 
mixture was concentrated in vacuo to remove excess TFA and solvent. The residue was 
triturated with freshly distilled ether to give solid TFA salt of the amine. To the solution 
of this amine salt in anhydrous dichloromethane under Ar atmosphere, 
diisopropylethylamine (82.7 mg, 0.64 mmol, 3 equiv.) was added immediately at -10 oC 
followed by the addition of 7-Dimethyl coumarin-4-acetic acid (53 mg, 0.21mmol, 1 
equiv.), HATU (98 mg, 0.26 mmol, 1.2 equiv.) and HOAt (35 mg, 0.26 mmol, 1.2 
equiv.) respectively. The reaction was allowed to room temperature gradually and 
stirred at room temperature for 5h. After completion of the starting material, the 
reaction mixture was diluted with water and extracted with dichloromethane. The 
organic layer was then washed with saturated NaHCO3 solution followed by brine 
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solution. The organic layer was then dried over anhydrous Na2SO4 and concentrated in 
vacuo to give oily residue. The oily residue was purified by column chromatography on 
silica gel (CHCl3/MeOH, 8/1+0.1%TEA) to afford compound 5-4 in 60% yield. Rf = 
0.4 (MeOH/CH2Cl2/0.1%TEA) 
General experimental procedure for the synthesis of 2-((2-(7-chloroquinolin-4-
ylamino)ethyl)(ethyl)amino)-N-(2-(2-(7-(dimethylamino)-2-oxo-2H-chromen4yl) 
acetamido)ethyl) acetamide:  To the solution of N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-
diaminoethane (16.8 mg, 0.07 mmol, 1equiv.) in dry acetonitrile, freshly dried 
potassium carbonate (18.6 mg, 0.135 mmol, 2equiv.) was added under Ar atmosphere 
followed by the addition of 7-(Coumarin-acetamide)aminoethyl-2-bromoacetamide 
(27.6 mg, 0.07 mmol, 1equiv.) at 0 oC. The reaction mixture was stirred at room 
temperature for 12h. After completion of the starting material, the reaction mixture was 
filtered through celite. The filtrate was concentrated in vacuo and the residue obtained 
was purified by flash chromatography on silica gel (CHCl3/MeOH, 8/1+0.1%TEA).  
 
2-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)-N-(2-(2-(7-(dimethylamino)-
2-oxo-2H-chromen-4yl) acetamido) ethyl) acetamide (5-16): Following the above 
general procedure and purification by flash chromatography (CHCl3/MeOH, 
8/1+0.1%TEA), 5 mg of compound 5-16 was obtained (solid, 75%).  Rf = 0.41 ( 
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CHCl3/MeOH, 9/1+0.1%TEA); IR (KBr)/cm-1: 1581.63, 1612.63, 1658.78, 2854.65, 
2924.09, 3363.86; 1H NMR (500 MHz, MeOH-d4): δ 0.95 (t, J = 7.0 Hz, 3H), 2.53 (q, J 
= 7.6 Hz, 2H), 2.70 (t, J = 6.3 Hz, 2H), 2.94 (s, 6H) 3.08 (s, 2H), 3.30 (t, J = 5.7 Hz, 
2H), 3.38 (m, 6H), 5.98 (s, 1H), 6.23 (d, J= 2.5 Hz, 1H), 6.44 (d, J= 5.7 Hz, 1H), 6.55 
(dd, J = 2.6, 9.5 Hz, 1H), 7.23 (dd, J = 2.0, 8.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 1H), 7.71 
(s, J = 2 Hz, 1H), 8.02 (d, J = 9.5 Hz, 1H), 8.29 (d, J = 5.7 Hz, 1H); 13C NMR (500 
MHz, MeOH-d4): δ 12.2, 14.5, 40.0, 40.1, 41.2, 50.3, 53.7, 59.0, 98.5, 99.5, 109.8, 
110.3, 110.5, 118.6, 124.8, 126.1, 126.7, 126.9, 136.7, 148.6, 151.5, 152.6, 153.0, 
















2-oxo-2H-chromen-4-yl)acetamido) ethyl) acetamide (5-17): Following the above 
general procedure and purification by flash chromatography on silica gel 
(CHCl3/MeOH, 8/1+0.1%TEA), 3 mg of compound 5-17 was obtained (solid, 85%). Rf 
= 0.44 (CHCl3/MeOH, 9/1 +0.1%TEA); IR (KBr)/cm-1: 1527.6, 1581.6, 1612.5, 1712.8, 
2862.4, 2931.8, 3333.0; 1H NMR (300 MHz, MeOH-d4): δ 0.87 (t, J = 6.4 Hz, 3H), 
1.52-1.57 (m, 2H), 1.62-1.74 (m, 2H), 2.41 (t, J = 7.0 Hz, 2H), 2.49 (q, J = 7.0 Hz, 2H), 
2.97 (brs, 8H), 3.21 (m, 2H), 3.38-3.40 (m, 4H), 3.63 (s, 2H), 5.98 (s, 1H), 6.34 (d, J = 
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2.3Hz, 1H), 6.43 (d, J = 5.8 Hz, 1H), 6.55 (dd, J = 2.6, 9.1 Hz, 1H), 7.25 (dd, J = 2.0, 
8.8 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.99 (d, J = 9.1 Hz, 1H), 
8.29 (d, J = 5.8 Hz, 1H); 13C NMR (125 MHz, MeOH-d4):  δ 12.1,  26.2, 27.1, 40.0, 
40.1, 40.2, 44.0, 47.4, 50.0, 55.7, 58.7, 98.6, 99.6, 109.7, 110.3, 110.5, 118.7,124.5, 
125.8, 126.8, 127.3, 136.2, 149.4, 152.2,152.7, 154.6, 157.1, 164.2, 171.5, 175.2; MS 
(ESI): m/z: 608.3 [M+2H]+. HRMS (ESI) m/z calculated 608.2848, observed 608.2847. 
 
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-
4-yl)acetamide (5-10): To the solution of 7-Dimethyl coumarin-4-acetic acid 4-31 (53 
mg, 0.12 mmol, 1 equiv.) in dry dichloromethane, triethylamine (36 mg, 0.36 mmol, 3 
equiv.), dicyclohexylcarbodiimide (27 mg, 0.18 mmol, 1.5 equiv.) and HOBt (18 mg, 
0.18 mmol, 1.5 eq.) were added in sequence under Ar atmosphere at 0 oC.  Then, N-(7-
Chloro-4-quinolyl)-1,2-diaminoethane (30 mg, 0.12 mmol, 1 equiv.) was added to 
reaction mixture at 0 oC. The reaction was warmed to room temperature gradually and 
stirred at room temperature for 6h. After completion of the starting material, the 
reaction mixture was concentrated in vacuo and the residue obtained was extracted with 
cold ethyl acetate separating the dicyclohexylurea by-product which precipitated out 
from the cold ethyl acetate. The solution was filtered and the filtrate was distilled under 
vacuum. The residue obtained was purified by flash chromatography on silica gel 
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(CHCl3/MeOH, 6/1+0.1% TEA) to afford 5-10 (solid, 67%). Rf (CH2Cl2/MeOH, 9/1 
+0.1% TEA) = 0.21; IR (KBr)/cm-1: 1535.3, 1620.2, 1705.1, 2924.1, 3063.0, 3325.3; 1H 
NMR (500 MHz, CDCl3): δ 2.97 (s, 6H), 3.37-3.41 (m, 4H), 3.62 (s, 2H), 6.02(s, 1H), 
6.41 (d, J = 7.0 Hz, 1H), 6.43 (d, J = 2.5 Hz, 1H), 6.56 (d, J = 5.1 Hz, 1H), 7.40 (s, 1H), 
7.42 (d, J = 8.9 Hz, 1H), 7.46 (brs, 1H), 7.78 (d, J = 2.5 Hz, 1H), 8.06 (d, J = 8.8 Hz, 
1H), 8.36 (brs, 1H),   8.39 (d, J = 5.7 Hz, 1H);  13C NMR (500 MHz, CDCl3): δ 37.4, 
37.5 42.3, 40.0, 97.2, 98.5, 108.0, 108.6, 109.6, 116.9, 124.0, 124.4, 125.7, 126.0, 
134.1, 147.1, 150.3, 150.8, 150.9, 152.5, 155.3, 160.6, 168.6, 168.7; MS (ESI): m/z: 











4-yl)acetamide (5-11): Following the above procedure and purification by flash 
chromatography on silica gel (CHCl3/MeOH, 6/1 +0.1%TEA) afforded compound 5-11 
(solid, 18 mg 85%). Rf = 0.20 (CH2Cl2/MeOH, 6/1+0.1%TEA); IR (KBr)/cm-1: 1535.3, 
1589.3, 1612.5, 1689.6, 2862.4, 2924.1, 3363.9, 3487.3; 1H NMR (500 MHz, CDCl3):  δ 
1.50-1.56 (m, 2H), 1.62-1.68 (m, 2H), 2.97 (s, 6H), 3.13 (t, J = 7.0 Hz, 2H) 3.25 (t, J = 
7.0 Hz, 2H), 3.58 (s, 2H), 5.99 (s, 1H), 6.46 (d, J = 5.1 Hz, 1H), 6.53 (d, J = 2.6 Hz, 
1H), 6.65 (dd, J = 2.5, 8.8 Hz, 1H), 7.30 (brs, 1H),  7.43 (dd, J = 2.0, 8.9 Hz, 1H), 7.53 
(d, J = 8.9 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 8.18 (brs, 1H),  8.26 (d, J =  9.5 Hz, 1H), 
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8.37 (d, J = 5.7 Hz, 1H); 13C NMR (500 MHz, CDCl3): δ 25.1, 26.6, 38.4, 42.0, 97.4, 
98.6, 108.1, 108.9, 109.3, 117.3, 124.0, 124.1, 125.9, 127.2, 133.4, 148.7, 150.2, 151.3, 
152.7, 155.3, 160.6, 167.6; MS (ESI): m/z: 479.2 [M+H]+. HRMS (ESI) m/z calc. 
479.1861, observed 479.1858. 
 
9H-fluoren-9-yl)methyl 3-hydroxypropylcarbamate (5-18): To a solution of the 3-
aminopropanol (3.76 gm, 50.0 mmol, 1 equiv.) in (10 mL) dioxane/water, Fmoc-Cl 
(8.92 gm, 50.0 mmol, 1.2 equiv.) was added and stirred for 12h at rt. After completion 
of the starting material, the reaction mixture was diluted with 50 mL of 
dichloromethane and then washed with distilled water and brine solution. The organic 
layer was dried over anhydrous Na2SO4 and concentrated in vacuo to obtain compound 
5-18 (solid, 86%) which was directly used for the next step. Rf (CH2Cl2 /MeOH, 9/1 
+0.1%TEA)= 0.75; IR (KBr)/cm-1: 1267.29, 1445.71, 1543.12, 1691.64, 2884.67, 
2947.36, 3326.39; 1H NMR (500 MHz, CDCl3): δ 1.70 (s, 2H), 2.46 (s, 1H), 3.36 (m, 
2H),  3.65 (d, J = 5.1 Hz, 2H), 4.22 (s, 1H), 4.44 (d, J = 7.0 Hz, 2H), 7.32 (m, 2H), 7.40 
(m, 2H), 7.59 (m, 2H), 7.76 (m, 2H); 13C NMR (500 MHz, CDCl3) δ 32.6, 37.6, 47.3, 
59.5, 66.7, 120.0, 125.0, 127.0, 127.7, 141.3, 143.9, 157.4. MS (ESI): m/z: 297.9 
[M+H]+, 320.18 [M+Na]+. 
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(9H-fluoren-9-yl)methyl-3-oxopropylcarbamate (5-19): To the solution of (9H-
fluoren-9-yl)methyl-3-oxo propyl carbamate 5-18 (0.10 gm, 0.34 mmol, 1 equiv.) in dry 
dichloromethane, Dess-Martin Periodinane (0.357 gm, 0.84 mmol, 2.5 equiv.) was 
added and stirred at room temperature for 3h. After reaction was complete the reaction 
mixture was filtered and the filtrate was removed in vacuo to obtain white solid which 
was further purified by flash chromatography (Hexane/EtOAc, 8/1) to give compound 
5-19 (white solid, 55%). Rf = 0.88 (1:1 Hexane/EtOAc); IR (KBr)/cm-1: 1269.22, 
1543.12, 1690.68. 1725.4, 2854.77, 2925.17, 2957, 3329.28;  1H NMR (500MHz, 
CDCl3): δ 2.75 (t,  J = 5.6 Hz, 2H), 3.49 (m, J = 5.7 Hz, 2H), 4.20 (t, J = 6.9 Hz, 1H), 
4.39 (d, J = 6.9 Hz, 2H), 5.51 (brs, 1H), 7.31 (t,  J = 7.6 Hz, 2H), 7.40 (t,  J = 7.6 Hz, 
2H), 7.56 (d, J = 7.6Hz, 2H), 7.76 (d, J = 7.6 Hz, 2H), 9.81 (s, 1H);  13C NMR (500 
MHz, CDCl3): δ 34.5, 44.1, 47.3, 66.7, 120.0, 125.0, 127.0, 127.7, 141.3, 143.9, 156.3, 
201.2. MS (ESI): m/z: 296.00 [M+H]+. 
 
(9H-fluoren-9-yl)methyl3-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)pro 
pyl carbamate (5-20): To the solution of (9H-fluoren-9-yl)methyl-3-oxopropyl carbam 
ate 5-19 (0.036 gm, 0.12 mmol, 2 equiv.) in dry CH2Cl2 (5 mL ) under argon 
atmosphere, N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-diamino ethane 5-12 (0.015 gm, 0.06 
mmol, 1 equiv.) was added at 0 oC followed by the addition of sodium 
triacetoxyborohydride (0.025 gm, 0.12 mmol, 2.0 equiv.). The reaction mixture was 
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stirred at room temperature for 4h. After completion of the starting material, the 
reaction mixture was diluted with water and extracted with ethyl acetate. The organic 
layer was then washed with saturated NaHCO3 solution followed by brine. The organic 
layer was dried over anhydrous sodium sulfate and concentrated in vacuo to obtain an 
oily residue which was purified by flash chromatography (CHCl3/MeOH, 9/1 + 0.1% 
TEA) to obtain the product 5-20 (solid, 80%). Rf = 0.35 (CH2Cl2/MeOH, 9/1 +0.1% 
TEA); IR (KBr)/cm-1 : 1378.29, 1457.2, 1645.35, 2925.17, 2958.93, 3384.25; 1H NMR 
(500 MHz, CDCl3): δ 1.05 (t, J = 6.9 Hz, 3H), 1.65 (m, 2H), 1.69 (m, 2H), 2.56 (q, J = 
6.9 Hz, 2H), 2.59 (m, 2H), 2.79 (m, 2H), 3.27 (m, 2H), 4.17 (t, J = 6.9 Hz, 1H), 4.39 (d, 
J = 5.7 Hz, 2H), 5.14 (brs, 1H), 5.14 (brs, 1H), 6.35 (d, J = 5.1 Hz, 1H), 7.27 (t, J = 7.6 
Hz, 2H), 7.30 (dd, J = 2.6, 9.1Hz, 1H), 7.38 (t, J = 7.6 Hz, 2H), 7.54 (d, J = 7.6 Hz, 
2H), 7.69 (d, J = 8.9 Hz, 1H), 7.74 (d,  J = 7.6 Hz, 2H), 7.94 (d,  J = 1.9 Hz, 1H), 8.51 
(d,  J = 5.7 Hz, 1H); 13C NMR (500 MHz, CDCl3): δ 11.7, 27.4, 39.5, 40.1, 46.8, 47.3, 
50.8, 51.5, 66.4, 99.2, 117.4, 119.4, 121.3, 124.9, 125.3, 127.0, 127.6, 128.7, 134.8, 
141.3, 143.9, 149.1, 149.7, 152.0, 156.4; MS (ESI): m/z: 529.2 [M+H]+; HRMS m/z 
calc. 529.2378, obs. 529.2377. 
 
N1-(2-(7-chloroquinolin-4-ylamino)ethyl)-N1-ethylpropane-1,3-diamine (5-22): To 
the solution of (9H-fluoren-9-yl) methyl 3-((2-(7-chloroquinolin-4-ylamino)ethyl) 
(ethyl)amino)propyl carbamate 5-20 (0.025 gm, 0.01 mmol, 1 equiv.) in dry CH2Cl2 (1 
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mL) under Ar atmosphere, piperidine (5 vol.) was added at 0 oC and reaction mixture 
was stirred for 30 min at room temperature. After completion of the starting material, 
the reaction mixture was distilled in vacuo to remove excess piperidine and the residue 
was purified by flash chromatography (CHCl3/MeOH, 4/1+0.1%TEA) to afford 13 mg 
of product 5-22 (solid, 85%)  . 1H NMR (500 MHz, CDCl3): δ 1.07 (t, J = 6.9 Hz, 3H), 
1.65 (m, 2H), 2.60 (m, 6H), 2.82 (t, J = 4.4 Hz, 2H), 3.30 (m, 2H), 6.35 (d, J = 5.1 Hz, 
1H), 7.35 (dd, J = 2.6, 9.1 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 1.9 Hz, 1H), 
8.51 (d, J = 5.7 Hz, 1H); 13C NMR (500 MHz, CDCl3): δ 11.8, 30.0, 40.1, 40.5, 47.1, 













amino)-2-oxo-2H-chromen-4-yl)acetamidetert-butyl (5-21): To the solution of 7-
dimethylcoumarin-4-aceticacid 4-31 (8 mg, 0.03 mmol, 1 equiv.) in dry 
dichloromethane (10 mL) under argon atmosphere, diisopropylethylamine (10.0 mg, 
0.06 mmol, 2 equiv.) was added at -10oC followed by the addition of N-1-(2-(7-
chloroquinolin-4-ylamino)ethyl)-N1-ethylpropane-1,3-diamine (10 mg, 0.03 mmol, 1 
equiv.), HATU (15 mg, 0.04 mmol, 1.2 equiv.) and HOAt (8 mg, 0.04 mmol, 1.2 
equiv.) respectively. The reaction was slowly warmed to room temperature and stirred 
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for 4h. After the completion of the starting material, the reaction mixture was diluted 
with water and extracted with ethyl acetate. The organic layer was washed with 
saturated NaHCO3 solution followed by brine. The organic layer was dried over 
anhydrous sodium sulfate and removed in vacuo to obtain gummy residue which was 
purified by flash chromatography on silica gel (CHCl3/MeOH, 8/1 + 0.1% TEA) to 
obtain compound, 5-21 (pale yellow solid, 12 mg, 77%). Rf  = 0.36 (CH2Cl2/MeOH, 9/1 
+0.1% TEA); IR (KBr)/cm-1: 1H NMR (500 MHz, CDCl3): δ 0.95 (t, J = 6.9 Hz, 3H), 
2.46 (m, 4H), 2.70 (t, J = 5.7 Hz, 2H), 2.95 (s, 6H), 3.17 (m, 2H), 3.33 (m, 2H), 3.55 (s, 
2H), 5.77 (brs, 1H), 5.98 (s, 1H), 6.28 (brs, 1H), 6.30 (d, 1H), 6.35 (d, 1H), 6.49 (dd, J 
= 2.5, 8.8 Hz, 1H), 7.31 (dd, J = 2.5, 8.8 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 7.65 (d, J = 
8.8 Hz, 1H), 7.91 (d, J = 1.9 Hz, 1H), 8.49 (d, J = 5.1 Hz, 1H); 13C NMR (500 MHz, 
MeOH-d4): δ  11.6, 27.5, 38.8, 40.0, 41.4, 51.8, 52.5, 98.6, 99.6, 109.6, 110.3, 110.4, 
118.6, 124.2, 126.1, 126.9, 127.4, 136.4, 149.4, 152.3, 152.4, 152.8, 154.6, 157.1, 
164.2, 171.0; MS (ESI): m/z : 536.3 [M+H]+; HRMS (ESI) m/z calc. 536.0650, obs. 
536.2441. 
β-Hematin Assay: The interaction of coumarin-tagged chloroquine analogues with 
porcine hematin was investigated by monitoring changes in the Soret band of hematin 
by the following procedure. Appropriate aliquots of hematin (2 mM stock solution in 
0.1 N NaOH), test compounds (0.2 mM in methanol or DMSO) were added to a cuvette 
(1 mL) containing 43% methanol in sodium acetate buffer (10 mM, pH 5.5), to give 
final concentration of 14 µM hematin, 10 and 32 µM test compounds. The solution was 
vortexed for 10 seconds and the spectrum was recorded from 250 to 650 nm. Under 
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these conditions the Soret band of hematin was observed at 400 nm. Correction for 
background absorbance was made using a solution containing test compound in buffer 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 06:09:40
DATE_d : Apr 10 2009
NS :             16
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :   500.1300490 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :           8.00 ppm
Stop :          -0.50 ppm
YScale :         200.00 %
SR :          48.73 Hz




































































































*** Acquisition  Parameters ***
DATE_t : 06:13:00
DATE_d : Apr 10 2009
NS :           1612
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :   125.7577906 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         180.00 ppm
Stop :           0.01 ppm
YScale :         100.00 %
SR :           1.62 Hz

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HPLC of mixture of standard amino acids 
 










































































Event#: 1 MS(E+)   Ret. Time : 13.800 -> 13.813 - 13.640 <-> 14.100   Scan# : 4141 -> 
4145 - 4093 <-> 4231 
 









Event#: 2 MS(E-)   Ret. Time : 13.800 -> 13.813 - 13.640 <-> 14.100   Scan# : 4142 -> 
4146 - 4094 <-> 4232 
 










Event#: 1 MS(E+)   Ret. Time : 14.620 -> 14.633 - 14.473 <-> 14.840   Scan# : 4387 -> 
4391 - 4343 <-> 4453 










Event#: 2 MS(E-)   Ret. Time : 14.620 -> 14.633 - 14.473 <-> 14.840   Scan# : 4388 -> 
4392 - 4344 <-> 4454 
 








Event#: 1 MS(E+)   Ret. Time : 17.140 -> 17.153 - 16.947 <-> 17.267   Scan# : 5143 -> 
5147 - 5085 <-> 5181 
 









Event#: 2 MS(E-)   Ret. Time : 17.140 -> 17.153 - 16.947 <-> 17.267   Scan# : 5144 -> 
5148 - 5086 <-> 5182 
 










Event#: 1 MS(E+)   Ret. Time : 17.347 -> 17.360 - 17.207 <-> 17.587   Scan# : 5205 -> 
5209 - 5163 <-> 5277 








Event#: 2 MS(E-)   Ret. Time : 17.347 -> 17.360 - 17.207 <-> 17.587   Scan# : 5206 -> 
5210 - 5164 <-> 5278 
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Event#: 1 MS(E+)   Ret. Time : 17.707 -> 17.720 - 17.587 <-> 17.920   Scan# : 5313 -> 
5317 - 5277 <-> 5377 
 









Event#: 2 MS(E-)   Ret. Time : 17.707 -> 17.720 - 17.587 <-> 17.920   Scan# : 5314 -> 
5318 - 5278 <-> 5378 
 











Event#: 1 MS(E+)   Ret. Time : 18.193 -> 18.207 - 18.060 <-> 18.233   Scan# : 5459 -> 
5463 - 5419 <-> 5471 
 









Event#: 2 MS(E-)   Ret. Time : 18.193 -> 18.207 - 18.060 <-> 18.233   Scan# : 5460 -> 
5464 - 5420 <-> 5472 
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Event#: 1 MS(E+)   Ret. Time : 19.180 -> 19.193 - 19.033 <-> 19.447   Scan# : 5755 -> 
5759 - 5711 <-> 5835 









Event#: 2 MS(E-)   Ret. Time : 19.180 -> 19.193 - 19.033 <-> 19.447   Scan# : 5756 -> 
5760 - 5712 <-> 5836 
 












Event#: 1 MS(E+)   Ret. Time : 20.513 -> 20.527 - 20.260 <-> 20.873   Scan# : 6155 -> 
6159 - 6079 <-> 6263 
 
 









Event#: 2 MS(E-)   Ret. Time : 20.513 -> 20.527 - 20.260 <-> 20.873   Scan# : 6156 -> 
6160 - 6080 <-> 6264 
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Event#: 1 MS(E+)   Ret. Time : 20.487   Scan# : 6147 
 
 












Event#: 2 MS(E-)   Ret. Time : 20.487   Scan# : 6148 
 











Event#: 1 MS(E+)   Ret. Time : 21.840 -> 21.853 - 21.680 <-> 22.253   Scan# : 6553 -> 
6557 - 6505 <-> 6677 










Event#: 2 MS(E-)   Ret. Time : 21.840 -> 21.853 - 21.680 <-> 22.253   Scan# : 6554 -> 
6558 - 6506 <-> 6678 











Event#: 1 MS(E+)   Ret. Time : 20.200 -> 20.213 - 20.107 <-> 20.253   Scan# : 6061 -> 
6065 - 6033 <-> 6077 
 
MW hydrolysis at 170 oC for 20 min 
 



























Event#: 1 MS(E+)   Ret. Time : 27.767 -> 27.780 - 27.607 <-> 28.187   Scan# : 8331 -> 
8335 - 8283 <-> 8457 
 













Event#: 2 MS(E-)   Ret. Time : 27.767 -> 27.780 - 27.607 <-> 28.187   Scan# : 8332 -> 
8336 - 8284 <-> 8458 














Event#: 1 MS(E+)   Ret. Time : 27.293 -> 27.307 - 27.140 <-> 27.600   Scan# : 8189 -> 
8193 - 8143 <-> 8281 
 221














Event#: 2 MS(E-)   Ret. Time : 27.293 -> 27.307 - 27.140 <-> 27.600   Scan# : 8190 -> 
8194 - 8144 <-> 8282 
 














Event#: 1 MS(E+)   Ret. Time : 26.773 -> 26.787 - 26.547 <-> 27.080   Scan# : 8033 -> 
8037 - 7965 <-> 8125 
 













Event#: 2 MS(E-)   Ret. Time : 26.773 -> 26.787 - 26.547 <-> 27.080   Scan# : 8034 -> 
8038 - 7966 <-> 8126 
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Event#: 1 MS(E+)   Ret. Time : 25.980 -> 25.993 - 25.800 <-> 26.573   Scan# : 7795 -> 
7799 - 7741 <-> 7973 
 
 













Event#: 2 MS(E-)   Ret. Time : 25.980 -> 25.993 - 25.800 <-> 26.573   Scan# : 7796 -> 
7800 - 7742 <-> 7974 
 













Event#: 1 MS(E+)   Ret. Time : 25.533 -> 25.547 - 25.420 <-> 25.800   Scan# : 7661 -> 
7665 - 7627 <-> 7741 
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Event#: 2 MS(E-)   Ret. Time : 25.533 -> 25.547 - 25.420 <-> 25.800   Scan# : 7662 -> 
7666 - 7628 <-> 7742 
 












Event#: 1 MS(E+)   Ret. Time : 24.200 -> 24.213 - 23.993 <-> 24.553   Scan# : 7261 -> 
7265 - 7199 <-> 7367 
 










Event#: 2 MS(E-)   Ret. Time : 24.200 -> 24.213 - 23.993 <-> 24.553   Scan# : 7262 -> 
7266 - 7200 <-> 7368 
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Event#: 1 MS(E+)   Ret. Time : 21.553 -> 21.567 - 21.240 <-> 21.893   Scan# : 6467 -> 
6471 - 6373 <-> 6569 
 











Event#: 2 MS(E-)   Ret. Time : 21.553 -> 21.567 - 21.240 <-> 21.893   Scan# : 6468 -> 
6472 - 6374 <-> 6570 
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Event#: 1 MS(E+)   Ret. Time : 20.340 -> 20.353 - 20.160 <-> 20.553   Scan# : 6103 -> 
6107 - 6049 <-> 6167 















Event#: 2 MS(E-)   Ret. Time : 20.340 -> 20.353 - 20.160 <-> 20.553   Scan# : 6104 -> 
6108 - 6050 <-> 6168 











Event#: 1 MS(E+)   Ret. Time : 19.093 -> 19.107 - 18.867 <-> 19.313   Scan# : 5729 -> 
5733 - 5661 <-> 5795 











Event#: 2 MS(E-)   Ret. Time : 19.093 -> 19.107 - 18.867 <-> 19.313   Scan# : 5730 -> 
5734 - 5662 <-> 5796 












Event#: 1 MS(E+)   Ret. Time : 17.720 -> 17.733 - 17.573 <-> 17.947   Scan# : 5317 -> 
5321 - 5273 <-> 5385 














Event#: 2 MS(E-)   Ret. Time : 17.720 -> 17.733 - 17.573 <-> 17.947   Scan# : 5318 -> 
5322 - 5274 <-> 5386 
 













Event#: 1 MS(E+)   Ret. Time : 17.160 -> 17.173 - 17.087 <-> 17.553   Scan# : 5149 -> 
5153 - 5127 <-> 5267 
 









Event#: 2 MS(E-)   Ret. Time : 17.160 -> 17.173 - 17.087 <-> 17.553   Scan# : 5150 -> 
5154 - 5128 <-> 5268 
 











Event#: 1 MS(E+)   Ret. Time : 16.320 -> 16.333 - 16.020 <-> 16.567   Scan# : 4897 -> 
4901 - 4807 <-> 4971 
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Event#: 2 MS(E-)   Ret. Time : 16.320 -> 16.333 - 16.020 <-> 16.567   Scan# : 4898 -> 
4902 - 4808 <-> 4972 
 















Event#: 1 MS(E+)   Ret. Time : 13.107   Scan# : 3933 
 











Event#: 2 MS(E-)   Ret. Time : 13.107   Scan# : 3934 
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